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Pancreatic cancer has the lowest survival rate among the 21 most common forms of cancer 
with only 5 % of patients surviving five years after their initial diagnosis. Several studies have 
investigated the potential of neo-adjuvant chemo- and / or radiotherapy to downstage 
tumours and increase the number of patients eligible for resection. Unfortunately, such 
treatments are often associated with significant off-target effects due to the non-specific 
nature of the chemotherapy regimen. Therefore, the development of targeted treatments 
that reduce side-effects related to systemic chemotherapy have enormous potential as neo-
adjuvant and palliative pancreatic cancer treatments by reducing tumour burden to either 
enable surgery or to provide symptom relief. 
Photodynamic therapy (PDT) is a clinically approved anti-cancer treatment that involves the 
activation of an otherwise inactive sensitisier drug with light, which in the presence of 
molecular oxygen, generates cytotoxic reactive oxygen species (ROS). In contrast, 
Sonodynamic therapy (SDT) is an emerging anti-cancer treatment that involves the 
activation of an otherwise inactive sensitiser drug using low-intensity ultrasound (US). The 
combination of sensitiser and ultrasound, in the presence of molecular oxygen, generates 
cytotoxic levels of ROS causing cell death via oxidative stress. As oxygen is a key 
requirement for the generation of ROS in PDT or SDT and given the fact that hypoxia is a 
characteristic of most solid cancerous tumours, treating hypoxic tumours using PDT or SDT 
can be a challenge. Therefore, an area of interest in this thesis was to investigate new 
methods for enhancing PDT and SDT efficacy in hypoxic tumors. 
Chapter 1 provided a background to current cancer treatments, PDT, SDT, improvement of 
tumor oxygenation and drug delivery systems while Chapter 2 detailed the materials and 
methods utilised in subsequent results chapters. The first results chapter, Chapter 3 
investigated whether combined SDT / gemcitabine treatment, using intravenously delivered 
oxygen carrying lipid stabilised microbubbles (MBs) as delivery vehicle, can provide a 
significant reduction in the volume of Mia-PaCa-2 tumours compared to SDT or gemcitabine 
treatment alone and evaluate potential toxic effects in healthy non-tumour bearing mice. It 
was observed that the combination of US with the Rose Bengal, Gemcitabine and oxygen 
loaded Microbubbles (O2MBs-RB/GEM) enhanced cytotoxicity when compared to either 
IV 
 
treatment alone in a panel of four pancreatic cancer cell lines. In addition, the treatment of 
ectopic Mia Paca-2 tumours with the combined SDT/antimetabolite therapy resulted in a 
statistically significant decrease in tumour volume compared to untreated tumours. The 
effects of multiple treatments on tumour growth was also investigated and it was observed 
that a second treatment 48h following the initial treatment also provided a significant delay 
in tumour re-growth. This work is under revision in the Journal of Controlled Release.   
 
The second results chapter (Chapter 4) evaluated whether external magnetic and low-
intensity ultrasound fields can enhance the efficacy of combined antimetabolite / 
sonodynamic therapy, delivered using magnetically responsive microbubbles, in an 
orthotopic murine model of pancreatic cancer. When decorated with the sensitiser Rose 
Bengal (RB) and the antimetabolite 5-FU and subjected to ultrasound treatment, magnetic 
responsive microbubbles (MagO2MB) conjugates induced a significant reduction in 
pancreatic cancer cell viability, of more than 50%. The combined application of external 
magnetic and ultrasound fields during IV delivery of the MagO2MB conjugates resulted in a 
48.3% reduction in orthotopic pancreatic tumour volumes 9 days after treatment, while the 
application of ultrasound alone resulted in a reduction of only 27.9%. In addition, a 
significant increase in apoptosis was observed in tumours that were treated with the 
MagO2MB conjugates and exposed to both magnetic and ultrasonic fields when compared 
to the ultrasound treatment alone or untreated groups. This work has been published in the 
Journal of Controlled Release. 
 
The third and final results chapter (Chapter 5) investigated the ability of calcium peroxide 
nanoparticles to improve oxygenation in a hypoxic environment and enhance PDT-mediated 
treatment of BxPc-3 pancreatic cancer cells in vitro and an ectopic Mia Paca-2 xenograft 
murine model in vivo. A significant elevation in tumour pO2 was observed 10 mins following 
IV administration of a suspension of the particles. This increase in tumour pO2 was also 
shown to have a dramatic effect on PDT efficacy with significant reductions in tumour 
growth observed in mice treated with the particles before PDT when compared to PDT 




Chapter 6 summarised the conclusions of all the results chapters and provides an outlook 
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1. General Introduction 
1.1 Prologue 
Cancer is the second leading cause of death worldwide, with 14.1 million people having 
been diagnosed with the disease and 8.2 million dying from it in 2012 alone. [1] The 
incidence rate of cancer is variable depending on its type, epidemiological factors and 
gender. In less developed countries, the most commonly diagnosed cancer in men is lung 
cancer while in women it is breast cancer. Breast cancer remains the most commonly 
diagnosed cancer for women in developed countries, while in men it is prostate cancer.[2] 
The occurrence of cancer in less developed countries is increasing as a result of population 
growth and aging, which increases the prevalence of known risk factors.  
Cancer can be defined as a class of diseases characterised by the abnormal division of cells. 
[3] Unlike normal cells, cancer cells negatively regulate cellular proliferation by producing 
growth factor ligands and up-regulate expression of anti-apoptotic proteins. As such, cancer 
cells are able to avoid programmed cell death, otherwise referred to as apoptosis. [4]  
Ten hallmarks of cancer have been proposed to provide a logical understanding of the 
diversified neoplastic disease. These hallmarks include (1) evasion of cell death, (2) evasion 
of immune destruction, (3) increasing angiogenesis, (4) resistance to growth suppressors, (5) 
uncontrolled cellular energetics, capability to (6) maintain proliferative signalling, (7) 
consistently replicate, (8) invade to normal tissue, (9) mutate the genome and (10) stimulate 
tumour inflammation. [4] These hallmarks encourage neoplastic growth or progression and 
lead to a more malignant phenotype. However, they have also provided targets for the 




Figure 1. 1 Therapeutic targeting of the hallmarks of cancer. Reproduced from ref [4]. 
On the basis of increasing experimental evidence, a therapeutic targeting agent normally 
focuses on one major pathway in a tumour, enabling some tumour cells to survive and 
continue replication. Such adaptive resistance can renew the tumour functional ability and 
lead to clinical recurrence. In addition, tumour cells may switch their dependence from one 
particular hallmark to another. For example, in certain animal models of cancer, it has been 
observed that upon successful suppression of angiogenesis, tumours can reduce their 
angiogenesis dependence and switch to a more invasive and metastatic phenotype. [5] 
Therefore, combination treatments that target two or more of the hallmark targets can lead 
to much more permanent and effective cancer treatments. 
The focus of the work outlined in this thesis is pancreatic cancer, which has the lowest 




1.2 Pancreatic Cancer 
1.2.1 Incidence and epidemiology  
In the UK, pancreatic cancer is the 11th most diagnosed cancer with approximately 9,000 
cases per year and is the 5th most common cause of cancer related deaths. [1] According to 
GlobalData Pharma, the incidence for pancreatic cancer in 2017 is estimated at 20.573 cases 
per 100,000 population and is projected to continually increase each year with an incidence 
of 22.742 cases per 100,000 population by 2021. 
Pancreatic cancer has a 5-year survival rate of approximately 5% and a 10-year survival rate 
of < 1.0% making it the most lethal of all the most common cancers. [1] Surgical resection of 
the pancreas remains the only cure for pancreatic cancer but only 20% of patients present 
with resectable disease on diagnosis. Approximately 40% of patients present with 
metastatic disease while the remaining 40%  are in a group referred to as locally advanced 
or borderline resectable pancreatic cancer (LAPC/BRPC), meaning that while the cancer is 
still confined to the pancreas, its size or anatomical location means it is not possible for the 
surgeon to remove all of the tumour. [6] When surgery is possible, 5-year survival rates 
improve 4-fold to approximately 20%, which while still low, represents a significant survival 
advantage when compared to un-resectable disease. Several strategies are being 
investigated to improve these dismal statistics and are designed to increase the number of 
patients eligible for surgical resection. These are (i) improved diagnostics; (ii) neo-adjuvant 
chemo-radiotherapy to downstage tumours and (iii) better awareness campaigns. [7] 
Currently, there is no simple blood or urine test for pancreatic cancer and as the disease is 
largely asymptomatic until the advanced stages, late diagnosis is a major issue. A significant 
amount of research is being devoted to develop a simple blood/urine test that could be 
used as a nationwide screening tool as is the case for prostate cancer. [8] By catching 
patients earlier, one would assume resection rates would increase. Similarly, the 40% of 
patients in the LAPC/BRPC could benefit from chemo- or chemo-radiotherapy before 
surgery with a view of down-staging tumours to again improve resection rates. Several 
studies have investigated the potential of neo-adjuvant treatments with promising results. 
[9] Better awareness campaigns are also necessary to enable the public and practitioners to 
become more familiar with the red-flag symptoms of pancreatic cancer so earlier referrals 
are increased.  
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There are many risk factors associated with pancreatic cancer, including cigarette smoking, 
age, diabetes and obesity. Among these, cigarette smoking is the most well established risk 
factor. Statistical analysis has shown that nearly 30% of pancreatic cancer patients have 
smoking histories; even after 10 years since cessation, the risk of progress to neoplasia is 
still increased by 75%. [10] One study has reported a remarkable interaction between heavy 
smoking and an Arg399Gln polymorphism of the DNA repair gene XRCC1, which indicated 
that individuals with a disabled DNA repairing system possess a higher risk of pancreatic 
cancer. [11] In a study of oncogene mutations, specific endogenous mutagens: KRAS, a 
member of the RAS oncogene family, significantly induced characteristic patterns of DNA 
alteration in pancreatic cells. KRAS mutation has been related to lifestyle such as heavy 
smoking and drinking alcohol. [12] Apart from cigarette smoking, about 10% of cases of 
pancreatic cancer have a family history. Several genetic syndromes are related to an 
increased risk of pancreatic cancer. Individuals with Peutx-Jeghers syndrome, induced by 
germline mutations in STK11 have a substantially increased risk of pancreatic cancer. [13] 
Additionally, Individuals with diabetes possess an extra 30% risk of pancreatic cancer, which 
lasts for over 20 years after the initial diagnosis of diabetes. [14] 
 
1.2.2 Molecular pathology and biology 
A common characteristic associated with the pathogenesis of cancer is the accumulation of 
somatic mutations that results in this malignant disease. (Figure 1.2) [15] Oncogenes, 
tumour-suppressor genes, and genomic maintenance genes are the three main categories of 
gene mutations in the majority of pancreatic cancer cases. [16] KRAS, as the most commonly 
mutated oncogene, plays a key role in mediating downstream signalling by the activation of 
transcription factors, which has been involved in over 90% of pancreatic carcinogenesis. The 
prevalence of KRAS mutation in patients with pancreatic cancers has been identified as a 
potential early detection label. [17] CDKN2As, also known as p16 tumour-suppressor gene, 
regulates the major cell-cycle of the pancreas, with inactivation in over 90% of pancreatic 
adenocarcinomas. TP53 tumour suppressor genes are another commonly mutated gene 
that plays a role in the cellular stress response and its mutational frequencies are evident in 
75% of pancreatic cancers. [18] Finally, MADH4 tumour suppressor genes control the 
downstream signalling by converting growth factor TGFβ receptor, which is inactivated in 





Figure 1. 2 Generally mutated oncogenes and tumour-suppressor genes in human pancreatic cancer. 
Reproduced from ref [15]. 
At the molecular biology level, the mechanisms correlating genetic mutations with invasive 
characteristic are connected not only to the activated oncogenes and inactivated tumour-
suppressor genes but also the crucial stress factors like cytokines and acidosis, which have 
an impact on the downstream signal transduction pathways in relation to the regulation of 
cell growth and proliferation. [20] This diversity of influence factors offers a significant 
growth and survival advantage in pancreatic cancer cells so that they possess a higher 
chance to develop into an advanced or metastatic pancreatic cancer, which are incurable 
with traditional anticancer treatments. Kleeff et al have demonstrated that various 
cytokines such as interleukin 1, 6 and 8, tumour necrosis factor α and transforming growth 
factor β are up-regulated in human pancreatic neoplasm. [21] The over-expression of these 
growth factors result in the resistance of cell death, activation of invasion and metastasis. 
Shi et al have shown that a low pH microenvironment or acidosis may lead to the over-
expression of vascular endothelial growth factor into the tumour tissue, especially in the 
area encapsulated by necrosis. [22] However, a better understanding of such factors 
involved in the pathophysiology of pancreatic cancer is required before innovative methods 




1.2.3 Current Pancreatic Cancer Treatments 
The current treatments for pancreatic cancer include surgery, chemotherapy, radiation 
therapy or combination of two or more of these treatments. The chosen treatment is 
decided on the basis of the general health of a patient and stage of pancreatic cancer in a 
multi-subject pathway. (Figure 1.3) [18] According to the American Joint Committee on 
Cancer, pancreatic cancer is classified into three different groups for treatment purposes, 
which are surgically resectable, unresectable locally advanced and metastatic. [23] 
 
Figure 1. 3 Schematic diagrams of treatment options for pancreatic cancer. Reproduced from ref [23] 
 
1.2.3.1 Surgery 
Currently, surgical resection is the only treatment that can cure patients with pancreatic 
cancer. Surgical procedures for pancreatic cancer contain pancreaticoduodenectomy, distal 
pancreatectomy with splenectomy, and total pancreatectomy. However, all these resections 
may lead to a reduced quality of life as the removal of the pancreas means the patients lack 
important enzymes that facilitate food digestion and absorption. This means patients must 
take dietary supplements, such as pancrelipase (eg CREON), for the rest of their life. The 
overall survival rates after surgical resection is highly dependent on the expertise and 
techniques available in the specialist pancreatic cancer centre. [24] Laparoscopic techniques 
have also been applied in surgery for various types of pancreatic cancers, such as mucinous 
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cystadenocarcinoma, neuroendocrine carcinoma, pancreatic ductal adenocarcinoma and 
intra-ductal papillary mucinous carcinoma.[25] A previous study has demonstrated that 
laparoscopic distal pancreatectomy of left-sided pancreatic ductal adenocarcinoma has 
several advantages over open surgery with a view to the survival rate and dramatically 
reduces the duration of hospital stay with faster recovery times, which result from 
eliminating the need for intricate reconstructions. [26] 
 
1.2.3.2 Chemotherapy  
1.2.3.2.1 Typical antimetabolite agents for pancreatic cancer 
The pyrimidine 5-fluorouracil (5-FU) has been used as an anticancer drug for over 60 years 
and was one of the earliest chemotherapies used in pancreatic cancer treatment. 
 
Figure 1. 4 Structure of 5-FU 
The mechanism of action for 5-FU can be divided into two major pathways as shown in 
Figure 1.5. The first involves the conversion from 5-FU to 5-fluorouridine triphosphate (FUTP) 
via phosphorylation by nucleotide kinases. FUTP is then incorporated into cellular RNA and 
leads to the inhibition of RNA transcription. [27] An alternative activation pathway includes 
the thymidine phosphorylase catalysed conversion of 5-FU to fluorodeoxyuridine (FUDR) 
and subsequent thymidine kinase (TK) phosphorylation to the active metabolite 5-fluoro-2′-
deoxyuridine monophosphate (FdUMP). [28] FdUMP is capable of inhibiting thymidylate 
synthase, which leads to an increased amount of deoxyuridine triphosphate (dUTP) 
recognised as damaged DNA. When the cell repair system is overloaded to set up a cycle of 
misincorporation and repair, single strand and double strand breaks result in cell death. [29] 
However, resistance can occur in pancreatic cancer patients when the metabolic rate of 5-
FU decreases or DNA repair efficiency increases. [30] Therefore, as the response rate to 5-




Figure 1. 5 Mechanism of 5-FU resulting in RNA and DNA damage. Reproduce from ref [29] 
 
Gemcitabine (GEM) was first investigated as an antiviral drug but soon- after was also 
identified for its anti-cancer activity in solid and haematological cancer models. [32] GEM 
was FDA approved in 1996 as single chemotherapy agent for metastatic pancreatic cancer 
with a better overall survival rate when compared to 5-FU. [21] Its molecular structure is a 
2′-deoxycytidine analogue where hydrogen is replaced by fluorines at the 2′ position of the 
furanose ring as shown in Figure 1.6.  
 
Figure 1. 6 Structure of GEM 
The mechanism of GEM action depends on its phosphorylation state leading to the 
inhibition of DNA repair and replication enzymes that result in cell death via apoptosis. GEM 
is first taken into the cells via human equilibrative nucleoside transporters (hENTs) or 
human concentrative nucleoside transporters (hCNTs). [33] The next step involves the 
conversion from GEM to gemcitabine monophosphate (dFdCMP) via phosphorylation by 
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deoxycytidine kinase, which is further phosphorylated by nucleotide kinase into the active 
diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleoside metabolites. [34] The major 
cytotoxic effect of GEM comes from the triphosphate metabolite, which is able to 
incorporate into the DNA strand resulting in destruction of DNA chain formation and single 
strand shatter via the inhibition of DNA polymerase activity. [35] Furthermore, dFdCDP and 
dFdCTP can inhibit the function of ribonucleotide reductase and deaminase respectively, 
which not only enhance the phosphorylation of GEM to the active metabolite dFdCTP but 
also inhibit deoxycytidylate (dCMP) deaminase activity producing mutated genes.  (Figure 
1.7) In spite of its broad-spectrum characteristic, resistance to this agent still exists due to 
several mechanisms. The main cause is the low level expression of the human equilibrative 
nucleoside transporter 1 (hENT1) resulting in the poor intracellular uptake of GEM. [36] In 
the ESPAC-3 trial study, the levels of hENT1 were discovered to have a great impact on the 
overall survival time of patients, where patients with lower levels of hENT1 more likely to 
die earlier than those with higher levels of hENT1.[36] 
 
Figure 1. 7 Mechanism of GEM leading to cell death via apoptosis. Reproduced from ref [32] 
 
1.2.3.2.2 Taxanes in Pancreatic Cancer 
Abraxane (albumin-bound paclitaxcel particles for injectable suspension) is a Cremophor-
free, 130 nm colloidal nanoparticle suspension that has been developed to overcome the 
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limitations of single-agent paclitaxel involving its poor solubility and the solvent-associated 
toxicities (Cremophor in this case). In September 2013, Gemcitabine plus nab-paclitaxel 
became a first-line therapy for metastatic pancreatic cancer (MPC) following positive 
outcomes from a global phase III trial (MPACT). [37] 
 
Figure 1. 8 Diagram illustrating the nab-paclitaxel complex. Reproduced from ref [38] 
  
The intra-tumor drug delivery mechanism utilised the biological characteristic of albumin. 
Firstly, albumin attaches to the cell surface receptor gp60 and activates the intracellular 
protein caveolin-1, leading to the formation of vesicular structures. [39] Albumin-bound 
complexes are then transferred through these vesicles into the interstitial space. Secondly, 
due to the crucial role of secreted protein acidic and rich in cysteine (SPARC) as a high-
affinity receptor for albumin, albumin-bound complexes are likely to accumulate in SPARC-
positive areas of tumors. SPARC is over-expressed in the stroma of pancreatic tumours and 
this is the most likely reason for the enhanced activity of nab-paclitaxel when compared to 




Figure 1. 9 Mechanisms of drug delivery of nab-paxclitaxel. Reproduced from ref [40] 
 
1.2.3.2.3 FOLFIRINOX and Pancreatic Cancers 
Since the result of the PRODIGE 4/ACCORD 11 trial was published in 2011, the FOLFIRINOX 
regimen (combination of infusional 5-FU, leucovorin, irinotecan and oxaliplatin) has 
emerged as a new treatment for patients with metastatic pancreatic cancer. [41] The 
mechanism of 5-FU delivery and metabolism has already been described in section 1.2.3.2.1. 
Leucovorin or folinic acid, is a reduced form of folic acid and improves the effectiveness of 
5-FU chemotherapy. With regard to the platinum compound Oxaliplatin, the excision repair 
cross-complementing rodent repair deficiency, complementation group 1 (ERCC1) play a 
crucial role in elimination of damaged DNA involving nucleotide excision repair and thus are 
regarded as potential biomarkers.[42] For instance, Fuereder et al. investigated the activity 
and safety of GEMOX (gemcitabine/oxaliplatin combination alongside erlotinib) and 
correlated the benefit with ERCC1 expression. The data showed that patients with higher 
ERCC1 staining pattern received a therapeutic effect.[43] As for irinotecan, the irinotecan 
target topoisomerase-I (TOP1) and carboxyl esterase-2 (CES2) were evaluated potential 
biomarkers in pancreatic cancer cells.  For the former, a recent clinical study demonstrated 
that increased TOP1 copy number benefited the overall efficacy of irinotecan. [44] For the 
later, a more integrated study involving genetic analyses demonstrated that patients having 
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metastatic pancreatic cancer with over expression of CES2 had a better OS and PFS rates 
when treated with FOLFIRINOX. [45] 
 
Figure 1. 10  Mechanisms of action and metabolism of the drugs in the FOLFIRINOX regimens. Reproduced 
from ref [46] 
 
1.2.3.3 Management of chemotherapy to different patients based on the presentation of 
disease 
It is important that each patient is given an appropriate treatment for their particular 
condition, therefore pancreatic cancer is divided into three main presentation classes, which 
are surgically resectable, locally advanced and unresectable, or metastatic pancreatic cancer. 
[47] 
For surgically resectable pancreatic cancer, patients will normally first undergo Whipple’s 
surgery to remove the tumour and then treated with adjuvant chemotherapy as soon as 
they are well enough to tolerate all 6 cycles, usually in the form of gemcitabine plus 
capecitabine or 5-FU plus leucovorin. With regards to patients who are not well enough to 
tolerate combination chemotherapy, adjuvant gemcitabine is recommended as the standard 
treatment. [48] 
For locally advanced and unresectable pancreatic cancer, the recommended treatment is 
chemoradiotherapy using capecitabine as a radiosensitiser.[49] In addition, systemic 
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combination chemotherapy including FOLFIRINOX, gemcitabine plus nab-paclitaxel, or 
nanoliposomal irinotecan plus 5-fluorouracil and leucovorin is recommended to patients 
who are well enough to tolerate it. Adjuvant gemcitabine is recommended to patients who 
are not well enough to tolerate combination chemotherapy. 
As for metastatic pancreatic cancer, FOLFIRINOX is regarded as the first-line treatment to 
patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 
Gemcitabine combination therapy is recommended to patients who are not well enough to 
tolerate FOLFIRINOX. With regards to patients who are not well enough to tolerate 
combination chemotherapy, adjuvant gemcitabine is recommended as the first-line 
treatment. With regards to second-line treatment, oxaliplatin-based chemotherapy is 
recommended to patients who have not first-line oxaliplatin; gemcitabine-based 
chemotherapy is recommended to patients whose cancer sustains progress even after the 
first-line FOLFIRINOX treatment. 
 
1.3 Targeted Cancer Treatments 
1.3.1 Photodynamic therapy (PDT) 
Photodynamic Therapy (PDT) involves three specific components: (i) a photosensitiser drug 
(PS), (ii) molecular oxygen and (iii) light of a specific wavelength (Figure 1.11). Each 
component exhibits no cytotoxcity independently, however, when utilised in combination, 
highly reactive singlet oxygen (1O2) and other reactive oxygen species (ROS) are generated 
which can cause significant cytotoxicity leading to rapid cell death via apoptosis or necrosis.  
 
 




The photophysical processes involved in PDT are illustrated in Figure 1.12.[50] First, an 
electron in the photosensitiser is excited by a photon of light from the singlet ground state 
(S0) to the first excited singlet–state (S1), which is relatively short-lived. Then, there are two 
options for the electron. One is to return to the singlet ground state, emitting a photon of 
light, which is known as fluorescence. Alternatively, it can change its spin state and engage 
in inter-system crossing (ISC), converting to the relatively long-lived first excited triplet state 
(T1). There are also two options for the triplet state electron: (i) to drop back to the ground 
state causing emission of energy, known as phosphorescence or (ii) engage in 
photochemical reactions, which lead to the production reactive oxygen species (ROSs). 
There are two types of such photochemical reactions, Type I and Type II. In the Type I 
reaction, the electron interacts with a bio-molecule (or oxygen) resulting in electron transfer 
(re-dox) that leads to production of free radicals such as the hydroxyl radical and superoxide 
radical. In the Type II reaction, energy from the excited triplet state is transferred to the 
triplet ground state of molecular oxygen, which generates singlet oxygen. The products from 
both types of reaction are cytotoxic and cause cellular damage via oxidative stress. [51] 
 
 
Figure 1. 12 Modified Jablonski diagram outline the photophysical processes involved in PDT. Photophysical 
processes involved in photodynamic therapy: 1) absorption, 2) fluorescence, 3) internal conversion, 4) 
intersystem crossing, 5) phosphorescence, 6) formation of free radicals by energy transfer from T1 
photosensitiser to biological substrates, and 7) formation of singlet oxygen (1O2) by energy transfer from T1 




Although both type of reactions are responsible for the therapeutic effect observed in PDT, 
Type I reactions are dominant in hypoxic environments while Type II reactions are dominant 
in normoxic environments. [53] In most situations, singlet oxygen is the major product of 
PDT reaction amongst ROSs. Singlet oxygen is a potent cytotoxic agent due to its highly 
oxidative nature, participating in non-selective reactions with biological substrates such as 
lipids, proteins and DNA. [54] A key feature of singlet oxygen is that it has a short half-life, 
and therefore the diffusion distance from the treatment tumour area is limited. [55] For 
these reasons, singlet oxygen is an ideal anti-cancer therapeutic in combination with a 
controlled light source, as together they can significantly reduce any cytotoxic effect to 
healthy tissue. [56] 
It is also believed that PDT is responsible for activating the body’s antitumour immune 
system. [57] In contrast; most conventional treatments for cancers are non-selective killing 
a variety of cells, including bone marrow cells which are responsible for producing immune 
cells. PDT can activate B and T cells at the treatment site resulting in a positive immune 
response. [58] Therefore, the process of killing cancer cells via PDT can arouse the immune 
response, recruiting macrophages and dendritic cells to the site of treatment. Kamangar et 
al. reported an immune response aroused by PDT in both in vitro and in vivo experiments. 
[59] Therefore, PDT is a promising treatment as it can kill tumour cells in a specific area and 
can elicit an immune response in regions other than the treatment area. [60] 
However, a major restriction of PDT is its ability to treat deep-seated lesions due to the poor 
ability of light to penetrate tissue. Tissues transparency to light is related to the wavelength, 
with longer wavelengths being capable of deeper penetration (Figure 1.13). [61] The near-
infrared (NIR) region is where light has its maximum penetration through tissue with the 








Figure 1. 13 Schematic diagram representing how tissue depth penetration is wavelength dependent. 
Reproduced from ref [63] 
 
To be useful for clinical application in PDT, photosensitisers should absorb strongly in the 
photo-therapeutic window and possess a high singlet oxygen quantum yield. Unfortunately, 
currently approved photosensitisers are mostly activated using wavelengths in the visible 
region of the electromagnetic spectrum and thus exhibit low tissue penetration. To 
overcome this deficiency, a relatively new concept of two-photon excited (TPE) PDT was 
proposed. [64] This process involves the excitation of a fluorophore/sensitiser by two 
photons of long wavelength light by a femtosecond laser, which is of relatively low energy 
and induces the same excited state as one photon of shorter wavelength of light with high 
energy. However, currently utilised photosensitisers have low two-photon extinction 
coefficients and therefore require a high amount of energy for excitation. At such high 
energies resulting in photodamage to healthy tissue is problematic. [65] 
  
1.3.1.1 First Generation Photosensitisers 
Photofrin, a hematoporphyrin derivative (HpD) is regarded as the first PS developed for use 
in anti-cancer PDT treatment. It was first approved by Canada for treating bladder cancer 
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and later FDA approved for the treatment of esophageal cancer. Currently, Photofrin has 
been used in PDT treatment for a range of cancers including head & neck, skin, lung and 
intestinal cancer. [66] 
Hematoporphyrin (HP) was discovered by removing the red pigment in blood (Haem). HP is 
able to transform to HpD following treatment with 5% sulfuric acid in acetic acid to produce 
a mixture of porphyrin monomers, dimers and oligomers with ether, ester, and carbon-
carbon linkages. The purified Photofrin product is then extracted from HpD by removing the 
monomeric components. [67] 
 
Figure 1. 14 Structure of Photofrin 
 
The attraction of Photofrin as a PS include (1) a relatively high singlet oxygen quantum yield 
(Φ1O2 = 0.89) and (2) a favorable safety profile from various clinical trials. [68] In one clinical 
trial involving patients with cutaneous Kaposi’s sarcoma, Photofrin was administrated to 
patients at 2mg/kg plus light treatment 48h post infusion at a dose of 200-300 J/cm2. Due to 
its minimally-invasive nature and excellent tolerability, this trial proved PDT to be an 
attractive alternative to conventional chemotherapy treatment. [69] However, several 
deficiencies were identified that limited a more widespread application of PDT using 
Photofrin.  Firstly, the extinction coefficient at the longest wavelength Q-band of Photofrin 
is low (ε at 630 nm = 3000 M−1 cm−1), which restricted the Φ1O2 when excited at this 
wavelength. In addition, 630nm wavelength light has only moderate tissue penetration (2-3 
mm) making it difficult to treat larger or more deeply-seated lesions. Furthermore, the 
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multicomponent nature of the mixed dimers / oligomers is not ideal. Therefore, much 
development work continued to identify a better PS to replace Photofrin.  
 
1.3.1.2 Second Generation Photosensitisers 
The development of second generation PS aimed to improve on the main limitations of the 
first generation PS, mainly absorbance inefficiency and the mixed final product composition.   
To enhance absorbance efficiency for a better therapeutic effect, meta-tetra 
(hydroxyphenyl) porphyrin (m-THPP) was developed since the enhanced conjugation 
resulted in more desirable characteristics. [70] Berenbauml et al. demonstrated m-THPP was 
25 to 30 times as effective as HpD for PDT-induced tumour necrosis by measuring the depth 
of necrosis on slices of the fixed tumors after illumination. [71] However, the existence of 
skin hypersensitivity limited the employment of this agent into clinical use.  
 
Figure 1. 15 Structure of m-THPP 
 
Protoporphyrin IX (PPIX) is another typical second generation PS that was FDA approved for 
the PDT treatment of actinic keratosis in 1999. [72] This PS can also be metabolically 
generated from the pro-drug: 1, 5-aminolevulinic acid (ALA) by human cells. The bio-
synthetic process of converting ALA to PPIX is via the heme pathway as shown in scheme 1.1 
with excess ALA facilitating cellular PPIX accumulation since the final step to generate heme 
is limited via its slow conversion rate. As a result, a concentration gradient of PPIX is evident 
between neoplastic and healthy tissue. [73] Furthermore, as ALA is converted relatively 
slowly to PPIX (8-12h) skin photo-toxicity was greatly reduced. [74] Kennedy et al. were first 
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to demonstrate successful PDT treatment of skin malignancies via the transdermal 
application of ALA. [75] Subsequently, ALA has been widely used in anticancer therapy 
including skin, head and neck cancer, bladder cancer and prostate cancer despite its 
inefficient 1O2 generation at its Q-band excitation wavelength (635nm, ΦΔ = 0.56). [76] 
 
Figure 1. 16 Biosynthesis scheme for the conversion of ALA to PPIX. Reproduced from ref [72]. 
The discovery of the chlorin group of PS, including meta-tetra (hydroxyphenyl) chlorin (m-
THPC) and NPe6 that were derived from chlorophyll a, represented another step forward in 
the development of second generation PS. When compared to porphyrin based PS, a double 
bond on one pyrrole ring was saturated in the chlorins, leading to a significant bathochromic 
shift (from 640nm to 700nm) in the Q-band absorbance (Figure 1.17). [77] This variation also 
enabled enhanced singlet oxygen quantum yields (ΦΔ = 0.87) and much better extinction 
coefficient at the peak wavelength than in the porphyrins (εmax ~ 35000 M
−1 cm−1). [78] Due 
to the efficient singlet oxygen production, a reduced dose was required for PDT treatment 
and m-THPC was approved in Europe for treating head & neck cancer and further clinical 
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trials were conducted to investigate its antitumour effect on prostate, breast and pancreatic 
cancers. [79] The only significant deficiency associated with m-THPC was the long circulatory 
half-life increasing the likelihood of skin phototoxicity.  
 
Figure 1. 17 Transformation of m-THPC from m-THPP. Reproduced from ref [77]. 
NPe6, is another representative second generation PS from the chlorin family and is capable 
of excitation using a wavelength in the red region of the spectrum (664nm) with a high 
extinction co-efficient (ε= 40000 M−1 cm−1).[80] It also possesses minimal dark toxicity and 
skin phototoxicity owing to the fast systemic pharmacokinetics resulting in its quick 
elimination from the body. In a phase II clinical study, NPe6 was administrated IV at 40 
mg/m2 and following 4h light irradiation post injection at 100 J/cm2 almost 85% of patients 
with endobronchial lung cancer responded to the therapy. [81] Therefore in 2003, NPe6 was 
approved for treating lung cancer in Japan and also demonstrated potential for treating oral, 
brain and liver cancer. [82] 
 
 
Figure 1. 18 Structure of NPe6. 
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Table 1.1 various photosensitisers with specific wavelength, power output of light and duration. 
Photosensitisers Wavelength Light power Duration Reference 
Photofrin 630nm 200-300 J/cm2 3 hours [69] 
5-ALA 635nm 200-300 J/cm2 2 hours [76] 
m-THPC 652nm 200 J/cm2 2 hours [79] 
NPe6 664nm 100 J/cm2 4 hours [82] 
 
Even though most of PSs have been based on a porphyrin type structures, some non-
porphyrin related compounds have demonstrated promise as sensitisers for PDT. One such 
compound is the hydrophilic xanthene sensitiser Rose Bengal (RB).  Substitution of Xanthene 
ring hydrogen atoms in fluorescein to halogen atoms in Rose Bengal, significantly enhanced 
the intersystem crossing process via the “heavy atom effect” with a corresponding dramatic 
increase in singlet oxygen quantum yield (ΦΔ = 0.76). [83] In addition, RB also possessed a 
broad excitation band in the green region of the spectrum (480-550nm) with an excellent 
extinction co-efficient (εmax = 99,800 M
−1 cm−1 at 532nm). [84] For these reasons, RB is 
regarded as an efficient photosensitiser that has been applied for a variety of PDT 
applications. [85] 
 
Figure 1. 19  Structure of RB 
 
1.3.1.3 Third generation Photosensitisers 
Third generation PSs differ from their 1st and 2nd generation counterparts in that they 
contain a tumor- targeting characteristic which can be achieved via two main approaches: 1) 
the attachment of biomolecules such as monoclonal antibodies (mAB) to the PS or 2) 
encapsulation of PS into delivery vehicles that direct the PS to their targets. For the first 
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approach, advantage is taken of the unique surface antigens on tumor cells in comparison 
with normal cells, which will selectively attach to a corresponding antibody derivativised PS 
without influencing surrounding tissue. [86] The avidin-biotin interaction is one common 
method employed to link the mAB and PS, which ensures a high dose PS delivery to the 
targeted site resulting in an enhanced PDT effect. [87] Wöhrle et al. have demonstrated the 
successful binding and excellent therapeutic effect of this mAB-PS system via an enzyme-
linked immunosorbent assay (ELISA). Breast carcinoma cells and colon carcinoma cells were 
treated with biotinylated antibody, avidin and biotinylated zinc phthalocyanine PSs 
successively, followed by illumination for 30s at 5 J/cm2 using a red light source. The results 
showed that cell cytolysis occurred on 90% of the breast carcinoma cells and 45% of the 
colon carcinoma cells respectively.[87] For the second approach, adenovirus Type 2 capsid 
proteins were utilised to covalently attach to an AlPcS4 PS via an ester linkage. These 
proteins display high selectivity and strong association with integrin receptors 
overexpressed via various cancer types such as breast cancer and lung cancer. Although in 
vitro data was limited, in vivo studies using a breast cancer EMT-6 murine model 
demonstrated increased uptake of the adenovirus Type 2 protein labeled AlPcS4 compared 




1.3.2 Sonodynamic Therapy  
While the use of NIR-absorbing PS and two-photon excitation schemes enables potential 
sensitiser excitation in the phototherapeutic window, the penetration depths are still 
limited to about 1 cm. [89] In this context, alternative methods for sensitiser excitation have 
also been explored. One such approach is Sonodynamic Therapy (SDT). Like PDT, SDT 
requires the combination of three individual components to enable the generation of ROS. 
Typically, the same sensitiser is employed and molecular oxygen is also a mandatory 
component. However, while light is used to excite the sensitiser in PDT, this is replaced with 
low-intensity ultrasound in SDT. (Figure 1.20) Ultrasound is widely used as an economical 
and safe imaging modality [90][91] and unlike light, its penetration depth in soft tissue 
enables sensitiser excitation at depths of tens of centimeters enabling the possible 





Figure 1. 20  Essential elements for SDT process and the generation of cytotoxic reactive oxygen species.  
 
1.3.2.1 Basic physical principles of ultrasound 
Ultrasound comprises sound waves with frequencies greater than 20 kHz, which exceed the 
upper range of human hearing. An US wave is a type of mechanical energy, which is 
transferred through a medium by vibrating molecules. It can be sub-divided into two types 
of wave: the first is a longitudinal wave, which involves the oscillation of molecules in a 
linear direction (in mediums such as gases, liquids, or plasma). The second is a transverse 
wave, which involves the oscillation of molecules vertical to the direction of the transmitted 










Figure 1. 21 The illustration of (a) a longitudinal sound wave and (b) a transverse sound wave 
To better understand this process, a few parameters are used to describe the mechanism of 
how US waves propagates through tissue. The frequency (f) of an US wave includes the cycle 
number or the variation of pressure that occurs in one second. Frequency is not influenced 
by the medium which sound travels through but by the source generating US.  The velocity 
(v) of an US wave is defined as the speed at which sound can pass through the medium. 
Unlike frequency, velocity is only determined by features of the medium including density 
and compressibility. Wavelength (λ) is described as the distance between two identical 
points on the US wave. It is determined by the frequency and velocity of the US wave as 
described in Equation 1.1. 
 
λ= v/f                                                      (Equation 1.1) 
 
Equation 1.1 shows that the wavelength and frequency of US are inversely related. In 
practical applications such as improving resolution in diagnostic imaging and procedural US, 
it is crucial to select a suitable source frequency. Generally speaking, lower frequency waves 





deeper tissues. In contrast, a higher axial resolution image can be generated by higher 
frequency waves. For this reason, it is ideal to apply high-frequency sources to image 
superficial structures (such as for stellate ganglion blocks). [93] 
 
Figure 1. 22 A comparison of the resolution and penetration of various ultrasound frequencies. 
 
For the ultrasound mediated SDT, the frequency used is typically in the region of 1-2 MHz. 
[94] Two further important characteristics of the ultrasound used in SDT are intensity and 
duty cycle. The intensity (power) of ultrasound is calculated in W/cm2 and determines the 
strength grade of the energy from this sound wave. Intensity is crucial when discussing 
bioeffects and safety, which varies in diagnostic ultrasound since it's highest at the center of 
the beam and falls off near the periphery. It also varies along direction of travel due to 
focusing and attenuation. Spatial Peak (SP) and Spatial Average (SA) intensity are used to 
describe the peak intensity and the average intensity of the ultrasound output over of the 
area of the transducer respectively. 
 




In pulsed ultrasound, intensity varies with time: it's zero between pulses and greater than 
zero during each pulse. Temporal peak (TP) is the greatest intensity found during a pulse, 
while temporal average (TA) includes the "dead" time between pulses. The pulse average 
(PA) is in between for a given pulse beam. PA and TA are related by the duty cycle and the 
duty cycle is measured as a percentage of the time in which the ultrasound is applied over 
the cumulative time of the treatment. This function is able to limit temperature increase in 
heat-sensitive applications. [95] 
 
Figure 1. 24  Schematic diagram to describe US pressure and intensity metrics in pulsed ultrasound. 
Reproduced from ref [96] 
 
1.3.2.2 Mechensim of ROS generation in SDT. 
While the mechanism for ROS generation in PDT is well understood at the molecular level, 
the mechanism for its generation following ultrasound irradiation in SDT is less clear.  A 
unique phenomenon called “cavitation” occurs when ultrasound interacts with an aqueous 
environment, where gas filled bubbles undergo a series of processes including their 
generation, expansion and collapse. Stable and inertial cavitations are terms applied to 
further subdivide this phenomenon. Stable cavitation leads to the generation of bubbles, 
which carries on oscillating and consequently stirring the surrounding media. Inertial 
cavitation is when the cavitation bubbles grow to a resonance size, before collapsing 
violently. The energy released by collapsing bubbles can transfer into extreme high 
temperature and pressure, which can reach up to 10,000K and 81MPa respectively. [97] 
These extreme micro-environmental conditions have been described as a “sonochemical 
reactor” [98] and forms the basis for the two main theories for ROS generation in SDT: 
sonoluminescence and pyrolysis.  
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Sonoluminescence is the process of light generation following ultrasound irradiation of a 
solution. Pickworth et al. have confirmed this light production by utilizing a photomultiplier 
tube and processing through pulse height analysis.[99] It has been suggested that the 
sonoluminescence generated from the process of cavitation [100] is then capable of 
activating sensitisers in a similar way as in PDT. The second theory of pyrolysis suggests that 
the sonochemcial reactor type conditions experienced by a sensitiser in the vicinity of 
bubble undergoing inertial cavitation results in sensitiser pyrolysis liberating reactive free 
radicals that subsequently react with surrounding endogenous substrates to generate ROS. 
[101] Mi   k et al have attempted to prove this theory and confirmed the production of free 
radicals through the application of electron paramagnetic resonance (EPR). They also 
investigated that these free radicals play a great role in the water dissociation to generate 
hydroxyl radicals and hydrogen peroxide. [102]  
Although neither mechanism has a substantial body of evidence as support, numerous 
studies are available to confirm that the irradiation of sensitisers with low-intensity 
ultrasound generates ROS with a corresponding cytotoxic effect. [103-105] However, given 
the exact mechanism of SDT remains uncertain, it is difficult to identify the ideal structure or 
characteristics of the sensitiser for optimum SDT efficiency. Despite this, various different 
photosensitisers, including porphyrins and xanthene derivatives, have also been identified 
as capable of generating ROS upon low intensity ultrasound irradiation and used as 
sonosensitisers in SDT.  Some examples of SDT anticancer treatment are provided below.   
 
1.3.2.3 SDT as an anti-cancer treatment. 
A pioneering study by Umemura et al. in 1999 demonstrated a significant 96% reduction in 
cell viability of sarcoma 180 after 60s US exposure (1 MHz, 5.9 W/cm2) in the presence of 
160 μM RB, while RB alone had only a minor effect. [106] A further study involving mice 
bearing intracranial glioma tumours treated with focused ultrasound at 25 W/cm2 (1 MHz) 
for 5min and Rose Bengal (50 mg/kg of body weight) resulted in a 80% reduction in tumor 
volume compared to untreated mice, without affecting surrounding brain tissues. [107] 
Although RB has attracted a significant amount of attention as a sonosensitiser, due to its 
hydrophilic nature, it suffered from a low accumulation capacity at the tumor region that 
seriously restricted its further development with regard to clinical use. When RB is delivered 
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via IV administration into systemic circulation, it is rapidly eliminated from the blood 
circulation and expelled through bile. [108] To overcome this deficiency, a series of 
amphiphilic RB derivatives were synthesised by adding a carboxyl group or alkyl chain to 
modify the structure as shown in Figure 1.25.  The tumor uptake capability of RBD1 was 
evaluated in colon 26 carcinoma mice model and results demonstrated a much better 
uptake in tumor tissue compared to non-tumor tissue, which indicated that tumor 
accumulation and SDT anticancer efficiency can be enhanced via the suitable structural 
modification of sonosensitisers. [109] Previous work by Nomikou et al has also investigated 
covalently attaching RBD2 to lipid microbubbles and observed an ultrasound-induced 
anticancer effect in RIF-1 cells in vitro. In vivo data also demonstrated a dramatic reduction 
in tumor growth via the combination of the conjugate and ultrasound but no effect on 
tumor growth in the absence of the ultrasound stimulus in mice bearing prostate LNCaP-Luc 
tumours. [110] 
 
Figure 1. 25 Structure of RB derivatives. Reproduced from ref [109] 
 
As porphyrins represented the earliest class of photosensitisers used in PDT, it is no surprise 
they have also been investigated for use in SDT, with photofrin, HP and PPIX being proven 




Figure 1. 26 Chemical Structure of some selected HP derivatives including Hematoporphyrin monomethyl 
ether (HMME), DCPH-P-Na(I) and ATX-70.  
 
Hematoporphyrin monomethyl ether (HMME) is a recently developed HP derivative with 
the ability to selectively accumulate in cancer cells, is nontoxic in the absence of ultrasound 
and is rapidly metabolised by the body. Previous in vitro studies demonstrated that HMME 
(10 µg/mL, incubated in dark for 2 h) exhibited significant cytotoxicity on C6 glioma cells 
following ultrasound irradiation (1.0 MHz and 0.5 W/cm2 for 2 min) and SDT induced cell 
apoptosis and necrosis was also observed as a result of ROS generation. [111][112] 
Furthermore, gene expression analysis indicated that HMME-mediated SDT treatment 
resulted in down-regulation of Bcl-2 expression, which is involved in the apoptotic signalling 
pathway. [113] Moreover, SDT mediated treatment of osteosarcoma in rats using HMME 
(20 mg/kg, IV) and ultrasound radiation (10.5 MHz) for 120 seconds at an intensity of 0.8 
W/cm2 demonstrating a significant 48.9% inhibitory rates of tumour volume compared to 
animals treated with drug or ultrasound alone. [114] 
The previously mentioned porphyrin derivatised DCPH-P-Na(I), has also demonstrated 
effective SDT mediated toxicity against a panel of human cancer cells (including human lung 
cancer cell lines, LU65A, RERFLC-KJ, HLC-1, VMRC, and KNS-62, human gastric cancer cell 
lines, MKN-1, MKN-28, MKN-45, MKN-74, and KATO-III, a human pancreas cell line, QGP-1, 
and a human prostate cancer cell line, PC-3) in vitro. [94] Furthermore, it was suggested that 
its effective SDT efficacy was derived from ROS generation since the DCPH-P-Na (I) mediated 
SDT effect was drastically decreased upon the addition of L-histidine as a scavenger of ROS. 
In addition, efficient tumor growth inhibition was observed in MKN-45 tumor bearing mice, 
when tumours were exposed for 10 min to ultrasound at 1 MHz, 2 W/cm2, 50 % duty cycle 
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following IV injection of DCPH-P-Na(I) (14.4 μg/kg). [94] These results suggested that DCPH-
P-Na(I) mediated SDT had great potential for use in the clinical treatment of cancer located 
too deep to be treated utilising regular PDT.  
In another study by Nakajima et al., it was demonstrated that a high concentration of the 
sonosensitiser ATX-70 is capable of accumulating in nitrosoamine-induced pancreatic 
tumours. [115] Pharmacokinetics and tissue distribution studies showed that 24h after drug 
administration the concentration ratio of tumor against plasma reached its peak value, 
indicating the optimal treatment time. [116] Furthermore, the potential ultrasound 
mediated effect of ATX-70 was investigated by Umemura et al. and the results showed that 
the damage on isolated mouse sarcoma 180 cells in air-saturated suspension was enhanced 
fourfold by ATX-70, compared to only twofold by the same concentration of HP upon 
ultrasound irradiation. [117] In vivo data was also impressive and suggested that the 
antitumor effect of ATX-70 was dramatically enhanced with an increasing dose of ATX-70 in 
combination with ultrasound exposure, while no obvious antitumor effect was observed for 
tumors treated with ultrasound or the drugs alone. [118] While still a relatively new area, 
the interested reader is directed to several prominent reviews on the efficacy of SDT as an 
anticancer treatment. [119][120][121] 
 
1.4 Drug delivery system 
1.4.1 Microbubbles as drug delivery vehicles 
Microbubbles (MBs) comprise a core-shell structure with a gas core covered by a coating 
involving lipids, proteins or polymers. This coating influences the half-life of microbubbles 
and prevents the gas from escaping. [122] MBs have been widely employed in diagnostic 
imaging as contrast agents. The principle of this application is to make use of the large 
acoustic impedance difference between MBs and surrounding tissues to generate nonlinear 
acoustic radiation under moderate ultrasound intensities, therefore the images can provide 
contrast enhancement via MBs at the target region. [123] 
Furthermore, MBs have been investigated as delivery vehicles through attachment of 
therapeutic agents into or on the MBs shell and subsequently destructing the MB using US 
to liberate the drugs at a target region. [124] The targeted destruction of the MBs means a 
31 
 
local release of the drugs at the target site reducing exposure in non-targeted tissue. This is 
particularly relevant when cytotoxic drugs are involved and can reduce side effects 
associated with treatment. In addition, microsteaming and microjetting effects as a result of 
MB cavitation can enhance drug diffusion through tumor tissue. [125] Furthermore, several 
biodegradable agents such as proteins and nucleic acids may avoid decomposing 
prematurely in the systemic clearance by incorporation into the shell of microbubbles.[126] 
Finally, drug-carrying microbubbles enables drug delivery to be tracked via ultrasound 
imaging if necessary. [127] 
1.4.2. Ultrasound-targeted microbubble destruction (UTMD) as a drug-delivery strategy. 
Several methods have been investigated to deal with the conjugation of drugs to 
microbubbles as shown in Figure 1.27. Drugs can be attached not only (a) inside the shell via 
dissolving in the oil phase, (b) in the shell via filling the shell gap but also outside the shell 
via (c) electrostatic, covalent and non-covalent interactions or (d) the avidin-biotin linking. 
 
Figure 1. 27  Schematic diagram of potential conjugation of drugs with microbubbles involving (a) inside the 
shell, (b) in the shell but also outside the shell via (c) electrostatic, covalent and non-covalent interactions or 
(d) the avidin-biotin linking. Reproduced from ref[124] 
Similar to film coated tablets or capsules, microbubbles are able to absorb drugs inside the 
shell to protect the therapeutic drugs from untimely decomposition. Unger et al. has 
investigated microbubbles containing acoustically active lipospheres (AALS), which involves 
a drug loaded oil phase acting as the intermediate layer between the gaseous core and lipid 
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shell. [124] This approach enabled a hundred times higher dosage of the paclitaxel (PTX) to 
be loaded in the oil phase when compared the standard IV injection. However, 
Shortencarier et al’s study have shown that AALS microbubbles are harder to destruct (burst) 
compared to normal lipid MBs due to their thick shells reducing the efficacy of cavitation. 
[128] 
Another pathway to protect drugs from degradation is to incorporate therapeutic agents in 
the microbubble shell. Frenkel et al. investigated a type of plasmid DNA (pDNA) carrying 
albumin microbubbles, which verified the existence of pDNA in the microbubble shell via 
tracking the propidium iodide labeled pDNA. Furthermore, they showed that the 
transfection efficacy of pDNA carrying microbubbles was significantly higher than a simple 
mixture of pDNA and albumin microbubbles. [129] Nevertheless, Klibanov et al reported 
that this type of negative charged MBs had a shorter half-life time and easily attached to the 
positive charged blood components leading to the premature release of agents. [122] 
Electrostatic interaction is a convenient method for the attachment of charged therapeutic 
agents to the surface of MBs. DNA, as a polyanion with several negative charged sugar 
phosphate fragments, can be readily attached to the cationic microbubbles. In 1996, Kim et 
al. administrated pDNA attached to albumin microbubbles into murine knees and 
demonstrated an enhancement in the transfection rate of DNA under ultrasound excitation. 
[130] Borden et al had further optimised this type of MBs with increased drug loading by 
incorporating an extra cationic polymer layer on the MBs. [131] This modification not only 
improved the limited loading on the MBs’ shell but also minimises the gas diffusion and 
subsequently enhanced the stability of MBs. On the other hand, the strong interaction 
between pDNA and cationic lipids on the shell may lead to the aggregation of rather large 
particles during MBs collapse. The size of these aggregates can be too large to pass through 
cell membrane and therefore decreased the transcription efficiency of the binding DNA. 
[132] 
Avidin-biotin interactions provide another method for the attachment of drugs to the MB 
shell via non-covalent interactions. In brief, biotinylated lipids such as DSPE-PEG-biotin 
constitute the lipid shell of microbubbles, avidin is then added as a cross-linker molecule 
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and eventually a biotinylated drug moiety is incorporated to form a biotin-avidin-biotin 
complex. (Figure 1.28) 
 
Figure 1. 28  Schematic diagram of a biotinylated MBs loading nanoparticles. Reproduced from ref [133] 
Avidin is a type of functional protein extracted from the egg white of oviparous vertebrates. 
Biotin has high affinity for avidin (Kd of 10
-13 to 10-15 M) and has only a minor effect on the 
host immune system. [134] Moreover, the separation half-life (T1/2) of avidin-biotin bridges 
lasts for up to three months. [133] Lum et al. were the first to investigate biotinylated MBs 
bound with avidinylated polystyrene globules. [135] Biotinylated liposomes have also been 
successfully attached to biotinylated MBs by adding excess avidin as cross-linker, which 
resulted in approximately 105 liposomes bound to each MB. [136] Moreover, liposomes are 
well-established as drug delivery carriers for several decades. Due to their particular 
structure (containing a bilayer coating exterior and hydrophilic core), hydrophobic, 
hydrophilic and amphiphilic drugs can all be loaded into liposomes.  Furthermore, there was 
no noticeable reduction in MB cavitation upon ultrasound excitation following attachment 
to liposomes or polystyrene beads. [135]  
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1.4.3 UTMD and SDT 
In 2011, McCaughan et al. demonstrated that two conventional photosensitising drugs, 
methylene blue (MB) and RB activated by light can be activated by ultrasound and were able 
to generate higher levels of ROS and lower LD50 values in chinese hamster ovarian cells 
than either light or ultrasound activation alone. [137] In 2012, since RB was a promising 
sonosensitiser, it was successfully attached to the surface of a lipid stabilised MB using a 
carbodiimide based coupling protocol and the resulting conjugate produced more singlet 
oxygen and was more effective in vitro and in vivo than the sensitiser alone at the same 
concentration. [110] However, these lipid MB conjugates displayed poor physical stability 
limiting their potential translation to the clinic. Hence, PLGA MBs were also investigated as 
an alternative to lipid MBs for the delivery of sensitisers in SDT. [138] PLGA MBs have 
significantly better stability at fridge and body temperature than lipid MBs. In addition, they 
still undergo ultrasound-induced destruction at therapeutically acceptable ultrasound 
intensities ensuring their capability as a targeted delivery vehicle. [138] When these MBs 
conjugated to a rose Bengal sensitiser, the resulting constructs demonstrated selective 
cytotoxicity while treating a HeLa cancer cell line in vitro and human xenograft pancreatic 
tumors in vivo. Therefore, PLGA MBs appear as promising candidates for use with 
conventional sensitizing drugs to provide a minimally invasive targeted treatment of cancer 
using SDT. Nevertheless, PLGA MBs are not FDA approved which limits their potential 
translation to the clinic. [138] In 2015, to test the potential SDT effect in a simulated tumor 
environment, McEwan et al. have synthesised oxygen loaded MBs attached to a Rose Bengal 
sensitiser via an avidin-biotin linkage. [139] This approach was successful in generating 
significantly more singlet oxygen in a simulated hypoxic environment than similar 
conjugates loaded with SF6 as the core gas. Moreover, a greater cytotoxic effect was 
observed when BxPc-3 cells, cultured in a hypoxic environment, were treated with the 
oxygen loaded MB conjugate and ultrasound compared to cells cultured under similar 
conditions and treated with the SF6 loaed MB conjugate and ultrasound. Finally, mice 
bearing human xenograft pancreatic BxPc-3 tumours treated with the oxygen loaded MB 
conjugate and ultrasound showed a 45% reduction in tumour volume five days after 
treatment while the volume of tumours in mice treated only with the conjugate increased 
by 180 % over the same time period. Overall these results demonstrate that SDT may be 
significantly enhanced by incorporating an approach that involves ultrasound- and 
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microbubble-mediated delivery of oxygen to hypoxic tumours. This approach could provide 
the basis for less invasive treatment of more deeply-seated lesions, together with 
addressing hypoxia which limits sensitiser-based approaches and is associated with less 
favorable prognoses. It also provides the basis for a novel treatment option for pancreatic 
cancer which is perhaps one of the most recalcitrant forms of cancer and where existing 
therapeutic options are extremely limited. [139] In 2016, McEwan et al. prepared a biotin-
5FU derivative suitable for attachment to the surface of a platform consisting of avidin-
functionalised MBs filled with O2 gas. [140] The MBs were shown to be more stable with 
respect to oxygen retention when compared to their earlier MB. Further experiments 
demonstrated that combining sonodynamic and antimetabolite therapy using the O2MB 
conjugates provided enhanced cytotoxicity in three different pancreatic cancer cell lines 
cultured under anaerobic conditions when compared with cytotoxicity yielded by either 
treatment alone. Similarly, treatment of ectopic BxPc-3 tumors with the combined therapy 
led to a statistically significant reduction in tumor volume when compared with the efficacy 
of either therapy alone. These results suggest that combined sonodynamic and 
antimetabolite therapy using ultrasound-responsive O2MBs could provide a promising 
alternative to chemotherapy for the treatment of locally advanced pancreatic cancer and 
could also be effective as a neo-adjuvant therapy. Furthermore, it is shown that the avidin-
functionalised MB platform is an effective vehicle for the targeted delivery of biotinylated 
payloads to ectopic BxPc-3 tumours upon application of externally applied ultrasound. In 
addition, as the first study characterising the effect of SDT at the molecular genetic level, 
the results have shown that this treatment approach has an effect on the expression of 
immune-associated signaling pathways. [140] 
 
1.4.4 UTMD using magnetic microbubbles  
Yang et al. were the first to produce a type of lipid-stabilised microbubbles loaded with 
superparamagnetic iron oxide nanoparticles (SPION) for image contrast enhancement. 
[141]The SPION MBs demonstrated a dramatic improvement in MRI image contrast 
compared to SPION alone. Park et al further developed this type of MBs with various kinds 




MagMBs for ultrasound-mediated delivery was first conceptualised by Stride et al. [143] In 
this study, the shell of MBs consisted of multilayer material, where the gas core was covered 
with an iron oxide fluid and the outer layer comprised a L-α-phosphatidylcholine surfactant. 
(Figure1.29) 
 
Figure 1. 29  Schematic diagram of MagMBs. Reproduced from ref [143] 
The transfection efficiency of this type of MagMBs in the absence or presence of magnetic 
or ultrasound fields were further investigated in vitro. pDNAs inserted with luciferase were 
incorporated into each MB and the bioluminescence intensity was tested for each sample. 
The results demonstrated that samples treated with both ultrasound and magnetic fields 
revealed a dramatic enhancement in DNA transfection while treatment with US or magnetic 
fields alone had little impact on the improvement of transfection. [143] This approach was 
also tested in vivo in a murine model, and the results again demonstrated that the strongest 
bioluminescence signal was observed when both the ultrasound and magnetic fields were 
applied together. [144] Although MagMBs for ultrasound-mediated delivery seems to be a 
promising pathway for clinical use, there remains a question of whether the localization of 
MagMBs will be affected by the distance between magnet and target tissue. As a reference, 
an in vivo study has revealed that localization of magnetic microparticles can be achieved 




1.5 Improving tumour oxygenation to facilitate PDT and SDT 
Both PDT and SDT require O2 to exert their therapeutic effect. Several strategies have been 
investigated to improve oxygenation of tissues during therapy and each will be discussed in 
turn. 
1.5.1 Hyperbaric oxygen therapy 
Hyperbaric oxygen therapy (HBO) is described as a therapy in which 100 % oxygen is 
administered to patients via a face-mask or endotracheal tube. It has been recommended 
and applied for a variety of medical conditions such as in decompression sickness and air 
embolism. [146] The mechanism of HBO is not fully understood but is associated with gas 
laws, the physiological and biochemical effects of hyperoxia on the basis of previous studies. 
According to Boyle’s law, the pressure and volume of gas are inversely proportional when 
the temperature is constant, which is the foundation for many aspects of hyperbaric 
therapy including a temperature increase during treatment. [146] According to Henry’s law, 
the amount of a given gas that dissolves in a given type and volume of liquid is directly 
proportional to the partial pressure of that gas in equilibrium with that liquid, which is the 
basis for increased tissue oxygen tensions with HBO treatment. [147] For instance, tissue 
oxygen tension is only 55 mmHg when breathing normobaric air but increased to 500mmHg 
when breathing 100% oxygen at threefold atmosphere absolute, providing a 20 fold 
increase of oxygen level dissolved in blood. [148] However, HBO increases generation of 
oxygen free radicals, which oxidise proteins and membrane lipids, damage DNA and inhibit 
bacterial metabolic functions. HBO is particularly effective against anaerobes, and facilitates 
the oxygen-dependent peroxidase system by which leukocytes kill bacteria. HBO also 
improves the oxygen-dependent transport of certain antibiotics across bacterial cell walls. 
[149] 
Current cancer therapy approaches that attempt to address hypoxia and enhance therapy 
include hyperbaric oxygen or carbogen breathing and the use of electronic affinic radio- or 
chemosensitisers (e.g. nitroimidazol compounds). [150] Patients have been treated with 
hyperbaric oxygen or carbogen in attempts to enhance tumour oxygenation.  However, 
these depend on respiratory function, which can sometimes be compromised in elderly or 
weaker individuals.  In addition, breathing pure oxygen has been shown to result in adverse 
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effects with unwanted oxidative events in off-target tissues. Therefore, these therapies have 
had very limited success. [151] Furthermore, the cost of HBO is quite high and not 
universally available. Therefore, further study is necessary to establish its safety and efficacy 
in clinical conditions. 
1.5.2 Oxygen diffusion enhancers 
Diffusion plays a key role in transferring small molecules such as oxygen in blood circulation. 
Furthermore, the diffusivity of oxygen is further challenged when oxygen consumption 
reaches a high level in situations such as shock or anoxia. [152] Enhancing the diffusivity of 
oxygen in hypoxic cells and tissues has been suggested as a potential route to overcome 
severe hypoxia in PDT treatments. 
Trans-sodium crocetinate (TSC) is a carotenoid compound which owes its ability to enhance 
tissue oxygen levels by promoting diffusivity of oxygen and glucose in treated tissue.[153]  
The compound has a novel mechanism of action, first proposed in the 1970s by Professor 
John Gainer, and has recently become better understood.  The diffusion coefficients of 
glucose and oxygen tested in water using various TSC concentrations are shown in Figure 
1.29. Although a big difference exists with the diffusion coefficient of oxygen in water 
compared to that of glucose in water, when the TSC concentration is over 5μM, the 
diffusivities of both solutions increase by 30 % in the presence of TSC. This suggests that TSC 
does affect oxygen or glucose diffusion indirectly. Nevertheless, hydrogen bonding of 
neighbouring water molecules is increased by TSC, a mechanism known as “structure-
building,” which decreases the hindrance of molecules such as oxygen and glucose. [154] 
Early studies with TSC involved the treatment of hemorrhagic shock in both rats and pigs. 
[155] For example, one study showed that TSC was capable of promoting survival in rats 
breathing 10% oxygen. TSC also was able to increase arterial pO2 values in a rat model of 





Figure 1. 30  Plot of increase of diffusivity of glucose and oxygen in TSC-water solution upon various loading of 
TSC. Reproduced from ref [155] 
1.5.3 Oxygen generating nanoparticles 
One strategy for the generation of molecular oxygen is via the hydrolytic decomposition of 
solid peroxides, e.g. calcium or magnesium peroxide, which occurs according to Equation 
1.2. [157] The reaction between calcium peroxide with water first produces hydrogen 
peroxide (H2O2) which then subsequently decomposes to molecular oxygen and water.  
 
2CaO2 + 4H2O → 2Ca(OH)2+2H2O2→ 2Ca(OH)2+ 2H2O+O2   Equation 1.2 
 
When compared to other solid peroxides such as BaO2, CaO2 has several advantages: 1) It 
possesses a higher aqueous solubility and consequently faster reaction rate with water than 
other solid peroxides; 2) CaO2 is easy to synthesise with high yield and purity. 3) CaO2 
powder is relatively inexpensive. [158] [159] However, the maximum rate of the 
decomposition reaction is dependent on particle size with smaller particles reacting faster 
than larger particles by virtue of their greater surface area. When CaO2 is synthesised in 
nanoparticulate form, the surface area increases dramatically and thus increases the rate of 






1.6 Aims and Objectives 
The major aim of the work conducted in this thesis was to develop approaches for enhanced 
PDT or SDT efficacy in pancreatic tumors. This involved the optimization and evaluation of 
oxygen carrying microbubbles or magnetically responsive microbubbles as delivery vehicles 
for sonodynamic and antimetabolite therapy of pancreatic cancer (Chapter 3-4) and 
investigating the effect of oxygen generating nanoparticles for improved photodynamic 
therapy of pancreatic cancer. (Chapter 5) 
 
1.6.1 Optimisation and Safety Evaluation of Oxygen carrying microbubbles as delivery 
vehicles for combined sonodynamic and antimetabolite therapy.  
The main aim for the work undertaken in Chapter 3 was to determine whether combined 
SDT / gemcitabine treatment, using intravenously delivered oxygen carrying lipid stabilised 
microbubbles as delivery vehicle, can provide a significant reduction in the volume of Mia-
PaCa-2 tumours compared to SDT or gemcitabine treatment alone and cause no significant 
toxicity to healthy non-tumour bearing mice. 
 
1.6.2 Magnetically Responsive Microbubbles as Delivery Vehicles for Targeted 
Sonodynamic and Antimetabolite Therapy of Pancreatic Cancer 
The main aim of the work undertaken in Chapter 4 was to evaluate whether external 
magnetic and low-intensity ultrasound fields can enhance the efficacy of combined 
antimetabolite / sonodynamic therapy, delivered using magnetically responsive 
microbubbles, in an orthotopic murine model of pancreatic cancer. 
 
1.6.3 Oxygen Generating Nanoparticles for Improved Photodynamic Therapy of Hypoxic 
Tumours 
The main aim of the work undertaken in Chapter 5 was to prepare and characterise CaO2 
NPs capable of oxygen generation upon decomposition in water. A pH-responsive 
methacrylate based terpolymer was also synthesised, characterised and used to coat the 
CaO2 NPs. The ability of the particles to improve oxygenation in hypoxic environments and 
enhance PDT-mediated treatment was also evaluated using BxPc-3 pancreatic cancer cells in 























2 Materials and Methods 
2.1 Reagents and Materials:  
Chemicals were purchased from commercial sources at the highest possible grade. Panc-1, 
BxPc-3 and Mia Paca-2 cells were obtained from the American Type Culture Collection (ATCC) 
and matrigel from BD Biosciences, Erembodegem, Belgium. SCID mice (C.B-17/IcrHanHsd-
PrkdcSCID) were bred in house. SPION was generously supplied from the Stride research 
group, Institute of Biomedical Engineering, University of Oxford. MBs were formed using a 
Microson ultrasonic cell disruptor, 100 W, 22.5 kHz, from Misonix Inc. (NY, USA). Optical 
microscope images were obtained using a Leica DM500 optical microscope. MB 
concentration and size were determined using purpose-written MATLAB software (2010B, 
MathWorks, Natick, MA, USA). Scanning electron microscopy (SEM) analysis was conducted 
using an “FEI Quanta”scanning electron microscope while dynamic light scattering (DLS) 
measurements were performed using a Malvern Zetasizer 3000HSA (Malvern, Worcs., UK). 
Dissolved oxygen measurements were recorded using a Thermo Scientific™ DO Probe 
Orion™ 083005MD (Fisher Scientific, Ottawa, ON, Canada) while nanoparticle solutions were 
mixed using a Silverson homogeniser (Silverson Machines Ltd., Chesham, U.K.). UV-Vis 
spectra were recorded with a Varian Cary spectrometer, using quartz cells with a path length 
of 1cm. Fluorescence measurements were undertaken using a Cary Eclipse 
spectrophotometer in aerated solutions with slits = 5 nm while 96 well plates were analysed 
using a Fluostar Omega plate reader. Tumour pO2 measurements were performed using an 
Oxylite oxygen electrode sensor (Oxford Optronics, Oxford, UK). NMR spectra were obtained 
on Varian 500 MHz instrument at 25.0 ± 1 °C and processed using Bruker software. Mass 
spectra were obtained using a Finnegan LCQ-MS instrument. HPLC analysis was carried out 
on a Shimadzu LC-8 preparative pump system (Shimadzu Corp., Kyoto, Japan). Error in 
measurements was expressed as % standard error of the mean while statistical analysis was 
undertaken using 2-tailed Students t-test. 
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2.2. Preparation of biotinylated Rose Bengal, biotinylated 5-FU and biotinylated 
Gemcitabine 
2.2.1. Synthesis of alcohol-functionalised biotin derivative (2)  N-(2-hydroxyethyl)-5-(2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide: To an ice-cooled solution of 
biotin-N-hydroxysuccinimide ester  (prepared by the reaction between biotin and 
Di(Nsuccinimidyl)carbonate), (3.75 g, 11 mmol) in anhydrous DMF (40 mL), was added 2-
aminoethanol (1.0 ml, 16.4 mmol) and the mixture stirred at 25 °C for 30 min. The reaction 
was monitored by thin layer chromatography (TLC) (Merck Silica 60, HF 254, 20:80 
methanol-dichloromethane v/v). The biotin-Nhydroxysuccinimide ester (Rf = 0.76) was 
consumed within 15 min with the concomitant formation of the alcohol product (Rf = 0.47). 
The reaction mixture was concentrated under reduced pressure and the residue co-
evaporated with DMF to remove excess amounts of 2-aminoethanol. The white residue was 
recrystallised from water to yield 2 as a light yellow solid (1.7 g, 38%). An analytical sample 
was obtained from a second recrystallization, m.p. 192-195 °C, 1H NMR (500 MHz, D2O) 
4.49-4.47 (m, 1H, -CH), 4.31-4.30 (m, 1H, -CH), 3.53-3.51 (m, 2H, CH2), 3.23-3.18 (m, 3H, CH 
and CH2), 2.85-2.64 (m, 2H, CH2), 2.15 (t, 2H, -CH2), 1.62-1.46 (m, 4H, CH2 X 2), 1.32-1.26 (m, 
2H, CH2). 
13C NMR (125 MHz, D2O) 177.09 (C=O), 61.98 (CH2), 60.19 (CH), 59.91 (CH), 55.24 
(CH), 41.29 (CH2), 39.61 (CH2), 35.42 (CH2), 27.77 (CH2), 27.56 (CH2), 25.02 (CH2). ESMS 
(M+H+): found 288.70, calculated for C12H21N3O3S = 287.13. 
2.2.2. Synthesis of Biotin-Gem conjugate (5) (2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-
yl)-4,4-difluoro-3 hydroxytetrahydrofuran-2-yl)methyl (2-(5-(2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamido)ethyl) carbonate): The synthesis of intermediate 2 has been 
described in section 2.2.1. To a DCM (10 mL) solution of 2 (0.28g, 0.9 mmol), 4-nitrophenyl 
chloroformate (0.59g, 2.9 mmol), DIPEA (0.50g, 3.9 mmol) and a catalytic amount of 
pyridine were added at 0oC and then stirred for 24 hrs at 18oC.  The reaction mixture was 
then concentrated to dryness and the crude residue containing 3 dissolved in 20 mL of DMF.  
To this solution, Gem (0.88g, 2.9 mmol) in DMF (5 mL) and TEA (1 mL) were added and the 
mixture stirred for a further 24 hrs at 18 oC.  After completion of reaction (monitored by 
TLC), excess diethyl ether (200 mL) was added to the reaction mixture and stirred for further 
45 min at 18oC.  The yellowish oil obtained was separated and washed three times with cold 
44 
 
diethyl ether (50 mL x 3). The crude compound was purified by preparative TLC using DCM / 
MeOH (9 : 1) as eluent to afford the target compound 5 (0.12g, 22% yield). 1H NMR, 500MHz 
(DMSO-d6): δ 7.99-7.91 (m, 3H, CH, NH2), 6.41-6.33 (m, 1H, CH), 6.12-6.01 (m, 3H, CH, NH X 
2), 4.30-4.16 (m, 1H, CH), 4.19-4.12 (m, 3H, CH, CH2), 3.90-3.75 (m, 2H, CH2), 3.69-3.58 (m, 
2H, CH2), 3.12-3.09 (m, 1H, CH), 2.93-2.88 (m, 2H, CH2), 2.83 (brs, 1H, OH), 2.82-2.77 (m, 2H, 
CH X2), 2.72 (brs, 1H, NH),2.49-2.04 (m, 2H, CH2), 1.49-1.28 (m, 6H, CH2 X 3).
 13C NMR, 125 
MHz (DMSO-d6): 175.0 (C=O), 166.3 (C), 165.5 (C=O), 156.3 (C=O), 156.1 (C=O), 141.3 (CH), 
125.3 (C), 95.2 (CH), 79.2 (CH), 67.2 (CH), 61.9(CH), 60.2 (OCH2), 55.5 (OCH2), 39.6 (CH), 37.8 
(CH2), 35.2 (CH), 28.3 (CH2), 28.0 (CH2), 25.3 (CH2). ESI-MS: cald for C22H30F2N6O8S, 576.18; 
found 577.2 (M + H+).   
2.2.3 Synthesis of Rose Bengal amine (6) 2-Aminoethyl 2,3,4,5-tetrachloro-6-(6-hydroxy-
2,4,5,7-tetraiodo-3-oxo-3H-xanthen-9-yl)benzoate: To a solution of Rose Bengal sodium salt 
(1.0 g, 1.0 mmol) in anhydrous DMF (10 mL) was added 2-bromoethylamine (0.32 g, 1.5 
mmol) and the mixture was stirred at 80 C for 7 h. The DMF was then removed under 
reduced pressure and the residue stirred for 18 h in diethyl ether (200 mL). The solution was 
filtered and the resulting solid stirred in water (200 mL) for 18 h. The solution was filtered 
and the solid crystallised from MeOH to yield the product as a dark red solid. 1H NMR (500 
MHz, DMSO-d6): 2.42 (t, CH2, 2H), 3.80 (t, OCH2, 2H), 7.26 (s, ArH, 2H), 7.60 (s, NH2, 2H). 
13C NMR (500 MHz, DMSO-d6): 19.0, 37.5, 49.3, 56.5, 62.7, 76.6, 97.9, 129.6 130.6, 132.4, 
133.4, 10.6, 110.9, 134.7, 135.7, 136.4, 137.0, 139.6, 157.5, 163.2, 172.3. HRMS: calculated 
for C22H9Cl4I4NO2 = 1016.5384, found 1016.1376. I.R. vmax (cm
-1) 3430, 2925, 2366, 1615, 
1546, 1450, 1337. 
2.2.4. Synthesis of biotin–Rose Bengal (7) 2-(5-(2-Oxohexahydro-1H-thieno[3,4-d]imidazol-
4-yl)pentanamido)ethyl2,3,4,5-tetrachloro-6-(6-hydroxy-2,4,5,7-tetraiodo-3-oxo-3H-xanthen-
9-yl)benzoate: To a solution of Rose Bengal amine (74 mg, 74 μmol) in 2 mL DMSO, NHS 
Biotin (25 mg, 74 μmol) dissolved in PBS buffer 2 mL (pH 9) was added. Triethylamine (10 μl, 
0.71 μmol) was added to the mixture which was then stirred at room temperature for 12 h. 
The resulting solution was placed in a solution of hexane: chloroform (200 ml 8:2) and 
stirred for 24 h at room temperature. The solution filtered and the filtrate retained. The 
filtrate was washed three times with diethyl ether and dried in a vacuum oven to yield the 
product as a red powder (14 mg, 10%). 1H NMR (500 MHz, DMSO-d6): 1.28 (m, CH2, 2H), 
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1.45 (m, CH2, CH, 3H), 1.57 (m, CH, 1H), 1.60 (t, CH2, 2H), 2.52 (q, CH, 1H), 2.58 (m, CH, 1H), 
2.79 (q, CH, 1H), 2.97 (t, CH2, 2H), 3.10 (m, SCH, 1H), 3.85 (t, OCH2, 2H), 4.09 (t, CH, 1H), 4.28 
(t, CH, 1H), 6.34 (s, NH, 1H), 6.41 (s, NH, 1H), 7.46 (s, ArH, 2H), 7.56 (brs, NH, 1H). 13C NMR 
(125 MHz, DMSO-d6): 8.98, 9.03, 25.52, 28.57, 29.45, 31.72, 35.52, 37.34, 46.07, 53.13, 
55.86, 59.66, 61.48, 64.65, 76.50, 97.69, 110.56, 124.271, 129.37, 130.48, 132.34, 134.79, 
135.50, 136.41, 139.79, 157.42, 163.13, 163.57, 172.23, 172.68, 228.31, 230.86 –ve ESMS: 
calculated for C32H23Cl4I4N3O7S = 1243.0 found = 1241. I.R. vmax (cm
−1) 3425, 2924, 2369, 
1683, 1576, 1541, 1342. M.P. 188–191 °C. 
2.2.5. Synthesis of 5-fluorouracil-1-carboxylic acid (9): 2-(5-Fluoro-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)acetic acid: A mixture of 5-Fluorouracil (5 g, 38.4 mmol), 
potassium hydroxide (9.07 g, 161.6 mmol) and chloroacetic acid (3.63 g, 38.4 mmol) in 100 
mL of water was refluxed for 2 h at 70 °C. After cooling to room temperature, the pH of the 
solutionwas adjusted to 5.5 by the addition of concentrated hydrochloric acid. The reaction 
mixture was then kept in a refrigerator (5 °C) for 18 h and the resulting white crystals 
isolated by filtration and washed with cold water to produce 9 in 52.5% yield. mp > 200 °C, 
1H NMR (500 MHz, D2O) 7.76 (d, 1H, J = 6 Hz, CH), 4.29 (s, 2H, CH2). 
13C NMR (D2O):173.58 
(C=O), 159.97 (C=O), 150.80 (C=O), 141.20 (C), 131.74 (CH), 51.48 (CH2). ESMS (M-H
+): found 
187.10, calculated for C6H5O4N2F = 188.11. 
2.2.6. Synthesis of biotinylated 5-FU (10) 2-(5-(2-Oxohexahydro-1H-thieno[3,4-d]imidazol-
4yl)pentanamido) ethyl 2-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetate: N-(2-
Hydroxyethyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (0.5 g, 1.7 
mmol), 5-Fluorouracil-1-carboxylic acid (4) (0.4 g, 2.1 mmol), DMAP (0.023 g, 0.17 mmol) 
and HOBT (0.023 g, 0.17 mmol) were added to 20 mL of anhydrous DMF in a 100 mL 2-neck 
round bottom flask under a N2 atmosphere. The mixture was heated at 40 °C and stirred 
until a homogeneous solution was obtained. DCC (0.4 g, 1.9 mmol) was then added to the 
reaction mixture and allowed to stir at room temperature for 12 h. The DMF was removed 
under reduced pressure, diethyl ether (50 mL) added and the contents stirred for 20 min. 
The resulting white semi-solid product was removed by filtration and after removing excess 
diethyl ether under reduced pressure, the crude product was purified by preparative HPLC 
(C-18 column) using acetonitrile/water (80:20 v/v) as mobile phase. The product 10 was 
obtained after lyophilisation of the desired fractions as a white semi-solid (0.24 g, 30 % 
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Yield). 1H NMR (500 MHz, D2O): 7.67 (d, 1H, J =6.0 Hz, CH), 4.50-4.47 (m, 1H, CH), 4.31-4.29 
(m, 1H, CH), 4.19(s, 2H, CH2), 3.54 (t, 2H, CH2), 3.22-3.19 (m, 2H, CH2), 2.89-2.86 (m,1H, CH), 
2.67-2.64 (m, 2H, CH2), 2.17-2.14 (m, 2H, CH2), 1.61-1.47(m, 4H, CH2 X 2), 1.47-1.28 (m, 2H, 
CH2). 
13C NMR 125 MHz, D2O):177.12 (C=O),173.74 (C=O), 165.33 (C=O), 160.01 (C=O), 
159.81(C=O), 141.14 (C), 131.71 (CH), 62.00(CH2), 60.22 (CH), 59.94 (CH), 55.26 (CH), 51.53 
(CH2), 41.31 (CH2), 39.64 (CH2), 35.45 (CH2), 27.79(CH2), 27.58 (CH2), 25.14 (CH2). ESMS (M-
H+) found 456.20, calculated for C18H24FN5O6S = 457.48. 
2.3. Preparation of O2 loaded microbubbles: For the preparation of DBPC MBs, DBPC (4.0 
mg, 4.43 mmol), DSPE-PEG (2000) (1.35 mg, 0.481 mmol) and DSPE-PEG (2000)-biotin (1.45 
mg, 0.481 mmol) in a molar ratio of 82:9:9 were dissolved in chloroform and placed in a 
glass vial. The solution was heated at 40 oC until all the chloroform had evaporated. PBS (pH 
7.4 ± 0.1) (5 ml) was added to the dried lipid film and the contents heated above the lipid 
phase transition temperature (>70 oC) under constant magnetic stirring for 30 min. The 
suspension was then sonicated with a Microson ultrasonic cell disruptor for 1.5 min (100 
Watts, 22.5 kHz at power setting 4), the headspace filled with perfluorobutane (PFB) gas and 
the gas/liquid interface sonicated (power 19) for 20 s producing PFBMBs. The MB 
suspension was cooled in an ice bath for approximately 10 min. An aqueous solution of 
avidin (50 mL, 10 mg/mL) was then added to the cooled MB suspension and stirred for a 
further 10 min. The suspension was then centrifuged (300 RPM, 10 min) and the resulting 
MB “cake” concentrated into 1 mL of PBS (pH 7.4 ± 0.1). This was divided into two freeze 
drying vials. For the PFBMBs the vials were then crimped (sealed with a metal cap). To 
create oxygen filled MBs the headspace of the vial and the MB suspension was sparged 
under a positive pressure of oxygen gas for 2 min and the vial was then crimped. Following 
preparation as described above, MB samples were imaged under conventional optical 
microscopy to determine their size distribution and concentration. 10 mL samples were 
removed from each suspension and diluted in 90 mL of PBS (pH 7.4 ± 0.1) followed by 
examination on a haemocytometer (Bright-Line, Hausser Scientific, Horsham, PA, USA). 
Images were obtained with a 40 X objective lens with a Leica DM500 optical microscope. 
The MB size distribution and concentration were then obtained using purpose written 
image analysis software in Matlab (2010B, The MathWorks, Natick, MA, USA). 
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2.4 Preparation of O2MB-Gem, O2MB-5FU and O2MB-RB: Saturated solutions of biotin-RB, 
biotin-5FU and biotin-GEM were prepared in a 0.5% DMSO solution in PBS (pH 7.4 ± 0.1). A 
0.3 mL aliquot of these stock solutions were then added separately to three 2 mL 
suspensions of avidin functionalised PFBMBs (2.1 x 109 MB/mL) and the contents vortex 
mixed for 15 min. The suspensions were then centrifuged (900 rpm) for 5 min and the MB 
conjugates isolated as a milky suspension floating on top of the solution. The solution was 
removed and replaced with a further 0.3 mL of stock solution containing either biotin-RB, 
biotin-5FU or biotin-GEM and the mixing/centrifugation steps repeated. The MB 
suspensions were then washed with PBS (5 mL), centrifuged (900 rpm) for 5 min and the 
MBs transferred to a clean centrifuge tube. This washing procedure was repeated again and 
the isolated PFBMB-RB, PFBMB-5FU and PFBMB-GEM conjugates placed in glass vial. The 
PFBMB-RB, PFBMB-5FU and PFB-GEM conjugates were then sparged with oxygen gas for 2 
min and the resulting O2MB-RB, O2MB-5FU and O2MB-GEM conjugates were then crimped 
in the vials and ready to use. The MB number and size were determined by withdrawing 10 
μL samples of the O2MB-RB, O2MB-5FU and O2MB-Gem conjugates and diluting them 
separately in 90 μL of PBS (pH 7.4 ± 0.1) followed by analysis using a haemocytometer 
(Bright-Line, Hausser Scientific, Horsham, PA, USA). Images were obtained with a 40 x 
objective lens using a Leica DM500 optical microscope. The MB size distribution was then 
obtained following processing using ImageJ software. Where appropriate, the O2MB-RB and 
O2MB-Gem conjugates were mixed together in a 1:1 ratio for combined chemo-
sonodynamic therapy treatments.  A fluorescence image of the mixed MB suspension was 
obtained using a Nikon Eclipse E400 epi-fluorescence microscope equipped with a B2A and 
G2A filter set using an excitation wavelength of 548nm with emission collected at 565nm. 
The drug loading on the surface of the MB conjugates was determined using UV-Vis 
spectroscopy for biotin-RB and reverse phase HPLC for biotin-5FU and biotin-GEM, using a 
Phenomenex C18 column (250 x 4.6 mm, 5 µm), a mobile phase consisting of acetonitrile: 
1.5 mM potassium phosphate monobasic (5:95 v/v), a flow rate of 1.0 mL/min-1 using 206 
nm as the detection wavelength.  
2.5 Preparation of avidin functionalised magnetic microbubbles (MagPFBMBs): Avidin 
functionalised magnetic MBs were prepared by following the procedure discussed in section 
2.3 except after the lipid suspension stirred for 30 min in a water bath, FluidMAG-Lipids NPs 
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(150 μL) were then added to the solution and the mixture was sonicated with a handheld 
sonicator probe for 1.5 min (100 W, 22.5 kHz, power setting 4). MagPFBMBs were analyzed 
using a Leica DM500 optical microscope to obtain the size distribution and concentration. 
For this, 10 μL of suspension was diluted in 190 μL of PBS and examined using a 
haemocytometer (Bright-Line, Hausser Scientific, Horsham, PA, USA). 30 images were 
obtained with a 40 x objective lens and analysed with customised image analysis package in 
MATLAB (2010B, MathWorks, Natick, MA, USA). The iron content in the MagPFBMBs was 
determined by atomic absorption spectroscopy using a Varian fast sequential atomic 
absorption spectrometer. A calibration curve was constructed using known concentrations 
of Fe(III) in 0.5 M HCl. Readings were taken at 248.3 nm, 0.5 nm slit width, 10.0 mA lamp 
current, with the following flame settings; flame type: air/acetylene, air flow: 13.50 L/min, 
acetylene flow: 2.00 L/min, burner height: 13.5 mm. A 300 μL sample of MagMBs was 
sonicated to destroy the bubbles and dissolved in 0.5 M HCl. The amount of Fe (III) present 
in the sample was calculated by reference to the calibration curve and the total iron content 
determined using a magnetite (Fe3O4) Fe(III):Fe(II) ratio of 2:1. 
2.6. Preparation of MagO2MB-Rose Bengal and MagO2MB-5FU conjugates: The synthesis 
of biotin functionalised Rose Bengal and biotin functionalised 5-FU have been described in 
section 2.2.2 and 2.2.5. Saturated solutions of biotin-RB and biotin 5-FU were prepared in a 
0.5% (v/v) DMSO: PBS (pH 7.4 ± 0.1) solvent mixture. 100 μL of biotin-5FU and biotin-RB 
were added to separate samples (2 mL each) of MagPFBMBs and allowed to mix for 5 min 
on a rotary shaker. Both samples were centrifuged (100 RCF, 5 min) to remove unbound 
material and PFBMB conjugates were re-suspended in 1 mL of PBS solution (pH 7.4 ± 0.1). 
This conjugation/centrifugation process was repeated three times. The final PFBMB-RB and 
PFBMB-5FU conjugates were transferred to glass vials. MagO2MB-RB and MagO2MB-5FU 
conjugates were obtained by sparging the MagPFBMB-RB and MagPFBMB-5FU with pure O2 
gas for 2 min and sealing the vial via crimping. A small sample (100 μL) of both the 
MagO2MB-RB and MagO2MB-5FU conjugates was retained and the MB number again 
counted using a haemocytometer. The remaining sample was sonicated in an ultrasonic 
bath for 5 min to burst the MBs and the Rose Bengal and 5-FU concentration determined 




2.7. Retention of MagMBs in a flow cell using an external magnetic field: MagPFBMBs 
without payload were used in this study to reduce wastage of biotin-5FU and biotin-RB. 1 x 
107 MagPFBMBs were placed in a 1 mL syringe, connected to an ibidi μ-Slide VI flow 
chamber using silicone tubing (1.6 mm internal diameter) and placed in a peristaltic syringe 
pump. A single N52 grade NdFeB permanent magnet cube (12.7 mm) with an internal 
magnetization of 1.14 x 106 A/m was positioned 1 mm from the base of the flow chamber. 
Values for a field of 0.46 T and gradient of 83.1 T/m inside the flow chamber were 
calculated using a model described and experimentally verified previously, [162] whereby 
the field was determined by breaking the magnet into a 3-dimensional lattice of evenly-
distributed point moments, and summing the contributed dipole field from each moment. 
The MagPFBMBs were pumped through the flow chamber at a rate of 0.6 mL/min. Once the 
syringe was empty, the magnetic field was removed and 1 mL of PBS (pH 7.4 ± 0.1) added to 
the syringe to flush the flow chamber's content into a clean vial. Collected MBs were 
counted using the method described above. As a control, the experiment was repeated in 
the absence of a magnetic field but under otherwise identical conditions. The number of 
MBs collected during the PBS flush was again recorded. 
2.8. Preparation of uncoated CaO2 NPs: CaO2 nanoparticles were prepared following the 
method described by Khodaveisi et al. [163] Ammonia solution (15.0 mL, 1 M) and PEG 200 
(120.0 mL, 0.6744 mol) was added to a stirred solution of calcium chloride (3.0 g, 0.027 mol) 
in distilled water (30 mL). A solution of 35% H2O2 (15 mL, 0.17 mol) was then added to the 
mixture at a rate of 3 drops per minute and the colourless solution stirred for a further 2 h 
at room temperature. A NaOH solution (0.1 M) was then added until a pH value of 11.5 was 
achieved when the solution changed to a white coloured suspension. The precipitate was 
separated by centrifugation (8000 g, 5 min) and the resulting pellet washed three times with 
NaOH (25 mL, 0.1 M). The precipitate was then washed with distilled water until the filtrate 
pH reached 8.4 and the resulting solid dried in vacuo at 80 °C for 2 h. The resulting particles 
were suspended in ethanol and sonicated for 5 min. The suspension was passed through a 
Millex Filter Unit (0.45 μm) to isolate larger particles and the filtrate concentrated to 
dryness providing the uncoated CaO2 nanoparticles as a white powder. The size of the 
nanoparticles was determined by SEM and DLS. 
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2.9. Determination of CaO2 content in the uncoated CaO2 NPs: The active CaO2 content of 
the NPs was determined by reaction with luminol in PBS. A 
chemiluminescence/concentration calibration curve for the reaction of H2O2 with luminol 
was performed according to the procedure adopted by Komagoe et al. [164] CaO2 NPs 
suspended in ethanol (50 μL, 35.6 μM) were added to a luminol solution (50 μL, 10 mg/mL 
in PBS) and the luminescence intensity determined using a plate reader. The CaO2 content 
was determined by indirectly measuring the number of moles of H2O2 produced (by 
reference to a calibration graph) from the fixed mass of CaO2 powder and assuming all the 
available CaO2 was converted to H2O2. 
2.10. Determination of singlet oxygen generation: The ability of the CaO2 NPs to enhance 
PDT mediated singlet oxygen generation was determined using the singlet oxygen probe 
SOSG. CaO2 NPs (2 mg) in de-oxygenated ethanol (1 mL) were added to a de-oxygenated 
PBS solution containing SOSG and RB resulting in final concentrations of 2.5 μM (SOSG), 5.0 
μM (RB) and 35.6 μM (CaO2 NPs). The solutions were then exposed to white light for 5 min 
(Fenix LD01 LED, 50 mW output, 113.0 J/cm2) Control experiments were also undertaken 
and included (i) CaO2 NP + light and (ii) RB +light. The intensity of SOSG fluorescence at 525 
nm upon excitation at 505 nm was recorded at the beginning and at the end of each 
experiment. 
2.11. Preparation of polymer 11: 2-(Dimethylamino) ethyl methacrylate (157.2 mg, 1 mmol), 
methyl methacrylate (100.1 mg, 2 mmol) and ethyl acrylate (100.1 mg, 1 mmol) and a 
catalytic amount of the free radical initiator (ABCN) were dissolved in anhydrous THF (5 mL) 
and placed in a Carious reaction vessel. The contents were then subjected to three freeze-
pumpthaw cycles, sealed under vacuum and placed in a Carious oven at 80 °C for 72 h. The 
contents were removed and hexane (20 mL) added to the facilitate precipitation followed by 
centrifugation for 5 min at 3500 g. The supernatant was removed, the pellet containing 11 
re-dissolved in anhydrous THF, precipitated again using hexane and centrifuged at 3743 × g. 
This purification procedure was repeated twice further before the pellet was dried in vacuo 
at 80 °C and characterised by 1H NMR spectroscopy. 
2.12. Coating of CaO2 NPs with polymer 11 to form CaO2-11 NPs: CaO2 NPs were coated 
with 11 using a modified single emulsion method. [165] CaO2 NPs (10 mg) were dispersed in 
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hexane (10 mL) and sonicated for 5 min. The NP suspension was then added dropwise at a 
rate of 2 mL/min to a solution of 11 (100 mg, 0.36 μmol) in ethanol (40 mL) using a Silverson 
homogeniser at 8000g for 5 min to ensure efficient mixing. After a further mixing period of 6 
h, excess solvent was allowed to slowly evaporate and the CaO2-11 NPs reconstituted in 
sterile water. Particle size was then determined using SEM and DLS. 
2.13. Dissolved oxygen experiments: For the dissolved oxygen experiments involving the 
uncoated CaO2 NPs, an ethanol solution containing the NPs (10.0 mg, 24 mmol) was added 
to 10 mL of de-oxygenated PBS solvent. The dissolved oxygen was then measured and 
recorded every minute using a dissolved oxygen meter. For dissolved oxygen experiments 
involving the CaO2-11 NPs, separate solutions of de-oxygenated water were pH adjusted to 
pH 7.4 or 6.2. The CaO2-11 NPs (2 mg) were then added to each solution and the dissolved 
oxygen measured using a dissolved oxygen meter 3 min following addition. Results were 
compared against identical solutions in the absence of CaO2-11 NPs. Both sets of 
experiments were repeated in triplicate. 
2.14. Solubility of CaO2-11 NPs with change in pH: The pH of an aqueous suspension 
containing CaO2-11 NPs (2 mg in 10 mL) was lowered from pH 7.4 to pH 6.2 in approximate 
0.1 pH increments following the addition of very small aliquots of 0.1 M HCl. Photographs of 
the resulting suspensions/solutions were taken at pH 7.4, 6.9 and 6.2. 
2.15 In vitro cytotoxicity of O2MB-GEM, O2MB-5FU and O2MB-RB: The human primary 
pancreatic carcinoma cell lines Mia Paca-2 and PANC-1 were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM) while adenocarcinoma BxPc-3 cells were maintained in 
RPMI-1640 medium, all of which were supplemented with 10% (v/v) foetal bovine serum in 
a humidified 5% CO2 atmosphere at 37
oC. A mouse pancreatic cancer cell line T110299 (KPC 
and a gift from Prof. J. Siveke, Technical University of Munich, Germany) was derived from a 
primary pancreatic tumour of genetically modified KPC mouse model. T110299 cells were 
maintained in high glucose DMEM with 10% FBS, 1% Non-Essential Amino Acids, 1% L-
glutamine and 1% Pen/Strep. 5x103 cells were seeded in 96 well plates and placed in an 
incubator (37 oC, 5% CO2) and 24 h later were treated with a suspension of either O2MB-
Gem,  O2MB-RB or a combination of O2MB-Gem / O2MB-RB  [MB] = 2.7 x 10
6; [RB] = [Gem] = 
5 µM. After 3 hours, selected wells were treated with ultrasound delivered using a Sonidel 
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SP100 sonoporator (1 MHz, 30 seconds, 3 Wcm-2, duty cycle = 50%). Untreated cells and 
cells treated with ultrasound only were used for comparative purposes. After 24 hours, cell 
viability was determined using a MTT assay. For the efficacy comparison between Gem and 
Biotin-Gem (5), 5x103 BxPc-3 and Mia Paca-2 cells were seeded in 96 well plates, placed in 
an incubator (37 oC, 5% CO2) and 24 h later were treated with 0, 5, 10, 25 100 and 100 µM 
of Gem or 4 and cell viability determined using a MTT assay 48h later. 
2.16 In vitro cytotoxicity of MagO2MB-GEM, MagO2MB-5FU and MagO2MB-RB: Human 
primary pancreatic adenocarcinoma cell lines Mia Paca-2 and Panc-1, were maintained in 
DMEM medium. The mouse primary pancreatic adenocarcinoma T110299 derived from a 
GEM mouse, was also maintained in DMEM medium while the human primary pancreatic 
adenocarcinoma cell line BxPc-3 was maintained in RPMI-1640 medium, all of which were 
supplemented with 10% (v/v) foetal bovine serum and grown in a humidified 5% CO2 
atmosphere at 37 °C. These cells were plated into the wells of a 96-well tissue culture plate 
at a concentration of 5× 103 cells per well and incubated for 24 h at 37 °C in a humidified 5% 
CO2 atmosphere. The media was then removed from each well and replaced with 100 μL of 
treatment suspension and 100 μL of fresh medium. This resulted in a final MB count and RB 
or 5-FU concentration as follows: MagO2MB-RB: 106 MB, [RB] = 5μM; MagO2MB-5FU; 107 
MB, [5-FU] = 100 μM and combined MagO2MB-RB/MagO2MB-5FU: 107 MB, [RB] = 5 μM, [5-
FU] = 100 μM. Where required, individual wells were then placed in direct contact with the 
emitting surface a Sonidel SP100 sonoporator with ultrasound gel used to mediate contact. 
Each well was treated with ultrasound for 30 s, using a frequency of 1 MHz, an ultrasound 
power density of 3.0 W cm−2 (ISATP; spatial average, temporal peak) corresponding to a 
peak to peak pressure of 0.8 MPa in water and 0.5 MPa inside the well as measured with a 
needle hydrophone (Precision Acoustics, Dorset, UK); and a duty cycle of 50% (pulse 
frequency =100 Hz). The solution was then removed from the wells and fresh medium 
added (200 μL). Plates were incubated in a humidified 5% CO2 atmosphere at 37 °C for 21 h 
and cell viability determined using an MTT assay. Results were compared with those 
obtained using untreated cells and cells exposed to ultrasound treatment alone. 
2.17. In vitro PDT experiments for uncoated CaO2 NP: BxPc-3 cells were seeded in a 96 well 
plate at a density of 5× 104 cells per well and incubated in a hypoxic chamber at 37 °C 
(O2/CO2/N2, 0.1: 5: 94.9, v/v/v) for 3 h. The cells were then treated with either (i) RB or (ii) 
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RB with CaO2 NPs to reach a final concentration per well of 1 μM (RB) and 25 μM (CaO2) 
respectively. The CaO2 NPs were initially prepared in EtOH that was diluted 1:1 v/v with PBS 
(100 μL total volume) immediately before addition to wells containing 100 μL media leading 
to a total EtOH concentration of 25% v/v. Control wells containing untreated cells or cells 
treated with vehicle alone (i.e. EtOH/PBS 1:1 v/v 100 μL) were undertaken for comparative 
purposes. The cells were allowed to incubate with the drug/NPs/vehicle for 5 mins; the 
medium was then removed and replaced with fresh media. The cells were then exposed to 
white light treatment for 30 s (Fenix LD01 LED, 50 mW output, 11.3 J/cm2). Following light 
treatment cells were incubated for a further 3 h in the hypoxic chamber and then for a 
further 24 h under normoxic conditions in a humidified 5% CO2 atmosphere at 37 °C. Cell 
viability was then determined using a MTT assay. 
2.18 In vivo cytotoxicity of O2MB-GEM, O2MB-5FU and O2MB-RB: All animals employed in 
this study were treated in accordance with the licenced procedures under the UK Animals 
(Scientific Procedures) Act 1986. Experimental procedures were approved by Ulster 
University ethic committee: Chair Finbarr O’Hart. All animal experiments were carried out 
under Professor Anthony McHale’s project licence (2733) and my personal licence number 
(PIL 1660). Mia Paca-2 cells (5x106) in 100 uL Matrigel were sub-cutaneously implanted into 
the rear dorsum of SCID (C.B-17/IcrHan®Hsd-Prkdcscid) mice. Tumours started to form 
approximately 1-2 weeks after cell implantation. Once the tumour became palpable, 
dimensions were measured using Vernier callipers. The geometric mean diameter was used 
to determine tumour volume using the equation 4πR3/3.  
The optimum US exposure conditions SCID mice was identified by the following procedures: 
Mice bearing ectopic Mia paca-2 tumours (241 ± 6 mm3) were randomly allocated into 12 
groups (n=5). Group 1 received no treatment; Group 2 the O2MB-Gem/RB conjugate alone; 
Group 3 the O2MB-5-FU/RB conjugate alone; Group 4 received US treatment alone at 1 MHz, 
3.5 W/cm-2 and 30% duty cycle; Group 5 received US treatment alone at 1 MHz, 3.5 W/cm-2 
and 50% duty cycle; Group 6 received US treatment alone at 1 MHz, 4.0 W/cm-2 and 30% 
duty cycle. Group 7 received O2MB-Gem/RB conjugate + US treatment at 1 MHz, 3.5 W/cm
-2 
and 30% duty cycle; Group 8 received O2MB-Gem/RB conjugate + US treatment at 1 MHz, 
3.5 W/cm-2 and 50% duty cycle; Group 9 received O2MB-Gem/RB conjugate + US treatment 
at 1 MHz, 4.0 W/cm-2 and 30% duty cycle; Group 10 received O2MB-5-FU/RB conjugate + US 
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treatment at 1 MHz, 3.5 W/cm-2 and 30% duty cycle; Group 11 received O2MB-5-FU/RB 
conjugate + US treatment at 1 MHz, 3.5 W/cm-2 and 50% duty cycle and Group 12 received 
O2MB-5FU/RB conjugate + US treatment at 1 MHz, 4.0 W/cm
-2 and 30% duty cycle. MB 
conjugates were administered by tail vein injection (100 µL) containing 1.6*108 MB/mL with 
[5-FU] = 344 µM; [Gem] = 442 µM and [RB] = 557 µM. Ultrasound application occurred 
during and for 3.5 min following injection with a second US treatment applied 30 min 
following the first. Tumours were measured daily using callipers and the tumour volume 
plotted for each group as a function of time. 
The effect of a second treatment on the tumour growth was done by following procedures. 
SCID mice bearing ectopic Mia Paca-2 tumours (213 ± 7 mm3) were randomly allocated into 
6 groups (n=5) as follows. Group 1 received no treatment; Group 2 US only; Group 3 the 
O2MB-Gem/RB conjugate only; Group 4 the O2MB-Gem/RB conjugate + US; Group 5 the 
O2MB-5FU/RB conjugate only and Group 6 the O2MB-5FU/RB conjugate + US. MB 
conjugates were again administered by tail vein injection (100 µL) (7.5*108 MB/mL with [5-
FU] = 2.02 mM; [Gem] = 2.55 mM and [RB] = 879 µM). Ultrasound application occurred for 
3.5 min during injection and a further 3.5 min following injection using the optimised 
parameters. Tumours were measured daily using callipers and the tumour volume plotted 
for each group as a function of time. 
 
2.19 In vivo cytotoxicity of MagO2MB-GEM, MagO2MB-5FU and MagO2MB-RB: BxPc-3 Luc 
cells were maintained in RPMI-1640 medium supplemented with 10% foetal calf serum as 
described above. Cells (1 × 106) were re-suspended in 100 μL of Matrigel® and orthotopically 
implanted into the head of the pancreas of female Balb/c SCID (C·B-17/IcrHan®Hsd-
Prkdcscid) mice. 19 days after implantation, animals were randomly distributed into 3 
groups (n = 4). Following induction of anaesthesia (intraperitoneal injection of Hypnorm/ 
Hypnovel), a 100 μL mixture of PBS containing MagO2MB-RB/ MagO2MB-5FU (MB = 1.6 × 
108, [RB] = 350 μM and [5-FU] = 700 μM) was administered by tail vein injection to Groups 2 
& 3 while Group 1 received vehicle only. For Group 2, ultrasound (frequency =1 MHz, 
ultrasound power density= 3.5 W cm−2 ISATP; spatial average temporal peak, corresponding 
to a free field peak to peak pressure of 0.85 MPa, duty cycle = 30% and pulse repetition 
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frequency =100 Hz) was directed to the tumour region (determined using prior 
bioluminescent imaging) via the abdomen for 3.5 min during and after injection (3.5 min 
total). For Group 3, in addition to ultrasound using the above parameters, a stack of 
permanent magnet discs (arranged to deliver the optimal magnetic force to the tumour 
region) [5] was directed to the tumour region (again via the abdomen) for 3.5 min during 
and after injection (3.5 min total), resulting in an approximate magnetic field at the tumour 
of 0.10 T and gradient 14.9 T/m. Treatments using the above conditions were repeated on 
Days 20 and 21 with animals sacrificed on Day 28. Tumours were then surgically excised and 
tumour volumes determined by direct measurement. 
2.20 Molecular Biology + qPCR analysis of tumour cells suspension in Chapter 3: To 
establish the effect of combined chemo-sonodynamic therapy on the expression of specific 
genes involved in the development and progression of pancreatic cancer, tumours in mice 
from groups 1 and 5 mentioned in section 2.18 were removed post-mortem following the 
final measurement on Day 8. Tumours were snap-froze using liquid nitrogen and RNA was 
extracted using Trizol reagent (Life Technologies) in accordance with the manufacturer’s 
instructions.[166] 1 µg of RNA per tumour was reverse transcribed using First Strand cDNA 
synthesis kit (Roche) in accordance with manufacturer’s instructions [167] and the cDNA 
from the tumours in each group were pooled. Samples were analysed in duplicate on Roche 
RealTime Ready custom 96 well panels (Roche) analysing nine specific genes involved in 
pancreatic cancer. The genes investigated were vascular endothelial growth factor (VEGFC), 
interleukin 8 (IL8), SMAD family member 4 (SMAD4), hypoxia inducible factor 1 (HIF1A), von 
Hippel-Lindau (VHL), runt-related transcription factor (RUNX2), sex determining region Y-
box 2 (SOX2), NANOG, epithelial cell adhesion molecule (EPCAM). The results were 
normalised to a reference gene set (Beta actin, 18s ribosomal RNA and GAPDH). The 
percentage changes in gene expression for treated tumours were compared against 
untreated tumours. 
2.21 Molecular Biology + qPCR analysis of tumour cells suspension in Chapter 4: Following 
the determination of tumour volume a single cell suspension was prepared from the excised 
tumours. This involved homogenising the tumour tissue in 4% FCS in RPMI 160 μL (30 
mg/mL) collagenase type II, 50 μL (2 μg/mL) DNAse and stirring for 15 min at room 
temperature. A further 160 μL of collagenase II was subsequently added and the contents 
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stirred for a further 15 min. The mixture was filtered through a 100 μm filter, centrifuged at 
400 RCF  for 5 min and re-suspended in 1 mL of Red Cell Lysis Buffer (RCLB) for 10 min. RCLB 
was neutralised by adding media containing FCS and cells were recovered by centrifuging at 
400 RCF. The pellet was washed twice with PBS, centrifuged and re-suspended in 700 μL PBS 
buffer. For BAX expression, 300 μL of single cell suspension in staining buffer was 
permeabilised using BD permeablisation buffer (BD Biosciences UK). Permeabilised cells 
were re-suspended in 300 μL of staining buffercontaining BAX antibody (Cell Signalling 
Technology, D2E11) (10 μg/mL) and incubated for 30 min at room temperature. The cells 
were washed in ice cold PBS and the cell pellet was re-suspended in FITC secondary 
antibody (Abcam, ab6717-1) for 1 h. Cells were washed three times by centrifugation at 400 
RCF for 5 min in ice cold PBS, resuspended in 650 μL of PBS buffer nd analysed by flow 
cytometry. For active caspase expression, the Pan Caspase NIR probe kit (Vergent Bioscience) 
was used according to the manufacturer's instructions. The kit utilises the caspase family 
inhibitor VAD-FMK conjugated to a near IR dye (780-VAD-FMK) as a marker that irreversibly 
binds to activated caspases in apoptotic cells. Essentially, 300 μL of tumour single cell 
suspension diluted in staining buffer was centrifuged, the pellet resuspended in 300 μL of 
1XCAS-MAP NIR probe and incubated at room temperature in the dark for 1 h. Cells were 
washed three times by centrifugation at 400 RCF for 5 min in ice cold PBS and re-suspended 
in 650 μL of staining buffer and analysed by flow cytometry. qRT-PCR was used to 
investigate the expression of TMBIM1 in tumours as previously described [8]. Briefly, RNA 
was extracted from microdissected slides using the RecoverAll Kit (Life Technologies, Paisley, 
UK). cDNA synthesis was carried out using the Superscript III First Strand cDNA synthesis kit 
(Life Technologies, Paisley, UK) using the reverse primer of each of TMBIM1 
(transmembrane BAX inhibitor motif containing 1) and the two housekeeping genes;18S 
rRNA and b-actin. qRT-PCR was carried out using the SYBR Green kit on the CFX96 
instrument (BioRad, UK). The qRT-PCR cycle was as follows: 95 °C for 3 min, 95 °C for 10 s, 
60 °C for 45 s for 40 cycles. For analysis, the geometric mean of 18S rRNA and b-actin was 
taken as the single housekeeping value. Statistical comparison between the groups was 
carried out using two-way ANOVA with Bonferroni post-hoc analysis. The primers used to 





Primer                                                                Sequence 
TMBIM1 Forward                                            CATCACTGCGGTGGTATCCA 
TMBIM1_Reverse                                            GTATTGGAAGTAGAGCACAATGCTAGT 
β-Actin Forward                                               CGTGGGCCGCCCTAGGCACCA 
β-Actin Reverse                                                TTGGCCTTAGGGTTCAGGGGGG 
18SrRNA_Forward                                           TGACTCAACACGGGAAACC 
18SrRNA_Reverse                                            TCGCTCCACCAACTAAGAAC 
 
2.22 Determining the toxicity of O2MB-RB / O2MB-Gem and MagO2MB-RB / MagO2MB-
5FU treatment in healthy non-tumour bearing mice: For O2MB-RB / O2MB-Gem treatment, 
Healthy MF1 mice (8 week old) were randomly distributed into 4 groups (n=10; 5 female 
and 5 male).  Group 1 received no treatment; Group 2 received a 100 µL IV (tail vein 
injection) of the mixed O2MB-RB / O2MB-Gem suspension containing (2.6 X10
8 MB / mL-1, 
480.0 µM Gem and 610.0 µM RB) while groups 3 & 4 received 100 µL IV (tail vein injections) 
of Gem (57.0 mM) or RB (1.0 mM) respectively. A second treatment was also administered 3 
days after the initial treatment. For MagO2MB-RB / MagO2MB-5FU treatment, healthy MF1 
mice (8 weeks old) were randomly distributed into four groups (n= 10). Group 1 received no 
treatment; Groups 2 & 3 received a tail vein injection (100 μL) of 5-FU (115 mM) or RB (1.03 
mM) respectively and Group 4 received a tail vein injection (100 μL) containing a suspension 
of MagO2MB-RB/MagO2MB-5FU ([MB] = 2.3 × 10
8, [RB] =570 ± 15 μM, and [5FU] = 503 ± 7 
μM)) on Day 1 and Day 8. Pre-treatment tail vein bleeds (0.10 mL) were collected in lithium 
heparinised tubes on Day 0 with the post-treatment bleeds taken in a similar manner on 
Day 15. Blood samples were taken 15 days following treatment and transferred to CTDS Ltd 
(Garforth, UK) for whole blood and plasma biochemistry analysis including urea test, Alanine 
Aminotransferase (ALT) test, Red Blood Cell Count (RBC), Haemoglobin test, Haematocrit 
test, Mean Corpuscular Volume (MCV) test, Mean corpuscular haemoglobin concentration 
(MCHC) test, Platelets count test, White Blood Cell Count (WBC), neutrophils count and 
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lymphocytes count. After harvesting blood samples, animals were sacrificed and the liver / 
kidneys were placed in formalin free fixative for 24 hours. The tissues were then placed in 
an automated tissue processor, Leica TP1020 system, passed between increasing 
concentrations of ethanol followed by xylene treatment and paraffin wax embedding. The 
following day, the wax embedded tissue samples were placed in moulds containing paraffin 
wax. Once the wax blocks had solidified, 5 µm sections were cut, placed on a glass slide and 
stained with haematoxylin and eosin (H&E) using an automated staining protocol. In some 
cases, additional stains (i.e. reticulin, Masson’s trichrome, Perl’s Prussian blue stain) were 
used when necessary. The stained sections were reviewed histologically by pathologists with 
expertise in liver and renal pathology. Liver architecture was initially assessed to establish if 
there was significant remodelling or fibrosis. The various liver compartments were 
subsequently examined for pathological changes. Portal tract and lobular inflammation 
grading was adapted from the Ishak (modified HAI) system. [168] Portal tract inflammation 
was graded numerically from 1 (none) to severe, affecting all portal tracts. Lobular 
inflammation was assessed at x10 magnification and graded as 1 (none) to 4 (severe, 
typically averaging >10 foci per x10 field). Fatty liver disease grading, referred to as 
steatosis/steatohepatitis, was undertaken based on parameters assessed in the NAFLD 
activity score. [169] In short, steatosis was graded based on a visual estimate of the 
percentage of liver cells affected as 1 = none or less than 5%; 2 = mild, (5- 33%); 3 = 
moderate (34 – 66%) and 4 = severe (greater than 67%). Kidney analysis was undertaken 
following a similar approach assessing the glomerular cellularity, glomerular basement 
membrane, tubular vacuolation, interstitial inflammation, interstitial fibrosis, vessel integrity 
and the collecting system. Statistical analysis was undertaken using a student’s t-test where 
the O2MB-Gem / O2MB-RB group or the MagO2MB-RB/MagO2MB- 5FU group was compared 
directly with the Gem, RB and untreated groups.  
2.23. Determination of tumour pO2 for CaO2-11 NPs experiments in vivo: All animals 
employed in this study were treated humanely and in accordance with licenced procedures 
under the UK Animals (Scientific Procedures) Act 1986. The ability of the CaO2-11 NPs to 
influence tumour hypoxia was examined in a mouse xenograft tumour model of human 
pancreatic cancer. Mia Paca-2 cells were maintained in RPMI- 1640 medium supplemented 
with 10% foetal calf serum. Cells were cultured at 37 °C under 5% CO2 in air. The cells (5 × 
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106) were resuspended in 100 μL of Matrigel® (BD Biosciences, Erembodegem, Belgium) and 
implanted subcutaneously into the rear dorsum of male SCID mice. Tumour formation 
occurred approximately 5 weeks after implantation and tumour measurements were taken 
every other day using callipers. Once the tumours had reached an average volume of 254 ± 
17 mm3 calculated from the geometric mean diameter using the equation tumour volume = 
(W X H X L/2), animals were randomly distributed into two groups (n = 3): (i) CaO2-11 NPs 
and (ii) vehicle only. Following induction of anaesthesia via intraperitoneal injection of 
Hyponym/Hypnovel (150 μL, i.p) of a mixture of 2:1:1; PBS: Hypnorm (0.315 mg/mL fentanyl 
citrate and fluanisone 10 mg/mL, VetaPharma Ltd., U.K.): Hypnovel (10 mg/mL midazolom, 
Roche, UK), the oxygen partial pressure (pO2) of tumours was recorded using an Oxylite 
oxygen electrode sensor. A fibre optic probe was inserted into a 21-gauge needle before 
insertion into the centre of the tumour tissue. The needle was withdrawn and the probe 
readings allowed to stabilise for 5 min. The pO2 in the tumours was recorded every second 
for 20 min. 100 μL aliquots of CaO2-11 NPs in a PBS vehicle (2 mg/mL) or PBS alone were 
administered to the respective groups by tail-vein injection with pO2 recorded every second 
for a further 40 min. This time period was chosen to avoid the need for re-administering 
anaesthesia. 
2.24. Effect of CaO2-11 NPs on PDT efficacy in vivo: Mia Paca-2 xenograft tumours were 
established as described above. Once the tumours had reached an average volume of 254 ± 
17 mm3 the mice were randomly separated into 4 groups (n = 5). Group 1 involved 
untreated animals, group 2 the PDT only group, Group 3 the CaO2-11 NPs only group and 
group 4 the PDT + CaO2-11 NPs group. For group 2 mice received an intratumoural injection 
(100 μL) of Rose Bengal (0.1 mg/mL) in a PBS solvent and the tumour was then exposed to a 
LED-based white light source for 3 × 3 min treatments (Fenix LD01 LED,50 mW output,205 
J/cm2) with a 1 min interval between each treatment. Group 3 received a tail vein injection 
(100 μL) of CaO2-11 NPs in a PBS vehicle (2 mg/mL) while group 4 also received a tail vein 
injection (100 μL) of CaO2-11 NPs in a PBS vehicle (2 mg/mL) in addition to an intratumoural 
injection (100 μL) of Rose Bengal (0.1 mg/mL) and light exposure administered 20 min after 
NP injection using the same conditions as described for group 2. The tumour volume was 
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Chapter 3 Optimisation and Safety Evaluation of Oxygen carrying 
microbubbles as a delivery vehicle for combined sonodynamic and 
antimetabolite therapy.  
3.1 Introduction 
As mentioned in section 1.4.3, previous work by McEwan et al. has demonstrated the ability 
of oxygen carrying lipid stabilised microbubbles to deliver combined sonodynamic and 
antimetabolite therapy for the treatment of pancreatic adenocarcimona (PDAC) in a murine 
model of the disease. [140] While successful in demonstrating the feasibility of this 
approach, the study had several limitations restricting translation of the technology to the 
clinic. These include: (1) the use of an intratumoural injection of the MB conjugates during 
the in vivo study. The clinical treatment of pancreatic cancer would require the MB-
conjugates to be delivered by intravenous injection and to be disrupted in the tumour 
vasculature using an externally applied ultrasound stimulus. (2) A single set of ultrasound 
exposure conditions was investigated to disrupt the MBs and activate the sensitiser in that 
study. It would be beneficial to determine the optimum ultrasound exposure conditions to 
ensure efficient activation of the sensitiser for maximum SDT effect. (3) A safety study was 
not undertaken to evaluate any toxic effects exhibited by the combined MB mediated 
treatment. Such safety information would form a significant component of any pre-clinical 
data package. (4) Treatment efficacy was only demonstrated in a single xenograft model 
(BxPc-3). It would be preferable to demonstrate efficacy in a second xenograft model such 
as Mia Paca-2. (5) The combined treatment involved the use of 5-FU as the antimetabolite 
drug of choice. This was primarily for synthetic convenience as the biotin derivative of 5-FU 
was easier to prepare than the biotin derivative of the more commonly used gemcitabine. 
However, it would be beneficial to determine the efficacy of MB delivered combined SDT / 
antimetabolite therapy using gemcitabine as the antimetabolite drug. In addition to the 
above, it would also be of interest to investigate effects of the treatment at the genetic level 
to determine how the treatment effects expression of a selected array of gene targets 
including those involved in signalling pathways driving processes such as 
apoptosis/autophagy, angiogenesis, and resistance.  
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In this chapter, studies will be undertaken to address each of the above limitations to 
identify the optimum treatment conditions and determine the safety of the treatment. 
 
3.2 Aims and Specific Objectives 
The major aim for the work undertaken in this chapter was to determine if combined SDT / 
gemcitabine treatment, using intravenously delivered oxygen carrying lipid stabilised 
microbubbles as delivery vehicle, will provide a significant reduction in the volume of Mia-
PaCa-2 tumours compared to SDT or gemcitabine treatment alone and cause no significant 
toxicity to healthy non-tumour bearing mice. The specific objectives were:  
1. To synthesise biotinylated RB (biotin-RB), biotinylated 5-FU (biotin-5FU) and biotinylated 
GEM (biotin-GEM) and prepare oxygen loaded MB conjugates of each biotin functionalised 
compound i.e. (O2MB-RB, O2MB-5FU and O2MB-GEM conjugates). 
2. To investigate the efficacy of O2MB-RB, O2MB-5FU, O2MB-GEM, O2MB-RB / O2MB-5FU 
and O2MB-RB / O2MB-GEM in a panel of three human pancreatic (Panc-1, Mia Paca-2 and 
BxPc-3) and one mouse primary (T110299) pancreatic cancer cell lines in the presence and 
absence of low intensity ultrasound.  
3. To determine the efficacy of the above treatments in mice bearing human xenograft Mia 
Paca-2 tumours using a range of US exposures. 
4.  To determine the safety of the MB formulations in healthy non-tumour bearing mice. 
5. To determine the expression of selected genes in harvested tumour tissues from treated 







3.3 Results and discussion 
3.3.1 Synthesis and Characterisation of biotin-Gem, biotin-RB and biotin-5FU. 
Three separate MB conjugates were required for the experiments to be conducted in this 
chapter. Two of these, O2MB-RB and O2MB-5FU have been prepared before by McEwan et 
al. [Figure 3.1 (a) and (b)]. [139,140] The remaining conjugate, O2MB-Gem [Figure 3.1 (c)] 
has not been previously prepared. Each conjugate utilised a generic avidin-biotin interaction 
to make a non-covalent bond between the surface of the MB and the drug compound itself 
and therefore it was necessary to prepare biotinylated derivatives of the target drug 
compounds to enable their attachment to the MB surface (Figure 3.1). 
 
Figure 3. 1 Schematic representation for the structure of the (a) O2MB-RB, (b) O2MB-5FU and (c) O2MB-GEM 
conjugates. 
 
3.3.3.1 Preparation of biotinylated-Gemcitabine. 
Biotinylated Gemcitabine (Biotin-GEM) was synthesised according to the three step 




Figure 3. 2 Synthetic procedure to Biotin-GEM from non-biotinylated GEM 
In the first step, the alcohol-functionalised biotin derivative 2 was prepared following a 
nucleophilic substitution reaction between 2-amino ethanol and biotin-NHS 1. Nitrophenyl 
chlorofomate was then reacted with 2 to form the alcohol reactive carbonate ester 
functionalised biotin 3. In the final step, 3 was reacted with gemcitabine to form biotin 
functionalised gemcitabine 5 (Biotin-Gem), with a carbonate ester linkage between the 
sugar hydroxyl and the biotin.   
The structure of the final product was confirmed by 1H-NMR, 13C-NMR and electrospray 
mass spectroscopy (ESMS) which are shown in Figures 3.3, 3.4 and 3.5 respectively. In the 
1H-NMR spectrum, the aliphatic protons from the butyl chain, biotin and sugar moiety were 
attributed to the upfield resonances from 1.2-4.2 ppm, while the urea protons from biotin 
were observed in the downfield region at 6.4 and 6.0 ppm. The protons of the GEM 
pyrimidinone ring appeared on resonances at 7.8 and 6.1 ppm, while the broader resonance 
at 7.9 ppm was attributed to the amine protons of the pyrimidinone ring. In the 13C NMR 
spectrum, the one alkene carbon of the pyrimidinone ring and the aliphatic carbons 
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appeared in the upfield region between 79 ppm and 23 ppm, while the one alkene carbon 
and one imine carbon of the pyrimidinone ring were observed further downfield at 166 ppm 
and 141 ppm. The four carbonyl carbons were also observed in the downfield region 
between 175 ppm and 156 ppm. ESMS, recorded in the positive mode, also confirmed the 
structure of biotin-Gem with a base peak at 577.2 Da consistent with the molecular weight 
of the [M+H]+ ion calculated to be 576.18 Da. Combined, these analytical data confirmed the 
successful formation of biotin-gemcitabine 5. 
 
Figure 3. 3 1H-NMR of Biotin-GEM recorded in DMSO-d6. 





Figure 3. 5 Positive mode ES/MS of Biotin-GEM. 
 
3.3.1.2 Preparation of Biotin-Rose Bengal 
The synthesis of biotin-RB has been reported previously and the same scheme (Figure 3.6) 




Figure 3. 6 Synthetic procedure for Biotin-RB. 
In the first step, amine functionalised Rose Bengal 6 was formed by a nucleophilic 
substitution reaction between Rose Bengal sodium salt and bromoethylamine. 7 was then 
reacted with biotin-NHS 1 in the presence of TEA to form an amide linkage between the RB 
and biotin units.  The final product was again confirmed by 1H-NMR, 13C-NMR and mass 
spectroscopy as shown in Figure 3.7, 3.8 and 3.9. The 1H-NMR spectrum reveals one sharp 
resonance at 7.30 ppm resulting from the Rose Bengal aromatic protons, with the urea 
protons of biotin observed slightly further upfield at 6.40 and 6.30 ppm. The methylene 
protons from the aliphatic chain appeared on a collection of resonances from 0.80-3.90 ppm 
that aslo included the two methylene protons of the biotin unit (E) at 2.95 ppm. Methine 
protons B, both attached to chiral carbons were observed on separate resonances at 4.05 
and 4.15 ppm.  In the 13C-NMR, the resonances in the upfield region between 22 and 61 
ppm were assigned to the aliphatic carbons, while the aromatic and carbonyl carbons were 
observed between 70 and 200 ppm. The molecular weight of 7 was confirmed by positive 
ESMS with a base peak at 1241.4 Da corresponding to the [M+H]+ ion. Again, these 
analytical data were consistent with those reported previously and confirm the successful 
synthesis of 7.  
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Figure 3. 7 1H-NMR spectrum recorded in DMSO-d6 for the Biotin-RB.  
 
Figure 3. 8 13C-NMR of Biotin-RB recorded in DMSO-d6. 
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Figure 3. 9 Positive mode ES/MS of biotin-RB. 
 
3.3.1.3 Preparation of Biotin-5FU 
As for compound 10, the synthesis of biotin-5FU 10 has also been reported before and the 





Figure 3. 10 Synthetic procedure for biotin-5FU from 5-FU.  
Alcohol-functionalised biotin derivative 2 was prepared as described in Figure 3.2. In parallel, 
5-FU was N-alkylated using chloro-acetic acid to produce the carboxylic acid functionalised 
5-FU intermediate 9.  
Compound 9 then underwent an amidation reaction with 2 under the assistance of HOBt, 
DCC and DMAP to form the target compound biotin-5FU 10, and the pure compound 
isolated following purification using preparative HPLC. The 1H-NMR, 13C-NMR and ESMS of 
the final product Biotin-5FU are shown in Figures 3.11, 3.12 and 3.13 respectively. The 1H-
NMR spectrum revealed broad resonances in the upfield region (1.0-2.3 ppm) 
corresponding to the methylene protons from the butyl chain. The methylene protons from 
the short ethyl spacer unit were observed at 2.7 and 3.5 ppm, while the methylene protons 
adjacent to the uracil ring were observed at 4.2 ppm. The two methylene protons of biotin 
(G) are diasteriotopic and again appear as separate resonances at 4.3 and 4.5 ppm due to 
their proximity to the chiral centre. The singlet resonance in the downfield region (7.6 ppm) 
resulted from the single aromatic proton of the uracil ring. In the 13C-NMR the aliphatic 
carbons were observed on the upfield region between 62 ppm and 25 ppm, while the two 
non-carbonyl carbons of the uracil ring appeared further downfield at 131 ppm and 141 
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ppm. The five carbonyl carbons were also observed in the downfield region between 177 
ppm and 159 ppm. The molecular weight of 7 was confirmed by ESMS recorded in the 
negative mode with a base peak at 456.2 corresponding to [M-H]- ion calculated to be 
457.48 Da. Again, these analytical data were consistent with those previously reported and 
confirm the successful preparation of 10. 
Figure 3. 11  1H-NMR of biotinlyated 5-FU recorded in D2O. 
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Figure 3. 12 13C-NMR of Biotin-5FU recorded in D2O. 
  




Exact Mass: 457.14 
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3.3.2 Preparation of O2MB-RB, O2MB-5FU and O2MB-Gem conjugates.  
As mentioned previously, the method chosen for attachment of Rose Bengal, 5-FU and 
Gemcitabine to the MB surface was the avidin-biotin interaction. This involved first 
preparing lipid stabilised MBs with the lipids DBPC, DSPE-PEG (2000) and DSPE-PEG (2000)-
biotin in a molar ratio of 82:9:9. The incorporation of DSPE-PEG (2000)-biotin in the shell of 
the MBs at 9% molar equivalence enables the subsequent attachment of avidin to the shell 
of the MB via a biotin-avidin interaction. As avidin has four binding sites for biotin, this also 
allows the subsequent attachment of biotinylated payloads (i.e. biotin-RB, biotin-5FU and 
biotin-Gem) to the remaining biotin binding sites on avidin. Therefore, avidin effectively 
functions as a crosslinking bridge between the MB and the biotinylated payload. One 
possible complication that may be encountered using this approach is that two separate 
MBs become crosslinked together via the avidin bridge. However, the possibility of this 
occurring is significantly reduced by using an excess of avidin to ensure all the MB biotin 
sites are saturated with avidin and not available for linking with other MBs. A schematic of 
the conjugation process is shown in Figure 3.14.  
 
Figure 3.14 Synthetic procedure for biotin functionalised O2-MBs 
The MBs used in this chapter were prepared according to the protocol outlined in section 
2.3 and shown in Figure3.14(i). A representative image of the MBs shown in Figure 3.15 (a) 
displays a spherical morphology with an average particle diameter calculated from analyses 




Figure 3. 15 (a) Optical microscope image taken with a 40 × objective lens of RB/GEM MB after dilution (1:10) 
in PBS. Scale bar is 20 μm; (b) size distribution of RB/GEM MB after centrifugation obtained from analysis of 
the optical microscope images.  (c) Fluorescent microscope image taken with a 40 × objective lens of RB/GEM 
MB after dilution (1:10 ) in PBS, excited at 560nm.  Scale bar is 20 μm. 
Avidin was then added to these MBs [Figure 3.14 (ii)] and the avidin coated MBs isolated by 
centrifugation. While not confirmed here, the successful attachment of avidin to the MB 
surface using this approach has been demonstrated previously by McEwan et al when a 
fluorescently labelled avidin was used instead of normal avidin and MBs with bright 
fluorescent shells were observed. [139] 
The next step in the preparation of the O2MB-RB, O2MB-5FU and O2MB-Gem conjugates 
was to attach the biotinylated drugs onto the surface of the avidin functionalised PFBMBs 
[Figure 3.14 (iii)]. This was accomplished by mixing the MBs with the biotinylated drugs and 
removing unbound drug using centrifugation and washing steps. The final PFBMB-drug 
conjugates were then sparged with oxygen [Figure 3.14 (iv)] gas for 2 min to generate the 
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O2MB-RB, O2MB-5FU and O2MB-Gem conjugates, the structures of which are shown in 
Figure 3.1. Confirmation of the attachment of biotinylated payloads to the surface of the 
avidin MBs is seen in Figure 3.15(c). The image reflects MBs loaded with RB, and clearly 
reveals bright red RB fluorescene from the shell of the MBs indicating successful attachment. 
 
3.3.3 Preparation of Drug Loaded MBs and quantifying drug loading attached to the 
O2MB. 
Following the development work mentioned above and the protocol outlined in section 2.4, 
batches of O2MB-RB, O2MB-5FU and O2MB-Gem were prepared. The drug concentration 
and MB number used in each of the subsequent biological studies will be presented in each 
relevant section. 
 
3.3.3.1 Rose Bengal 
To determine the amount of Biotin-RB present on the O2MBs, a UV-Vis calibration curve for 
biotin-RB stock solution was constructed [Figure 3.16(a)]. Following the procedure described 
in section 2.4, the UV-Vis spectra of the various biotin-RB standard solutions were recorded 
at 560 nm and a calibration curve of Intensity vs. concentration generated. [Figure 3.16(b)] 
Good linearity was observed in the 0-20 μM range with a R2 value of 0.99. By using the 
equation of the line of the calibration curve, it was possible to determine the amount of RB 
attached to the MBs by recording the UV-Vis spectrum of a sample following their 





Figure 3. 16(a) UV-Vis spectra for increasing concentrations of Biotin-RB and (b) Plot of absorbance of RB at 
560 nm against concentration for Biotin-RB, constructed utilizing the spectra shown in Figure 3.11(a). 
 
3.3.3.2 5-Flurouracil 
Due to the absence of a suitable chromophore within the  structure of the 5-FU molecule, 
and the possible interference by other low wavelength absorbing components of the MB 
shell, UV-Vis spectroscopy was not deemed suitable to determine the concentration of 5-FU 
on the MB surface. Instead, high-performance liquid chromatography (HPLC) was used to 
separate and quantify 5-FU in samples of O2MB-5FU. Following the procedure described in 
section 2.4, a calibration curve was again constructed using increasing concentrations of 
biotin-5FU. The HPLC traces are shown in Figure 3.17(a) and reveal a concentration 
dependent increase in concentration at a retention time of 4.5 min.  An intensity / 
concentration plot is shown in Figure 3.17(b) and displays good linearity in the 0-0.4 μM 
range with an R2 value of 0.99. 
Again, using the equation of the calibration line, samples of O2MBs-5FU were analysed for 5-
FU content by HPLC following preparation. 
y = 0.0352x 

























Figure 3. 17 (a) HPLC chromatograms for increasing concentrations of biotin-5FU and (b) Plot of peak area 




For the same reasons as outlined for 5-FU above, the biotin-GEM loading was also 
determined by HPLC. Following the procedure described in section 2.4, the HPLC 
chromatograms of increasing concentrations of biotin-GEM (0.01, 0.1, 0.2, 0.3, 0.4 μmol) 
were recorded. A structured peak was observed for biotin-Gem with a retention time 
centred at 3.3 min. While this was not ideal, when the area of the peak was plotted as 
function of concentration, good linearity was obtained (R2 = 0.98) in the 0 to 0.4 µM range 
and it was decided the method was acceptable for the determination of gemcitabine 
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Figure 3. 18(a) HPLC chromatograms for increasing concentrations of biotin-GEM and (b) Plot of peak area 
against concentration for biotin-GEM, constructed utilizing the average peak area of trace shown in Figure 
3.13(a). 
 
3.3.4.4 Optimization of biotinylated drug loading on the MBs 
When preparing the MB-drug conjugates it is advantageous to maximise the drug loading on 
the MB surface. This can be achieved in several ways: (i) increase the amount of DSPE-PEG 
(2000)-biotin in the MB shell (ii) ensure all the MB biotin sites are bound to avidin and (iii) 
ensure all the remaining avidin sites are bound with drug.  It is also advantageous to keep 
the number of coupling, washing and centrifugation steps to a minimum in order to retain a 
high yield of drug loaded MBs. Previous work has suggested that 9 % of DSPE-PEG (2000)-
biotin incorporation within the MB shell was optimum in terms of MB stability and oxygen 
retention. [140] Therefore, to optimise drug loading, the effect of the avidin coupling and 
the biotin-drug loading steps were investigated to identify the optimum protocol for 
maximum conjugation.  
The first experiment undertaken involved the amount of avidin added to the MBs post 
preparation. 250, 500 and 750 µL aliquots of a saturated avidin solution (75.8 µM) were 
added in a single coupling step to separate PFBMB suspensions and the amount of biotin-RB 
that could be attached to the surface of the PFBMBs determined. Biotin-RB was used as the 
payload in these studies as the UV-Vis method for its quantification was the most 
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the different volumes of avidin is shown in Figure 3.19 and revealed a significant increase in 
loading from 182 µM to 287 µM when the avidin volume increased from 250 µL to 500 µL 
but no significant increase was observed when the volume increased from 500 µL to 750 µL. 
Therefore a single coupling using 500 µL of avidin was identified as the optimum.  
 
Figure 3. 19 Plot of the concentration of biotin-RB present in batches loaded with 250, 500 and 750μL of avidin 
saturated solution. 
The number of biotin-drug couplings to the MB surface was investigated next. A saturated 
solution of biotin-RB (10 mM) was prepared and the amount loaded to the MB surface 
following 1, 2, 3, 4 or 5 sequential coupling steps using 100 µL of the ligand determined. 
Following each coupling step the MB number was also counted. The results [Figure 3.20 (a) 
and (b)] reveal a steady increase in biotin-RB concentration from 264 µM to 875 µM on 
increasing the number of couplings from 1-4 but the 5th coupling step had no significant 
effect.   In addition, the MB number was also found to decrease steadily from 2.3 x 109 MB 
per mL to 1.1 x109 MB per mL from 1-4 couplings but reduced only slightly following the 5th 




Figure 3. 20 (a) Plot of the concentration of biotin-RB present in batches loaded with 1-5couplings of biotin-RB 
saturated solution (5mg/mL, 100μL). 
 
Figure 3.15(b) Plot of each couplings of biotin RB solution with the decrease in total MB number. 
While 4 coupling steps appear advantageous in terms of increasing the drug loading on the 
MB surface, this can be counterproductive if the overall MB number also decreases. 
Therefore, the effect of performing two coupling steps involving 200 µL biotin-RB compared 
to four coupling steps involving 100 µL was also investigated to determine if this could 
maintain a high loading while minimising the reduction in MB number. The results are 
shown in Figure 3.21 and reveal no significant variation in the loading between the two 
experiments suggesting two 200 µL couplings of biotin-drug to be optimum. Using these 
parameters of a single 500 µL of 75.8 µM avidin followed by two 200 uL couplings of 
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saturated biotin drug solution, batches of O2MB-RB, O2MB-5FU and O2MB-Gem were 
prepared.  
 
Figure 3. 21 Plot of the concentration of biotin-RB present in batches loaded with 4 couplings of biotin-RB 
saturated solution (5mg/mL, 100μL) and 2 couplings of biotin-RB saturated solution (5mg/mL, 200μL). 
 
3.3.4 Evaluation of Combined SDT / Antimetabolite treatment in vitro. 
Having successfully prepared batches of O2MB-RB, O2MB-5FU and O2MB-Gem conjugates, 
the next step was to determine the efficacy of combined SDT /antimetabolite treatment in a 
panel of pancreatic cancer cell lines. In advance of this however, it was first necessary to 
ensure that the newly prepared biotin-Gem ligand displayed similar activity to the parent 
compound gemcitabine giving its modification at the sugar hydroxyl position. A range of 
biotin-Gem concentrations were tested in human pancreatic BxPc-3 cells against similar 
concentrations of unmodified Gemcitabine and cell viability determined by a MTT 24 h later. 
The results are shown in Figure 3.22 and reveal no significant difference in efficacy between 
biotin-Gem over the concentration range tested with 5 µM resulting in 78% reduction in 




Figure 3. 22 Plot of viability for BxPc-3 cells treated with GEM and Biotin-GEM (0.1, 5, 10, 25, 50 μM). Error 
bars represent ± the standard error where n=6.Statistically significance versus untreated cells : p <0.001 
 
In addition to ensuring that the biotin modified Gemcitabine (5) possessed similar efficacy 
to Gemcitabine alone, the optimum ultrasound exposure conditions required to minimise 
dark toxicity and maximise SDT efficacy of Rose Bengal was also investigated in advance of 
testing in the four different cell lines. BxPc-3 cells was chosen as the candidate cell line and 
the cell viability determined following treatment with O2MBs-RB (5 µM, 1.2x10
9/mL) in the 
absence and presence of 4 different ultrasound conditions using a frequency of 1 MHz, a 
power of 3 W/cm2 but differing in treatment duration and duty cycle. The four US exposure 
conditions are listed below: 
1. 1MHz 3W/cm2 30% duty cycle for 20s,  
2. 1MHz 3W/cm2 30% duty cycle for 30s,  
3. 1MHz 3W/cm2 40% duty cycle for 20s,  
4. 1MHz 3W/cm2 40% duty cycle for 30s.  
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The results are shown in Figure 3.23 and reveal the optimum treatment time to be 30 sec 
with a duty cycle of 40 % as the differential between US only and SDT was the greatest using 
these conditions. Therefore, US exposure conditions using a frequency of 1 MHz, a power 
density of 3 W/cm2, 40% duty cycle and 30 sec treatment duration were used to investigate 
the effect of combined SDT / antimetabolite therapy on the panel of four pancreatic cancer 
cell lines.  
 
Figure 3. 23 Plot of cell viability for cells treated with O2MB-RB (5 µM, RB) and then exposed to various 
ultrasound exposures. Cells treated with Ultrasound only and O2MB-RB only used for control purposes. US at 
1MHz, 3W/cm2 was used for various times at a duty cycle of 30% or 40%. Statistically significant difference 
versus untreated cells: * p < 0.05, *** p < 0.001. Error bars represent ± the standard error where n=6. 
 
3.3.4.1 Efficacy of combined SDT/antimetabolite therapy in BxPc-3, Mia-Paca2, Panc-01 
and KPC cell lines.  
Human primary pancreatic adenocarcinoma cell lines, BxPc-3, Panc-01 cells, human primary 
carcinoma cell line Mia Paca-2 and the mouse T110299 pancreatic (KPC) were investigated 
as target cell lines.  [170] 5 x 103 cells were seeded in 96 well plates and incubated for 24 h 
with a suspension of either PFBMB-5FU, PFBMB-RB, PFBMB-GEM as well as combined 
PFBMB-5FU / PFBMB-RB or PFBMB-GEM / PFBMB-RB under normoxic conditions. In each 
case the concentrations of drugs were as follows: [RB] = 5 µM, [5-FU] = 100 µM and [Gem] = 
5 µM.   Following the 24h incubation period, selected wells were treated with US using the 
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conditions identified above.  Untreated cells and cells treated with US only were also utilised 
as controls.  The results are shown in Figure 3.24 a-d and reveal that combined chemo-
sonodynamic therapy using the MB platform was more effective than chemotherapy or SDT 
alone in all four cell lines. In addition, chemo-sonodynamic therapy using gemcitabine MBs 
proved more efficacious than the analogous treatment using 5-FU MBs in the BxPc-3, Panc-1 
and Mia Paca-2 cell lines, while in the KPC cell line the efficacy was similar.  These results 
confirm those from similar studies [140,171] and illustrate the complimentary nature of 
antimetabolite and SDT treatments where the cancer cells are attacked using two different 
mechanisms, with the former causing cellular death by disrupting the synthesis of DNA and 

















Figure 3. 24  Plot of % cell viability for (a) BxPc-3 (b) T110299 (c) Mia Paca-2  and (d) Panc-01 after treatment 
with (i) untreated, (ii) ultrasound only, (iii) PFBMB-RB only, (iv) PFBMB-RB plus ultrasound, (v) PFBMB-5FU 
only, (vi) PFBMB-GEM only, (vii) combined PFBMB-RB and PFBMB-5FU, (viii) combined PFBMB-RB and PFBMB-
5FU plus ultrasound, (ix) combined PFBMB-RB and PFBMB-GEM, (x) combined PFBMB-RB and PFBMB-GEM 
plus ultrasound. Statistically significant difference versus untreated cells: ** p < 0.01, *** p < 0.001, ΔΔ p < 
0.01, ΔΔΔ p < 0.001. Error bars represent ± the standard error where n=6. 
86 
 
3.3.5 Effect of US exposure conditions on the efficacy of combined chemo-sonodynamic 
therapy using O2MBs as delivery vehicles. 
Previous work by McEwan et al has established the benefit of chemo-sonodynamic therapy 
using O2MB as the delivery vehicle for the treatment of pancreatic tumours in mice. [140] 
However, these studies involved direct intra-tumoural injection of the O2MB conjugates and 
5-FU as the antimetabolite drug. In addition, the animal model utilised in those studies was 
an ectopic BxPc-3 xenograft that does not carry the KRAS mutation. As mentioned in section 
3.1, it is advantageous to demonstrate efficacy following intravenous injection of the MB 
conjugates instead of intratumoural injection as this is the route that would be used in the 
clinic should this technology undergo clinical translation. In addition, it is also beneficial to 
demonstrate efficacy in two different xenograft models. As chemo-sonodynamic therapy 
using gemcitabine MBs also proved more efficacious than the analogous treatment using 5-
FU MBs in the in vitro studies discussed above, it was of interest to determine how the 
treatments would compare in vivo. Therefore, ectopic Mia Paca-2 tumours were established 
in the dorsum of SCID mice. This cell line carries the KRAS mutation and has been used 
extensively as an in vivo model in pancreatic cancer research. [172] Once tumours reached 
an average volume of 241 mm3, they were randomly allocated into 12 groups. Where 
appropriate, the MB-conjugates were administered by tail vein injection and ultrasound 
applied to the tumour for 3.5 minutes during the injection to disrupt the MBs and release 




Figure 3. 25 A schematic diagram showing combined chemo-sonodynamic therapy using O2MBs as delivery 
vehicles in an ectopic model. 
A second US administration using the same parameters was applied 30 min following the 
first US application, the function of which was to activate the Rose Bengal (i.e. SDT). Tumour 
volume was measured each day for a total of 9 days following treatment. In these studies, 
three different US exposures were investigated involving various power densities (3.5 or 4 
W/cm2) and duty cycles (30 % and 50 %) to identify the optimum in terms of tumour growth 
control. Untreated animals and those treated with the various conjugates alone or 
ultrasound alone were used for comparative purposes.  The exact conditions used for each 













Table 3.1 the list of different treatment groups on SCID mice bearing ectopic Mia Paca-2 tumours (n=5). 
Group Treatment condition 
1 Untreated 
2 the O2MB-Gem/RB conjugate alone 
3 the O2MB-5FU/RB conjugate alone 
4 US treatment alone at 1 MHz, 3.5 W/cm-2 and 30% duty cycle 
5 US treatment alone at 1 MHz, 3.5 W/cm-2 and 50% duty cycle 
6 US treatment alone at 1 MHz, 4.0 W/cm-2 and 30% duty cycle 
7 O2MB-Gem/RB conjugate + US treatment at 1 MHz, 3.5 W/cm
-2 and 30% duty cycle 
8 O2MB-Gem/RB conjugate + US treatment at 1 MHz, 3.5 W/cm
-2 and 50% duty cycle 
9 O2MB-Gem/RB conjugate + US treatment at 1 MHz, 4.0 W/cm
-2 and 30% duty cycle 
10 O2MB-5FU/RB conjugate + US treatment at 1 MHz, 3.5 W/cm
-2 and 30% duty cycle 
11 O2MB-5FU/RB conjugate + US treatment at 1 MHz, 3.5 W/cm
-2 and 50% duty cycle 
12 O2MB-5FU/RB conjugate + US treatment at 1 MHz, 4.0 W/cm
-2 and 30% duty cycle 
 
The results from the 12 groups are shown in three separate plots for clarity (Figures 3.26(a)-
(c)). Figure 3.21(a) shows the results for the untreated, ultrasound only and MB conjugate 
only treated groups (i.e. Gps 1-6) while Figure 3.26(b) and (c) show results for treatments 
with mixed MB preparation containing either GEM (Figure 3.26(b)) or 5-FU (Figure 3.26(c)) 
plus ultrasound. No significant differences were observed for the MB-conjugates only (Gps 2 
& 3) or US stimulus only treatments (Gps 4-6) when compared against the untreated 
controls. For animals treated with the mixed MB preparation containing Gemcitabine, all 
three US exposures resulted in statistically significant reductions in tumour growth when 
compared to the control 8 days following treatment with both the 3.5W/cm2 & 30% DC (Gp 
7) and 4.0 W/cm2 & 30% DC (Gp 9) exposures producing greater tumour reductions than the 
3.5W/cm2 & 50% DC (Gp 8) exposure, although this difference was not statistically 
significant. For animals treated with the mixed MB preparation containing 5FU, only those 
animals treated with a US exposure of 3.5W/cm2 & 30% DC (Gp 10) produced a significant 
reduction (p < 0.01) in tumour volume 8 days following treatment when compared to the 
untreated control, although the magnitude of the tumour reduction and the tumour delay 
profile was similar to Gps 7 & 9. These results suggest that US exposure conditions of 
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3.5W/cm2 & 30% DC provide the best tumour response no matter if the antimetabolite drug 



























Figure 3. 26 Tumour growth plots of mice exposed to O2MB-Gem/RB or to O2MB-5-FU/RB conjugates using 








3.3.6 Effect of treatment schedule on the efficacy of combined chemo-sonodynamic 
therapy using O2MBs as delivery vehicles.  
Having established the optimum US exposure conditions, the next step was to investigate 
the effect of adding an additional chemo-sonodynamic therapy treatment on the tumour 
growth delay. From the results of the single chemo-sonodynamic therapy treatment 
discussed above, it was observed that for Gps 7, 9 & 10, while the tumour volume initially 
reduced below the pre-treatment value for 3 days following treatment it then subsequently 
increased. Therefore, it was decided to administer a second treatment on day 3 following 
the initial treatment to identify if the tumour growth delay period could be extended.  
Animals were randomly allocated into 6 groups and once the tumours reached an average 
volume of 213 mm3 they were treated as described in table 3.2. Group 1 received no 
treatment, group 2 the optimum US stimulus, groups 3 & 4 received the mixed MB 
preparation containing either 5FU or Gemcitabine respectively while groups 5 & 6 received 
the same mixed MB preparations as groups 3 & 4 but also received the optimum US 
stimulus. Treatments were administered on Days 0 and Day 3 with the tumour volumes 
recorded for 8 days following the initial treatment.  
 
Table 3.2 the list of different treatment groups on SCID mice bearing ectopic Mia Paca-2 tumours (n=5). 
Group Treatment condition 
1 Untreated 
2 US only 
3 the O2MB-Gem/RB conjugate only 
4 the O2MB-Gem/RB conjugate + US 
5 the O2MB-5-FU/RB conjugate only 
6 the O2MB-5-FU/RB conjugate + US 
 
The results are shown in Figure 3.27 and again show no significant impact on tumour 
growth for animals treated with ultrasound alone (Gp 2) or the mixed MB preparations (Gps 
3 & 4). However, the results do highlight the value of the second chemo-sonodynamic 
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therapy treatment with the tumour volume of animals treated in groups 5 & 6 remaining 
below their pre-treatment value for 6 days following the initial treatment compared to the 3 
days observed following a single treatment. Interestingly, there was no significant difference 
in the tumor growth delay profile for either Gp 5 or Gp 6, indicating a similar cytotoxic effect 
for either 5-FU or Gemcitabine when part of the mixed MB preparation. To better illustrate 
the impact of the second treatment, two further plots were constructed that included the 
tumor growth delay data for both the single and double treatments [Figure 3.27(b) and 
Figure 3.27(c)] and reveals a significant reduction in tumour volume 8 days following the 
initial treatment for the twice treated animals compared to those receiving a single 
treatment.  
Combined, the above in vivo data suggests that there is no statistically  significant difference 
for chemo-sonodynamic therapy of ectopic Mia Paca-2 tumours using either the O2MB-RB / 
O2MB-5FU or O2MB-RB / O2MB-Gem mixed MB preparations and the optimum US 
conditions (frequency  =  1MHz, power density = 3.5 W/cm2, duty cycle = 30% and pulse 
repetition = 100 Mz). However, the O2MB-RB / O2MB-Gem mixed MB preparation was more 
responsive across a wider range of US exposures compared to the O2MB-RB / O2MB-5FU 
mixed MB preparation. Importantly, a significant benefit was observed in terms of tumour 
growth delay when animals were treated for a second time 3 days after the first treatment. 
This is highly significant as it indicates the tumours do not become quickly resistant to the 
combined antimetabolite / SDT treatment. Future work should explore the benefit of 








Figure 3. 27 (a) Tumour growth plots following two treatments on Days 0 and 3 using the O2MB-GEM/RB and 
O2MB-5-FU/RB conjugates. Control groups also shown. (b) Plot showing overlay of tumour growth following a 
single and double treatment using the O2MB-GEM/RB conjugate + US. (c) Plot showing overlay of tumour 
growth following a single and double treatment using the O2MB-5-FU/RB conjugate + US. *** p <0.001 for 
untreated compared to O2MB-5-FU/RB conjugate + US double treatment and O2MB-5-FU/RB conjugate + US 
single treatment compared to O2MB-5-FU/RB conjugate + US double treatment. * p <0.05 for O2MB-GEM/RB 
conjugate + US single treatment compared to O2MB-GEM/RB conjugate + US double treatment. 
(C) 






























3.3.7 Determination of how combined antimetabolite / SDT treatment affects the 
expression of genes involved in pancreatic cancer.  
Given the impressive results observed for the combined antimetabolite / SDT  in the in vitro 
and in vivo studies discussed above, it was also of great interest to identify any changes in 
the expression of genes involved in apoptosis, autophagy, angiogenesis, hypoxia, resistance 
and malignant progression pathways in pancreatic cancer. [173] To determine this, SCID 
mice bearing ectopic Mia Paca-2 tumours with an average volume of 273 mm3 were 
randomly allocated into 3 groups (n=3). Animals in group 1 received no treatment, those in 
groups 2 received an IV injection (100 μL) of the mixed O2MB-RB and O2MB-Gem conjugate 
containing (2.6 X108 MB / mL, 480.0 µM Gem and 610.0 µM RB) while animals in group 3 
received an IV injection (100 μL) of the mixed O2MB-RB and O2MB-5FU conjugate containing 
3.2 X108 MB / mL, 2.1 mM 5FU and 700 µM RB. Animals in groups 2 and 3 were also 
exposed to US using the optimum parameters as determined in section 3.3.5. 8 days 
following treatment, the animals were euthanised and the tumours removed. The tumours 
were processed as described in section 2.21 and the cellular suspension analysed using qRT-
PCR. The results for the expression of selected genes in tumours harvested from groups 2 
and 3 were compared directly against the same genes in tumours harvested from the 
untreated control group 1. The results are shown in Figures 3.28(a) and (b) for Group 2 and 
Group 3 respectively for 18 different genes associated with apoptosis, hypoxia, stem cell 
differentiation, apoptosis and autophagy in pancreatic cancer. Mia Paca-2 tumours are 
known to be extremely hypoxic [139] and hypoxic stress selects for resistant cancer cells to 
become established and present a more malignant genotype/phenotype.  Hypoxia insult up-
regulates pro survival genes associated with proliferation, stem cell maintenance and 
malignant progression. [174-176] Expression of the hypoxic markers HIF-1α and VHL were 
significantly reduced in both the treatment groups, suggesting that treated tumours were 
less hypoxic than the untreated tumours. Furthermore, a significant decrease was also 
observed for the pro-angiogenic gene VEGFC in both treatment groups suggesting that a 
decrease in endothelial cell recruitment prevents support of the tumour vascular.  RUNX2 is 
a master regulator of bone formation [177] but also has pro-oncogenic functions. Under 
hypoxic stress, RUNX2 becomes elevated to help cancer cells survive [178,179]. The 
presence of RUNX2 has been noticed in several cancer types including, prostate, breast, 
pancreatic and melanoma [178,180-182]. High expression of RUNX2 in tumours contributes 
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to a more resistant aggressive phenotype by targeting genes associated with metastasis, 
apoptosis and angiogenesis [22,178,179,183]. In this study, both treatments caused a 
reduction in RUNX2, although the reduction was not statistically significant for Group 2.   
Cancer stem cells (CSC) are a small population of cells that exist within a cancer tumour. 
[184] Recently it has been noted that CSCs are involved in tumour initiation, growth, 
metastasis and resistance to therapy. [184-187] The data reveals a reduction in CSC 
associated genes (NANOG and EPCAM) in both treatment groups, with group 3 
demonstrating a significant decrease in all three genes examined (SOX2, NANOG and 
EPCAM).  NANOG has been positively identified in human pancreatic adenocarcinoma cells 
[188] and this CSC marker was reduced to 63% and 11% for groups 2 and 3 respectively.    
The expression of three pro-apoptotic (BID, BAX andBAD) and two anti-apoptotic genes 
(BCL2 and BCL2L1) were also analysed. BCL2 is an anti-apoptotic gene that is highly 
expressed in human primary pancreatic tumours. The expression of BCl2 was reduced in 
both treatment groups although the magnitude of decrease was greater for Group 3 
compared to Group 2. Interestingly,   it was significantly decreased by 50% in O2MB-5FU/RB 
+ US compared to untreated, which has also been noted in a previous communication.[140] 
The data reveals that three out of four of the autophagy marker genes (TFE3, ARL8B and 
CLCN7) were up regulated in both treatment groups.  Autophagy is a stress response, 
correlated to the apoptosis pathway that can enhance survival of cells that have been 
damaged. [189] From a mechanistic perspective, the results demonstrate that autophagy is 
clearly playing a role in providing residual cancer cells with survival capabilities after 
treatment. These observations could suggest that targeting autophagy could provide 
additional therapeutic benefit. In general, these results indicate that the combined 
SDT/antimetabolite treatment does not involuntary stimulate any factors that could lead to 
more aggressive disease and the further study should be focused on utilizing more specific 
molecular targeted modalities. 
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Figure 3. 28 Comparison of gene expression in tumours excised on days 8 from mice treated with (a) O2MB-
GEM/RB + US or (b)O2MB-5FU/RB + US compared to untreated. Data in scatter plots were generated using 
quantitative PCR arrays, which were carried out on pooled RNA from tumours excised at each time point (n =3 
per group). Comparison of gene changes on day 8 between untreated and (c) O2MB-5FU/RB + US or (d) O2MB-
GEM/RB + US.  
















































































































































































































3.3.8 Identification of any toxic effects of combined Chemo-Sonodynamic therapy in 
Healthy Non-Tumour Bearing Mice.  
While the active agents used in combined chemo-sonodynamic therapy treatment (i.e. Rose 
Bengal, 5-FU, Gemcitabine and phospholipid based MBs) are approved agents with 
established pharmacokinetic / safety profiles, and given that the targeted nature of the MB 
delivered treatment means that the amount administered is considerably less than that 
used for systemic treatment, it was still deemed prudent to ensure no deleterious 
interaction occurred when the MBs were combined with the active agents. Therefore, 
healthy non-tumour bearing MF1 mice (8 weeks old) were randomly allocated into nine 
groups (n=10; 5 male and 5 female) and treated as described in Table 3.3.  
Table 3.3 the list of different treatment groups on healthy MF1 mice (n=10; 5 male and 5 female to identify 
gender specific effects) 
 
Mice were treated on day 0 and 8 via IV injection with either O2MB-5FU, O2MB-RB, O2MB-
GEM, O2MB-RB / O2MB-5FU, O2MB-RB / O2MB-Gem and a clinically relevant murine dose of 
the free drugs (RB, 5FU and GEM). Blood samples were taken on Days 8 and 15 mice and 
analysed for key biochemical markers in both the whole blood and serum.  Following blood 
collection on Day 15, the liver and kidneys were removed. The body weights of the animals 
in each group were also analysed on a daily basis throughout the study. The results of the 
Group Treatment condition 
1 Untreated 
2 a tail vein injection of the O2MB-RB conjugate 
3 a tail vein injection of the O2MB-Gem conjugate 
4 a tail vein injection of the O2MB-5-FU conjugate 
5 a tail vein injection of the O2MB-Gem-RB mixed conjugate 
6 a tail vein injection of the O2MB-5-FU/RB mixed conjugate 
7 a tail vein injection of free RB 
8 a tail vein injection of free 5-FU 
9 a tail vein injection of free Gem 
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body weight analysis are shown in Figure 3.29 and reveal no significant difference between 
any of the groups indicating a lack of acute adverse effects of free drugs or MB based 
treatments. The blood biochemistry results are presented in Figure 3.30 and again reveal no 
major differences between the free drugs or MB based treatments for any of the key 
biochemical markers. Meanwhile, it was noteworthy that alanine aminotransferase levels 
(ALT) were lower, while neutrophil were slightly higher in the O2MB-Gem / O2MB-RB group, 
relative to the Gem or RB treated groups. Elevated ALT levels are an indicator of liver 
damage while low platelet and neutrophil levels are commonly observed following 
chemotherapy treatment. [190,191]These differences are most likely lower due to the lower 
dose of Gem and RB delivered using the MB platform. In addition, one would expect 
neutrophil counts to be lower following administration of gemcitabine and the trend 
suggests this to be the case in the studies. However, it was interesting to note that 
neutrophil counts were higher in animals treated with the microbubble preparations. It is 
belived that this is again a consequence of targeted delivery of the chemotherapeutic drug 
and administration of overall lower doses to these animals. Similarly, histological analysis of 
liver and kidney sections also revealed no significant changes between the free drugs and 
MB based treatment groups, although there was a slight increase in hepatic lobular 
inflammation and steatosis for these groups relative to the untreated group. Analysis of 
kidney sections showed slightly raised levels of tubular vacuolation for the O2MB-Gem / 
O2MB-RB group, but again these levels were raised in the Gem and RB groups and the 
differences were non-significant. It is worth to notice that the mean score for the liver and 
kidney histology never exceeded 2, which is considered mild. These results reveral that 
O2MB with a sensitiser or antimetabolite payload is safe and nono-toxic and is able to be 





Figure 3. 29 Plot of % change in body weight against time during treatment, group1 untreated, group2,3,and 4 
were clinically relevant doses of RB, GEM and 5FU, group 5, 6 and 7 were O2MB-RB, O2MB-5FU and O2MB-









Figure 3. 31 Mean score of liver (top) and kidney (bottom) sections harvested from healthy MF1 mice treated 









The results obtained in this chapter demonstrate the potential of combined 
SDT/antimetabolite therapy, delivered using O2MBs as a potential treatment of pancreatic 
cancer. SDT involves the activation of RB using low intensity ultrasound. Therefore, in the 
absence of US stimulation, RB is inactive with minimal dark toxicity. The use of O2MBs to 
target gemcitabine delivery to pancreatic tumours also means that much less gemcitabine 
can be used when compared to systemically delivered gemcitabine, also reducing off-target 
toxic effects. Therefore, this approach is not only efficacious but also promises to be 
significantly less toxic than systemic GEM or 5-FU treatment. 
Results from the in vitro experiments demonstrated that the newly prepared biotin-GEM 
ligand could been successfully attached to the avidin functionalised MBs. Combined 
SDT/antimetabolite treatment using O2MB-RB/GEM formulation was generally more 
efficacious when used to treat pancreatic cancer cell lines than the corresponding 
formulation comprising O2MB-RB/5FU. The optimum US conditions for treatment in vivo 
was identified as 3.5W/cm2 & 30% DC for 3.5 mins. However, the efficacy of both O2MB-
RB/GEM and O2MB/5FU were similar when activated using these US conditions. Currently, 
there is no explanation as to why these particular US conditions appear to be best for 
activating the combined treatment in vivo and this is currently an area of on-going 
investigation. Genetic analysis of treated tumours also generated significant difference in 
several genes involved in pancreatic tumour progression when compared to untreated 
tumours. These changes may provide the opportunity for the addition of adjuvants to 
enhance further the efficacy of the treatment. Results from the safety study demonstrated 
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Chapter 4 Magnetically Responsive Microbubbles as Delivery Vehicles for 
Targeted Sonodynamic and Antimetabolite Therapy of Pancreatic Cancer 
4.1 Introduction 
The work undertaken in Chapter 3, investigated the ability of combined antimetabolite and 
sonodynamic therapy (SDT), delivered using oxygen loaded lipid stabilised MBs to cause 
tumour growth delay in an ectopic murine model of the disease. While the study involved IV 
delivery of the MB conjugation and investigated a range of treatment conditions on efficacy 
and safety, the ectopic model used was not reflective of the true clinical situation. Efficacy 
data obtained from ectopic murine models is acceptable for submission as part of a pre-
clinical dossier to regulators such as the MHRA for clinical trial approval. However, to fully 
test the suitability of a delivery vehicle, particularly MBs, to treat internal tumours, an 
orthotopic tumour model presents a greater challenge. Therefore, in this chapter, the ability 
of lipid stabilised microbubbles to deliver combined antimetabolite / sonodynamic therapy 
to orthotopic pancreatic tumours will be assessed. To enable the deposition of more 
payload than would be possible with ultrasound mediated MB destruction alone, the MB 
shell was also functionalised with magnetic lipids to add an additional layer of targeting to 
the delivery platform. 
4.2 Aims and Specific Objectives 
The major aim of the work undertaken in this chapter was to determine if external magnetic 
and low-intensity ultrasound fields can enhance the efficacy of combined antimetabolite / 
sonodynamic therapy, delivered using magnetically responsive microbubbles, in an 
orthotopic murine model of pancreatic cancer.  The specific objectives were:  
1. To prepare lipid stabilised O2MBs with magnetic lipids embedded in the shell (MagO2MB) 
and loaded with Rose Bengal (MagO2MB-RB) or 5-FU (MagO2MB-5FU). 
2. To determine the ability of the MagMB conjugates to be retained during flow using an 
externally applied magnetic field.  
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3. To investigate the efficacy of MagO2MB-RB, MagO2MB-5FU and MagO2MB-RB / 
MagO2MB-5FU conjugates in vitro using a panel of three human pancreatic (Panc-1, Mia 
Paca-2 and BxPc-3) and a mouse primary (T110299) pancreatic cancer cell lines both in the 
presence or absence of ultrasound.  
4. To determine the efficacy of the combined MagO2MB-RB / MagO2MB-5FU conjugates in 
mice bearing orthotopic BxPc-3 Luc tumours in the presence of external ultrasound and / or 
magnetic fields. 
5. To evaluate the effect of the combined antimetabolite / sonodynamic therapy on the 
expression of selected genes and proteins in harvested tumour tissues. 
















4.3 Results and Discussion 
4.3.1 Preparation and Characterisation of MagMBs. 
As described in section 2.5, MagMBs were prepared by sonication of DBPC, DSPE-PEG 
(2000) and DSPE-PEG(2000)-biotin lipids in the presence of PFB gas and superparamagnetic 
iron oxide nanoparticles (SPIONs). The magnetic nanoparticle formulation comprised an iron 
oxide core with a lipid coating to facilitate incorporation of the magnetic nanoparticles into 
the MB shell. A schematic representation of the MagMBs is shown in Figure 4.1(a) and 
indicates how the lipid nanoparticles (red sphere) embed in the MB shell. The PFB 
containing MagMBs (MagPFBMBs) had an average diameter of 1–2 μm with a concentration 
of approximately 1.97 × 109 MB/mL as determined by analysis of optical microscopy images. 
(Figure 4.1(b))  
 
Figure 4. 1(a) Photomicrograph taken with a 40x objective lens of MagMBs after centrifugation (300 RCF, 5 
min) and dilution (1:10) in PBS. Scale bar is 20µm. (b) Size distribution of MagMBs obtained from analysis of 
the optical microscope images detected by ImageJ analysis software. 
Following isolation of the MagPFBMBs by centrifugation and surface coating with avidin, 
biotin-RB and biotin 5-FU were added to separate batches of the MagPFBMBs to generate 
RB loaded MagPFBMBs (MagPFBMB-RB) and 5-FU loaded MagPFBMBs (MagPFBMB-5FU) 
respectively. The PFB core gas was then exchanged with oxygen by sparging a MagMB 
conjugate suspension with pure oxygen gas for 2 min generating the MagO2MB-RB and 




Figure 4. 2 Schematic representation of the MagO2MB-5FU and MagO2MB-RB conjugates. 
4.3.1.1 Determination of Iron NPs loading on MagMBs 
To determine the loading of the SPIONs in the MagMB shell, the Iron (III) content was 
determined using atomic absorption spectroscopy (AAS). A calibration curve was first 
constructed by measuring the Fe (III) intensity at 248.3 nm in standard samples (Figure 4.3) 
and good linearity (R2 = 0.99) observed in the 0 – 6 mg/L range. The amount of Fe (III) in a 
fixed amount of the MagMBs was then determined. As the SPIONs are formed from 
magnetite (Fe3O4) which is a mixture of Fe (III) and Fe (II) oxides in a ratio of 2:1, the total 





mg/L )by 1.5 to obtain a final value of 286.2mg/L corresponding to 0.286 mg per 109 MB. 
 
Figure 4. 3 Plot of Atomic absorbance intensity against Fe (III) concentration for a range of Fe (III) standard 
solutions.  
 
4.3.1.2 Retention of MagMBs in a flow-phantom using an external magnetic field. 
In order to determine the magnetic response of the platform, suspensions of MagO2MBs (1 
mL) were placed in a syringe and pumped through a flow chamber (0.6 mL/min) with a fixed 
magnet (0.46 T) positioned on the underside of the flow chamber during the course of the 
experiment. (Figure 4.4) 
y = 0.0058x 






























Figure 4. 4 Schematic of the syringe driver and flow chamber, in the absence (top) and presence (bottom) of a 
fixed magnet, to determine magnetic responsiveness of the MBs flowing through the flow chamber. 
A control study was also performed in the absence of a fixed magnet but under identical 
conditions. At the end of each experiment, the number of MagO2MBs retained in the flow 
cell was counted as shown in Figure 4.5. A significant increase in MagO2MBs number 
(p<0.01) was observed when the fixed magnet was present indicating the ability of the 
MagO2MBs to be retained against flow using an external magnetic field. Blood flow rates 
within the human body vary considerably depending on vessel type and size with blood 
leaving the aorta (2400 cm min-1) at a flow rate approximately 3 orders of magnitude 
greater than in capillaries (1.8 cm min-1).[192] In tumours, the increased viscous and 
geometrical resistance presented by the vasculature can compromise its blood flow, 
meaning the average velocity of blood in tumour vessels can be an order of magnitude 
lower than in normal vessels.[193] Therefore, the flow rate used in the current study was 
towards the upper limit of rates chosen to study tumour perfusing resistivity which suggests 
that magnetic targeting may be effective in helping MBs retain in the tumour vasculature 




Figure 4. 5 Plot of MBs retained after injection through a flow-cell in the presence and absence of a fixed 
magnet.  
In order to retain a useful proportion (10%) of injected microbubbles at these blood flow 
rates, an estimated magnetic field gradient of 0.15 T/m would provide sufficient force to 
capture superparamagnetic particles flowing the capillary vessels. [194] When considering 
the possible translation of such technology to the clinic, both transabdominal and 
endoscopic sources are viable methods for the delivery of magnetic fields to the pancreas. 
In the context of the above capillary flow rates, optimised permanent magnet designs with a 
volume of 1.02 cm3 [195] would be capable of targeting a tumour through the duodenal wall 
as part of an endoscopic probe, where the approximate distance to the head of the 
pancreas is in the region of 10 mm. (This was informed by our clinical colleagues.) In the 
case of transabdominal delivery, where the distances are more variable depending on the 
patient’s body to mass index (BMI), the optimised permanent magnet volume would be in 
the region of 1.66 cm3, based on a distance of 50 mm from the outside of the abdomen to 
the pancreas. Even at flow rates 5 times higher than the capillary flow rate used above, the 
estimated field gradient to retain the same fraction of MBs would be 2.48 T/m, requiring 
permanent magnet volumes in the region of 1.5 cm3 for an endoscopic device, which is 
readily achievable. [197] Given endoscopic ultrasound (EUS) analysis is a common diagnostic 
tool used in staging pancreatic cancer, a EUS device configured to deliver both magnetic and 




4.3.2 In vitro cytotoxic efficacy of sonodynamic treatment with MagO2NPs 
The efficacy of combined antimetabolite / sonodynamic therapy has previously been 
established in a range of pancreatic cancer cell lines by McEwan et al [140] and also in 
Chapter 3 of this thesis. These experiments were also repeated in this chapter to ensure the 
presence of the redox active Fe (II) or Fe (III) does not negatively impact on the SDT or 5-FU 
efficacy. This is particularly valid for SDT as the active agent is ROS that could potentially be 
impacted by Fe (II) or Fe (III) by participating in electron transfer reactions. Human 
pancreatic BxPc-3, Mia Paca-2 and Panc-01 cancer cells were chosen as targets in addition to 
a mouse primary T110299 cell line. [170] 5000 cells per well were seeded in 96 well plates 
and treated with a suspension of either MagO2MB-5FU, MagO2MB-RB or combined 
MagO2MB-5FU / MagO2MB-RB with selected wells then exposed to low-intensity ultrasound 
(3.5W/cm2 & 30% DC for 3.5 mins). Untreated cells and cells treated with ultrasound only 
were used as controls. Cell viability was then determined 24h later using a MTT assay. A 
magnetic field was not used in this in vitro study as the purpose of the fixed magnetic field 




Figure 4. 6 Plot of % cell viability for (a) BxPc-3 (b) T110299 (c) Mia Paca-2 and (d) Panc-01 after treatment with 
(i) untreated, (ii) ultrasound only (iii) MagO2MB-5FU only (iv) MagO2MB-RB only, (v) combined MagO2MB-RB 
and MagO2MB-5FU and (vi) combined MagO2MB-RB and MagO2MB-5FU plus ultrasound. Significance of (vi) 
versus (ii), (iii), (iv), or (v): *** p <0.001. 
A significant reduction (p<0.001) in cell viability was observed in all cell lines that received 
the combined treatment (i.e. MagO2MB-RB / MagO2MB-5FU + US) (Figure 4.6). In contrast, 
both the MagO2MB-5FU and MagO2MB-RB alone (i.e. no US) demonstrated only a slow cell 
proliferation reduction (<10%) meaning it was possible to control the generation of 
cytotoxicity using the ultrasound stimulus. Therefore, these results suggest that application 
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of ultrasound not only facilitates at the same time the release of encapsulated O2 gas with 
the attached RB/5-FU into the extracellular medium but is also able to activate RB after 
sonostimulation, leading as consequence to ROS generation. [140] It is also possible that 
application of the ultrasound could be enhancing the action of 5-FU by means of 
sonoporation.  Indeed, it has been shown that this strategy can be employed to enhance the 
action of cancer chemotherapeutics by affording transient intracellular access of the drug 
via sonoporation. [198] 
 
4.3.3 Investigating the effect of combined 5-FU / SDT treatment using MagO2MBs for 
therapeutic effect in an orthotopic pancreatic cancer murine model. 
After obtaining promising results with the combined antimetabolite/SDT therapy using the 
MagO2MB platform in the in vitro studies outlined above, the next step was to evaluate the 
benefit of magnetic targeting in an in vivo model. For this purpose, orthotopic human 
xenograft BxPc-3-Luc pancreatic tumours were established in SCID mice.  
 
Figure 4. 7 A schematic diagram showing magnetic MBs to improve targeting further in an orthotopic model. 
This was achieved by surgically implanting BxPC-3-Luc cells into the head of the pancreas. 
















(n=4): group 1 received no treatment; group 2 received a MagO2MB-5FU / MagO2MB-RB 
suspension administered intravenously with the tumour region exposed to low-intensity 
ultrasound during and following injection for a total exposure of 3.5 min; group 3 also 
received an IV injection of the MagO2MB-5FU / MagO2MB-RB suspension but in addition to 
ultrasound treatment, a permanent magnet was also directed at the tumour during 
ultrasound treatment. Treatments were repeated on days 20 and 21 with the mice 
sacrificed on day 28. [199] This treatment schedule was determined on the basis that as the 
main use of this technology will be as a neo-adjuvant treatment to downstage tumours in 
advance of surgery, an aggressive treatment of the tumours with three successive 
administrations was the preferred choice. 
 
Figure 4. 8 (a) Photograpies of orthotopic BxPc-3 Luc tumours removed from SCID mice 28 days following 
implantation after (i) no treatment (top), (ii) treatment with combined MagO2MB-RB and MagO2MB-5FU plus 
ultrasound (middle) or (iii) treatment with MagO2MB-RB and MagO2MB-5FU plus ultrasound and magnet 
(bottom). Treatments were administered on day(s) 19, 20 and 21. (b) Plot of % change in tumour volume 





A statistically significant reduction in tumour volume of 48.3% (p < 0.05) was observed in 
mice treated with MagO2MB-5FU / MagO2MB-RB and the permanent magnet directed at 
the tumour during ultrasound treatment, compared to untreated mice. For mice treated 
with MagO2MB-5FU / MagO2MB-RB and ultrasound but no magnet, the tumours were 
27.9% smaller than untreated tumours although the reduction was not statistically 
significant. This improvement in efficacy in the presence of a magnetic field could be due to 
more MBs being retained in the tumour microenvironment, so that ultrasound exposure can 
enable enhanced deposition of MB payloads and subsequent activation of the sensitiser. 
These results suggest a benefit of incorporating magnetic targeting into the MB platform to 
enhance the combined chem-sonodynamic therapy of orthoptic tumours.  
 
4.3.4 Investigation of the treatment efficacy on the expression of Caspase and Bax 
biomarkers 
Since the combined antimetabolite / sonodynamic therapy using the MagO2MB conjugates 
showed encouraging results both in the in vitro and in vivo experiments, the effect of the 
treatment on caspase and BAX protein expression was investigated. For this purpose, mice 
from in vivo experiments described in section 4.3.3 were euthanized following treatment, a 
single cell suspension was prepared from the excised tumours. The cell suspension was 
analysed for active caspase and BAX protein expression using flow cytometry. RNA was also 
extracted from tissue and gene expression analysed using qRT-PCR for relative expression of 
TMBIM1 (Transmembrane BAX Inhibitor Motif-Containing Protein 1). The results are shown 
in Figure 4.9 and reveal that activated caspase and BAX protein levels were both 
significantly elevated in tumours treated with the combined MagO2MB-RB / MagO2MB-5FU 
conjugates and ultrasound / magnetic fields compared to expression of those proteins in 




Figure 4. 9 (a) Plot showing presence of active caspase in single cell suspensions derived from tumours 
removed from SCID mice 28 days following implantation and left untreated (i), (ii) or treated with combined 
MagO2MB-RB and MagO2MB-5FU plus ultrasound (middle) or (iii) MagO2MB-RB and MagO2MB-5FU plus 
ultrasound and magnet fields (right). Caspase activity, reflective of apoptosis, was performed evaluating Pan 
Caspase probe fluorescence intensity via flow cytometry. (b) Plot of evaluation of BAX protein expression via 
flow cytometry. *p < 0.05 for (iii) compared to (i). (c) Plot of relative expression of TMBIM1 in untreated 
control tumours and those receiving combined treatment. ***p<0.001. 
 
Increases in activated caspase and BAX protein levels are indicative of increased apoptosis 
[200] and consistent with the increased treatment efficacy observed for Group 3. Although 
BAX and caspase were not significantly increased in group 2, a trend in tumour size 
reduction was observed for this group (Figure 4.9).  Previous studies by MecEwan et al have 
shown that ectopic BxPc-3 tumours receiving combined antimetabolite / SDT treatment in 
the absence of a magnetic field resulted in decreased tumour size and expressed markers 
for increased apoptosis. [140] Although significant differences exist in the manner in which 
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this and the previous study done by McEwan et al [171] were performed both from the 
perspective of the model type (orthotopic vs. ectopic) and that of the dosing regimen 
(multiple vs. single), it was felt that the reduction ‘trend’ observed in group 2 in the current 
study (Figure 4.9) warranted further consideration. To this end, qRT-PCR analysis 
demonstrated that TMBIM1 was significantly downregulated in tumours receiving the 
combined treatmentand exposed to US only (i.e. in the absence of a magnetic field) (Figure 
4.9). Since TMBIM1 is an inhibitor of BAX, [201] its down regulation in these tumours could 
lead to enhanced BAX-mediated apoptosis without an observable change in BAX 
concentration. However, it is realised that the data presented in Figures 4.9(b) and (c) were 
derived from tumours removed at a specific time point (9 days) following treatment and 
these data may differ if longer or shorter time-points were chosen. Continuing studies will 
include a more in-depth examination of gene expression at various time points in order to 
more clearly elucidate the interplay between both of these genes and their role in 
treatment-induced apoptosis.    
 
4.3.5 Determining the safety of MagO2MB conjugates-in a healthy mouse model 
It was also observed during the above studies that animals who received the magnetically-
responsive platform treatment did not suffer any overt adverse effects and no significant 
change in body weight was observed over the course of the experiment [Figure 4.10(a)]. As 
undertaken in Chapter 3, a more detailed toxicology study was performed to investigate this 
safety aspect further by administering the MagO2MB-5FU / MagO2MB-RB suspension to 10 
healthy non-tumour bearing MF1 mice by tail vein injection on Days 0 and 8. Similar 
experiments were undertaken involving MF1 mice treated with 5-FU or RB alone at 
concentrations higher than those present on the MagO2MBs in order to reflect clinical 
doses. Blood samples were harvested from each group of animals on Day 15 and analysed 
for a range of key biochemical markers [Figure 4.10(b)]. No major differences in profile were 
observed between MagO2MB-5FU / MagO2MB-RB group and the other groups, which would 
raise any concern regarding toxicity of the combined MB-based treatment. Indeed ALT 
activity, which is a measure of liver function, was lower in the MagO2MB-5FU / MagO2MB-
RB group compared to the other groups. While there was an increase in platelet and 
lymphocyte levels for the MagO2MB-5FU / MagO2MB-RB group relative to the untreated 
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group, levels were also raised in 5-FU and Rose Bengal treated animals and the differences 












Figure 4. 10 (a) Average body weight of mice following treatment with vehicle only, i.e. MagO2MB, a 
suspension of MagO2MB-RB / MagO2MB-5FU + ultrasound, or a suspension of MagO2MB-RB / MagO2MB-5FU + 
ultrasound + magnet. (b) Whole blood and serum biochemistry analysis from healthy MF1 mice (i) untreated 
control, or treated with (ii) a suspension of MagO2MB-RB / MagO2MB-5FU, (iii) 5-FU alone, or (iv) RB alone. 



























Similarly, there was evidence of mild neutropenia in the three treatment groups relative to 
the untreated group, but again the difference between the MagO2MB-5FU / MagO2MB-RB 
group and the 5-FU and RB groups was not significant. Furthermore, histological analysis of 
liver and kidney sections removed post-mortem on Day 16 also revealed no significant 
changes between the MagO2MB-5FU/MagO2MB-RB group and the 5-FU or RB treated 
groups (Figure 4.11).  
 
Figure  4. 11 Scoring for sections of (a) liver and (b) kidney following (i) no treatment, or treatment with (ii) 5-
FU alone, (iii) RB alone, or (iv) a suspension of MagO2MB-RB / MagO2MB-5FU conjugates. Portal inflammation 






A slight increase in liver steatosis score was observed in MagO2MB-5FU/MagO2MB-RB group 
but this was not significant when compared to the 5-FU or RB groups. It has been reported 
in literature that liver steatosis, also known as fatty liver disease,  can also be influenced by 
certain chemotherapeutic drug treatment, including antimetabolites. [202] The slight 
increase in score for the MagO2MB-5FU / MagO2MB-RB group relative to 5-FU or RB may be 
due to the uptake and metabolism of the lipid component of the MBs and on that basis is 
likely a transient change of limited clinical significance. Analysis of kidney sections showed 
slightly raised levels of glomerular cellularity and tubular vacuolation for the MagO2MB-
5FU/MagO2MB-RB group also observed in the 5-FU and RB groups. It must be stressed, 
however, that any effect observed in the liver or kidney histology analysis was deemed to be 
mild and in no case the mean score exceeded 2. Collectively, these results indicate the 
potential of MagO2MBs as a safe and effective platform for the delivery of combined 









Figure 4. 12 Representative H&E images of liver (top) and kidney (bottom) sections taken from animals 








4.4 Conclusions  
Magnetically responsive MBs were successfully prepared and shown to be retained at a 
target site in the presence of an externally applied magnetic field. When decorated with the 
sensitiser RB and the antimetabolite 5-FU and subjected to ultrasound treatment, MagO2MB 
conjugates induced a significant reduction of pancreatic cancer cell viability, greater than 
50%. The combined application of external magnetic and ultrasound during IV delivery of 
the MagO2MB conjugates resulted in a 48.3% reduction in orthotopic pancreatic tumour 
volumes 9 days after treatment, while the application of ultrasound alone resulted in a 
reduction of only 27.9%. In addition, a significant increase in apoptosis was observed in 
tumours that were treated with the MagO2MB conjugates and exposed to both magnetic 
and ultrasound fields when compared to the ultrasound treatment alone or untreated 
groups. The results presented in this chapter confirm the effectiveness of combined 
sonodynamic/antimetabolite therapy using MagO2MB as delivery platform in a pancreatic 
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Chapter 5 Oxygen Generating Nanoparticles for Improved Photodynamic 
Therapy of Hypoxic Tumours 
5.1 Introduction 
Combatting hypoxia is a major challenge in the treatment of solid tumours using PDT or SDT 
as oxygen is a key requirement for the generation of ROS using these techniques. This is 
particularly true for tumours of the pancreas [203] and hypoxia is now recognised as an 
indicator of poor prognosis for many types of cancer.[204,205] Inefficient gas and mass 
transfer resulting from atypical vascularisation together with elevated oxygen demand by 
hyper-proliferating tissues results in hypoxia in most solid tumours. Once a hypoxic 
environment develops in the tumour, cell populations become resistant to many 
conventional cancer chemotherapeutic agents through a variety of adaptive survival 
mechanisms. Similarly, for radiotherapy, oxygen has been shown to play a very significant 
role in enhancing radiation induced damage to nucleic acid in target tissues. [139] One of 
the major challenges associated with the latter has been to provide oxygen to the target 
tissues during therapy. A number of approaches have been employed including, hyperbaric 
oxygen breathing and breathing pure oxygen or carbogen at atmospheric pressure. [157] 
Such approaches, however, have delivered limited success and there is still a significant un-
met need in this area. Previously, work by McEwan et al, has demonstrated that the 
selective destruction of oxygen loaded microbubbles in the tumour microenvironment using 
low intensity ultrasound provided a temporary boost in tumour oxygen levels that enhanced 
the sonodynamic therapy (SDT) treatment of pancreatic tumours [158] and this approach 
was adopted in Chapters 3 & 4. However, in this chapter, the development of in situ oxygen 
generating nanoparticles as an alternative method to improve tumour oxygenation during 
PDT will be explored.  
The principle of O2 generation using CaO2 NPs has been discussed in section 1.5.3. However, 
if CaO2 NPs are to be used in biological applications and in particularly in vivo, it is 
imperative they remain stable in circulation until taken up by target tissue (i.e. tumour) so 
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that inadvertent systemic activation is limited. In theory, it should be possible to coat the 
NPs with a polymer that has low aqueous solubility at physiological pH (i.e. 7.4) but 
possesses increased solubility in environments where the pH is mildly acidic. Tumour tissue 
interstitial fluid is known to be more acidic (pH = ~6.0) than normal tissue, as hypoxia 
generates an overproduction of acid by inducing the production of energy from glycolysis 
via the Pasteur effect. [206] This difference in pH has been utilised in numerous pH-
responsive cancer therapeutics and diagnostic probes. [207] In the context of using CaO2 
NPs as a means for in situ oxygen generation, it may be possible to use this difference in pH 
to facilitate targeted oxygen delivery during PDT and enhance its effectiveness in hypoxic 
environments.  
The aim of the work presented in this chapter was to develop a pH responsive coating for 
CaO2 NPs that would protect the particles from rapid decomposition at neutral pH but 
facilitate the process in a mildly acidic environment. Eudragit E was chosen as a starting 
point as this polymer has been shown to suppress drug release at pH 7.4 when used as a 
tablet coating but rapidly dissolves in acidic medium to release the active drug. [208] 
Eudragit E contains a tertiary amine that ionises in acidic medium facilitating its dissolution.  
Therefore, in this chapter, a pH responsive polymer 11, similar in structure to Eudragit E was 
developed to coat the CaO2 NPs and protect them from decomposition in water at pH 7.4 
but facilitate their dissolution when the pH reduced to 6.0. The effect of this oxygen 




Figure 5. 1 Schematic representation of core-shell based NPs, where CaO2 comprises the core with pH-














5.2 Aims and objectives 
The main aim of the work undertaken in this chapter was to prepare and characterise CaO2 
NPs capable of oxygen generation upon decomposition in water. A pH-responsive 
methacrylate based terpolymer was also synthesised, characterised and used to the coat 
CaO2 NPs. The ability of the particles to improve oxygenation in hypoxic environments and 
enhance PDT-mediated treatment has been evaluated using BxPc-3 pancreatic cancer cells 
in vitro and an ectopic Mia Paca-2 xenograft murine model in vivo.  
 
The specific aims were: 
1. To synthesise and characterise uncoated CaO2 NPs. 
 
2. To determine the ability of the uncoated CaO2 NPs to generate molecular oxygen upon 
contact with water and improve oxygen levels in the immediate environment. 
 
3. To determine the ability of the CaO2 NPs to improve PDT mediated ROS production in 
BxPc-3 pancreatic cells cultured in a hypoxic environment. 
 
4. To synthesise the pH-responsive methacrylate based terpolymer (11) and coat the CaO2 
NPs using a modified oil-in-water emulsion technique. 
 
5. To determine the ability of the CaO2-11 particles to generate oxygen as a function of 
solution pH by monitoring the increase in dissolved oxygen. 
 
6. To determine the ability of the CaO2-11 particles to enhance tumour oxygenation in an in 





5.3 Results and Discussion 
5.3.1 Synthesis of bare CaO2 nanoparticles 
CaO2 NPs were prepared following a hydrolysis-precipitation procedure similar to that 
developed by J. Khodaveiside et al. [163] that utilised CaCl2 as a calcium precursor and 
polyethylene glycol 200 (PEG200) as a surface modifier. The CaCl2 and PEG200 were stirred 
in an aqueous ammonium solution to ensure the solution was basic. Hydrogen peroxide, 
unstable in basic pH, was added dropwise to the CaCl2 solution, oxidising the CaCl2 to form 
CaO2. As a molar excess of hydrogen peroxide was used relative to calcium chloride and 
ammonia, upon completion of the stirring period the solution was made basic using NaOH 
which decomposed the remaining hydrogen peroxide and also precipitated the CaO2 
nanoparticles that were collected by centrifugation. An equation for reaction is shown in 
equation 5.1 
 
CaCl2 + 2H2O2 + 2NH4OH  CaO2 + 2NH4Cl + 2H2O                                                     Equation 5.1 
 
5.3.2 Characterisation of bare CaO2 nanoparticles 
5.3.2.1. Particle size determination. 
Dynamic light scattering (DLS) and scanning electron microscopy (SEM) were used to 
determine the size of CaO2 nanoparticles. The principle behind DLS is derived from the 
Brownian motion of particles in solution interacting with coherent light irradiation leading 
to light scattering at a particular frequency. This frequency change, known as a Doppler shift, 
is linearly associated with the size of the particles. [209] The average hydrodynamic 
diameter of the CaO2 NPs, recorded in pure ethanol solution to reduce the possibility of 
degradation, was determined as 20.3 ± 6.2 nm. (Figure 5.2a) To further confirm the particle 
size, the  NPs were also analysed by SEM which identified spherical particles with an average 
diameter of 116.0 ± 7.6 nm. (Figure 5.2b), much greater than observed by DLS. This was 
surprising as DLS normally yields larger diameters than SEM due to the attraction of solvent 
molecules to the particle surface. Closer inspection of the particle morphology in the SEM 
image, however, revealed the appearance of several smaller particles coalesced together to 
form the larger sized NPs. One possible explanation for the variation in particle daimaeter 
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using the two techniques is that when dispersed in ethanol, the larger particles detected by 
SEM disaggregate into the smaller particles observed by DLS in solution. 
 
 
Figure 5. 2 Representative (a) DLS plot and (b) SEM image of CaO2 NPs. 
 
5.3.2.2 Active CaO2 present in nanoparticle powder 
In order to quantify the percentage of CaO2 present in the NPs, the reaction between 
luminol and H2O2 was utilised (Figure 5.3). Chemiluminescence (λmax=458nm) production 
relies on the reaction between luminol and H2O2 to generate the electronically excited 
product amino phthalate, which generates luminescence when it returns to the ground 
state. [210] Hence, active CaO2 can be determined by reacting the NPs with water first to 




Figure 5. 3 Reaction scheme of luminol and H2O2. Reproduced from ref[210] 
A calibration curve for the reaction H2O2 with luminol was constructed following the 
procedure described in section 2.10. The plot, shown in Figure 5.4, displayed good linearity 
(R2 = 0.99) in the 0-0.4 μmol range for H2O2. 
 
Figure 5. 4 Calibration curve for 0.035% H2O2 in NaOH/EtOH solution 
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Using the equation of the line from Figure 5.4 and the stoichiometric ratio identified in 
equation 5.1, it was possible to calculate the amount of active CaO2 present in a fixed 
amount of NP powder. 
A solution (50 µL) of dried nanoparticle powder (8.5 x 10-3 mg) in ethanol was reacted with 
luminol generating a luminescent signal that corresponded to 0.053 mmol H2O2.   
From equation 5.1: 
 
2CaO2 + 4H2O → 2 Ca(OH)2+2H2O2→ 2 Ca(OH)2+ 2H2O+O2    
2 moles of CaO2 reacts to produce 2 moles of H2O2.  
Therefore, 8.5 x 10-3 mg of dried nanoparticle powder produced H2O2 (0.053 mmol) that 
resulted from an equimolar amount of CaO2. Using the RMM of CaO2 = 72 g, the weight of 
active CaO2 is 0.053 mmol x 72 = 3.82 x 10
-3 mg (44.9%). Using this approach, the active 
CaO2 content of the NPs was determined as 44.9 ± 2.1 %, with the remainder most likely 
comprising the other main excipient PEG (200) used in preparation of the NPs. 
 
5.3.2.3 Oxygen generating capability of CaO2 nanoparticles in de-oxygenated PBS solution. 
To identify the capability of the unmodified CaO2 NPs to generate oxygen upon reaction 
with water, a PBS solution (pH = 7.4 ± 0.1) was de-oxygenated to generate a simulated 
hypoxic environment. After determining the baseline % dissolved oxygen reading, a known 
quantity of the CaO2 NP powder was added to the solution and the change in % dissolved 
oxygen monitored over time. The results are shown in Figure 5.5(a) and reveal a rapid 
increase in dissolved oxygen level (37.25%) 10 minutes after NP addition with no further 
increase observed over the next 10 min suggesting all the CaO2 NPs were used up. In 
contrast, a deoxygenated PBS solution that was exposed to the open atmosphere increased 
by only 4.10 % over the same time period.  When a second bolus of CaO2 NP was added to 
the solution at t = 20 min, the dissolved oxygen reading again increased 2.5 min later and 
levelled off 5 min after the addition, suggesting the solution became saturated with oxygen 
[Figure 5.5(b)]. These results demonstrate that the CaO2 NPs rapidly decompose when they 
come into contact with aqueous medium generating a significant enhancement in the 








Figure 5. 5 (a) Plot of dissolved oxygen for a solution of deoxygenated PBS over a period of 20 min in the 
absence (diamonds) or presence (circles) of CaO2 NPs. (b) Showing the effect of a second bolus of CaO2 NPs 
20mins after the first bolus was added. 
 
5.3.2.4 Ability of CaO2 NPs to enhance singlet oxygen generation in PDT. 
It has been widely recognised that ROS generation is highly dependent on adequate oxygen 
supply in different biological systems and, in particular, in photodynamic therapy (PDT) of 
solid tumours. [211] To identify if the improved dissolved oxygen levels generated by the 
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the singlet oxygen probe sensor green (SOSG) was utilised. SOSG is inherently non-
fluorescent but reacts with singlet oxygen to generate a fluorescent product with the 
fluorescence intensity being proportional to the amount of singlet oxygen generated (Figure 
5.6). [212] 
 
Figure 5. 6 Schematic graph of SOSG reaction with singlet oxygen. PET= photoinduced electron transfer. 
Reproduced from ref [212] 
 
A deoxygenated PBS solution (2:98; EtOH: H2O) containing SOSG (2.5µM) and the sensitiser 
RB (5 µM) was added to an ethanol solution containing CaO2 NPs added to reach a final 
concentration of 35.6 µM. The solution was then irradiated with white light for 5 min at 
which point the fluorescence intensity at 530 nm was measured. Control experiments in the 
absence of the CaO2 NPs (i.e. RB, SOSG and light) and CaO2 NPs only (i.e. CaO2 NPs, SOSG, 
and light) were also conducted for comparative purposes. The results are shown in Figure 
5.5 and reveal a significant increase in the amount of SOSG fluorescence observed for the 
solution containing CaO2 NPs, RB and treated with light compared to either the CaO2 NPs+ 
light (324.8 % less) or the RB + light (112.9 % less) control groups, indicating the ability of 
the NPs to provide oxygen during the photodynamic event and enhance ROS generation in 




Figure 5. 7   Plot of % increase in SOSG fluorescence at 510 nm for solutions containing (i) deoxygenated PBS 
(ii) deoxygenated PBS and CaO2 NPs (iii) deoxygenated PBS and Rose Bengal (RB) and (iv) deoxygenated PBS, 
RB and CaO2 NPs. Groups (ii)-(iv) also received light treatment. Statistically significance of deoxygenated 
PBS/RB/NPs versus deoxygenated PBS, RB and CaO2 NPs: ***p <0.001. 
 
5.3.3 Ability of unmodified CaO2 NPs to enhance PDT efficacy in BxPc-3 cells cultured in an 
anaerobic cabinet. 
Having determined the ability of the CaO2 NPs to improve the light induced ROS generation 
of RB in a simulated hypoxic environment, the next step was to determine if this improved 
ROS generation would also result in increased RB mediated PDT induced toxicity using 
human BxPc-3 pancreatic cancer cells as a target. However, in advance of undertaking the 
PDT experiments, it was first necessary to identify the optimum CaO2 concentration to use. 
This involved treating BxPc-3 cells with a range of CaO2 concentrations (0-1.0 mM) and 
determining cell viability using a MTT assay. The results are shown in Figure 5.8 and reveal 
no significant reduction in viability for cells treated with either 25 or 50 µM CaO2 NP 
concentrations. At higher concentrations, the cell viability reduced from 84 % at 100 µM to 
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80 % at 1000 µM. Therefore, a 50 µM concentration was identified as optimum for use in 
the PDT experiments.   
 
 
Figure 5. 8 Plot of cell viability for BxPc-3 cell line after exposure to different concentration of CaO2 NPs 
solutions (25, 50, 100, 250, 500,750, 1000µM).  Error bars represent ± the standard error where n=6. 
Statistically significance versus untreated cells (represented by 100%): ns p>0.05, *p < 0.05, **p < 0.01, ***p < 
0.001. 
 
In addition to identifying the maximum amount of unmodified CaO2 NP that could be used 
without producing a significant reduction in the viability of BxPc-3 cells, it was also 
necessary to identify the ideal concentration of Rose Bengal and light dose to be used. 
“Ideal” in this context refers to the conditions required to generate a sub-lethal PDT effect 
for Rose Bengal + light (i.e. in the absence of CaO2 NPs) so that any beneficial effect afforded 
by the NPs could be determined.  PDT experiments were undertaken using a range of RB 
concentrations (0.5, 1.0, 2.0, 2.5 and 3.0 μM) and two different light doses (=532nm ± 
10nm, fluency 15.92 or 31.84 J/S.m2) corresponding to 30s or 1 min irradiation time. 24h 
following treatment, the cell viability was determined by MTT assay with the results 
presented in Figure 5.9.  A concentration dependent reduction in cell viability was observed 
for cells treated with Rose Bengal and light with the maximum Rose Bengal concentration of 
3.0 μM producing 46% and 52% reductions following 30 sec or 60 sec irradiation 
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respectively.  However, 60 sec irradiation in the absence of Rose Bengal was also found to 
produce a substantial 18% reduction in viability while 30 sec produced a much less 5% 
reduction. Based on this finding, 30 sec irradiation was identified as the optimum to be used. 
As mentioned above, the goal of these experiments was to identify conditions that 
produced a sub-lethal PDT effect i.e. that produced a moderate but not maximum reduction 
in viability so that any beneficial improvement of the CaO2 NPs could be identified.  Upon 
analysis of the results it was decided that 1 µM Rose Bengal and 30 sec irradiation time 
would be the ideal conditions as they provided a significant 22% reduction in cell viability 
with scope remaining for further reduction.  Therefore, conditions involving 1 µM Rose 
Bengal, 30 sec irradiation time, and 50 µM CaO2 NPs were chosen to determine the effect of 
the CaO2 NPs to improve PDT mediated efficacy in a hypoxic environment.  
 
Figure 5. 9 Plot of cell viability for BxPc-3 cells grown in normoxic conditions and then incubated with different 
condition of RB (0.5, 1, 2, 2.5 and 3 μM) and exposed to green light source (Wavelength 532nm ± 10nm, 
output power 15.92 J/S.m2) for 30 or 60 seconds. Error bars represent ± the standard error where n=6. 
Statistically significance versus untreated cells: ns p>0.05, *p < 0.05, **p < 0.01, ***p < 0.001. 
 
BxPc-3 pancreatic cancer cells were cultured in an anaerobic cabinet (O2/CO2/N2, 0.1: 5: 94.9 
v/v/v) for 3h to generate a hypoxic environment and then treated with RB (1µM) and 
incubated for a further 3h under anaerobic conditions. The cells were then incubated with 
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an ethanol: PBS (50:50) suspension of the NPs (50 µM) for 5 min before being subjected to 
light treatment for 30 sec. The NP suspension was then removed, the cells washed with 
fresh PBS and incubated in fresh medium under normoxic conditions for a further 21 h 
before cell viability was determined using a MTT assay. The use of a 25% v/v ethanolic NP 
suspension in these experiments was not ideal but care was taken to ensure that contact 
time with the cells was kept to a minimum. Controls involving RB only, light only and NP 
only were also undertaken for comparative purposes. The results are shown in Figure 5.10 
and reveal a significant (p < 0.01) reduction in viability for those cells treated with PDT in the 
presence of CaO2 NPs (33.3%) compared to PDT treatment alone (10.8%). These results 
suggest that treatment of hypoxic BxPc-3 with CaO2 NPs prior to PDT can enhance oxygen 
levels improving the PDT mediated efficacy. 
 
Figure 5. 10 Plot of cell viability for BxPc-3 cells grown in hypoxic conditions and then treated with RB (50 µM) 
or RB + NPs (50 µM) and then exposed for 30 seconds to green light sources (Wavelength 532nm ± 10nm, 
output power 15.92 J/S.m2). Error bars represent ± the standard error where n=12. Statistically significance of 
cells treated with RB + EtOH versus cells treated with RB + NPs: **p<0.01  
5.3.4 Synthesis and Characterisation of pH responsive terpolymer 
If CaO2 NPs are to be used in vivo it is imperative they remain stable in circulation until taken 
up by tumour tissue so that inadvertent systemic activation is avoided. Terpolymer 11, 
similar in structure to Eudragit E, was prepared by the free radical co-polymerisation of 2-
























ratio. 11 contains a tertiary amine side chain making it possess low aqueous solubility as the 
free base but were soluble once ionised. [213] The successful preparation of Polymer 11 was 
confirmed by 1H NMR spectroscopy with the stacked spectra of each monomer and 11 
shown in Figure 5.11. The olefinic protons present in the spectra of the monomers between 
5.5 and 6.5 ppm were not present in 11 indicating they had been successfully polymerised 
to form the backbone of 11. The peak at 0.81 ppm, not present in the spectra of the 
monomers but present in the spectrum of 11 most likely corresponds to the newly created 
methylene protons of the polymer backbone. In addition, the peaks were generally much 
broader in the spectrum of 11 than in the monomers, which is characteristic of protons in or 
near the backbone of polymers due to an ineffective averaging of their chemical shift 
anisotropies. [214] The proton NMR spectra shown in Figure 5.11 reveal the successful 
preparation of polymer 11. However, it was not possible to obtain an accurate molecular 
weight for this polymer. 
 
Figure 5. 11 Stacked 1H NMR spectra of (i) methyl methacrylate (ii) ethyl acrylate (iii) 2-(dimethylamino)ethyl 




5.3.5 Synthesis and characterization of 11 coated CaO2 NPs 
To coat the CaO2 NPs with polymer 11, a modified single emulsion method was utilised. 
CaO2 NPs were dispersed in hexane and homogenised at 9000 RPM for 5 minutes. In parallel, 
polymer 11 was dissolved in ethanol and also homogenised at 5000 RPM for 2 min. The 
CaO2 NPs/hexane suspension was added dropwise with at 2mL/min to the polymer/ethanol 
solution with continuous mixing at 9000 RPM. Once all the NP suspension was added the 
suspension was mixed for a further 6 h when the solvents were removed by evaporation.   
The polymer coated NPs (CaO2-11 NP) were then dispersed in aqueous solution and their 





Figure 5. 12 (a) DLS plot of polymer CaO2-11 NPs in EtOH solution, (b) SEM image of polymer CaO2-11 NPs. The 
bar is 5μm.  
The SEM image is shown in Figure 5.12(b) and again reveals spherical particles with an 





nm) determined by DLS. In addition, the particle morphology in SEM was uniform and did 
not appear to be a collection /aggregation of smaller particles as observed for the uncoated 
particles. [Figure 5.12(b)] This increase in size, relative to the uncoated NPs can be 
attributed to the polymeric coating.     
 
5.3.6 Ability of CaO2-11 NPs to elevate dissolved oxygen levels upon response to lowering 
solution pH.  
The ability of the CaO2-11 NPs to generate oxygen as a function of solution pH was 
determined by monitoring the increase in dissolved oxygen. Degassed aqueous solutions 
containing CaO2-11 NPs (1 mg/mL) were pH adjusted to either pH 7.4 or pH 6.2 and the 
change in dissolved oxygen measured at each pH stable for 5 minutes later. The results are 
shown in Figure 5.13(a) and reveal a 45% increase in dissolved oxygen at pH 6.2 compared 
to only 7% increase at pH 7.4. This increase in dissolved oxygen results from dissolution of 
the polymer coat at lower pH that exposes the CaO2 core to the aqueous environment. 
Indeed, when an aqueous suspension containing CaO2-11 NPs was pH adjusted from pH 7.4 
to pH 6.2, the visual appearance changed from a milky suspension to a more transparent 
solution. These results suggest that the CaO2-11 NPs should remain stable in the systemic 









Figure 5. 13 (a) Plot of the percentages of dissolved oxygen in de-oxygenated water at pH 6.2 and pH 7.4 in the 
absence or in presence of polymer CaO2-11 NPs. (b) Representative photograph showing an aqueous 
suspension of the polymer 11 coated CaO2 NPs at pH 7.44, 6.88 and 6.19. Statistical significance of polymer 
CaO2-11 NPs in pH 6.2 versus polymer CaO2-11 NPs in pH 7.4: *** p≤ 0.001. 
 
5.3.7 Ability of CaO2-11 NPs to improve tumour oxygenation in vivo.  
To determine the ability of the CaO2-11 NPs to enhance tumour oxygenation in an in vivo 
model, ectopic human xenograft Mia Paca-2 tumours were established in SCID mice. The 
Mia Paca-2 model is known to form hypoxic tumours and has previously been used in 





BxPc-3 cell line, Mia Paca-2 cells also express the KRAS mutation making it a more 
representative model of the disease in vivo. Once the tumours reached an average volume 
of 254 ± 17 mm3, the mice were separated into two groups (n=3). The treatment group 
received a tail vein injection of the CaO2-11 NP suspension in a PBS buffer vehicle (pH 7.4 ± 
0.1), with the control group receiving the same volume of vehicle only. Tumour pO2 readings 
were recorded using an Oxylite oxygen electrode sensor for 20 min before and 40 min after 
injection. The results are shown in Figure 5.14(a) and reveal no significant change in the pO2 
reading in the 20 min period before injection for either group with a mean pO2 reading of ~ 
2.0 mmHg. However, approximately 10 min after injection, tumour pO2 levels in the CaO2-11 
NP group increased dramatically reaching a peak of 16 mmHg before levelling off at ~6 
mmHg 30 min after injection. In contrast, mice treated with vehicle alone showed no 
noticeable change in tumour pO2 over the time course of the experiment. To put the above 
results in context, previous studies have indicated that the response to radiotherapy 
treatment is highly dependent upon tumour oxygenation with an increase from 2.5 mmHg 
to 6 mmHg significantly affecting loco-regional tumour control in advanced squamous cell 
head and neck carcinoma. [216] While similar data are not available for PDT, the technique 
is known to be negatively impacted by hypoxia and the increase in tumour pO2 levels 
provided by the CaO2-11 NPs would be expected to have a beneficial effect on PDT 











Figure 5. 14 (a) Tumour pO2 plot in mice bearing ectopic Mia Paca-2 pancreatic tumours. pO2 was  recorded for 
20 min before and 40 min following an IV injection of CaO2-11 NPs in a PBS (pH 7.4 ± 0.1)  (red line) or an IV 
injection of vehicle only, i.e CaO2-11 NPs, (blue dashed line). Arrow indicates when the injection occurred. (b) 
Plot showing the integration of mean oxygen level obtained from the plot (a). the mean tumour pO2 for 
various time intervals before and following IV administration of CaO2-11 NPs or vehicle only, i.e. CaO2 NPs, 








5.3.8 Effect of CaO2-11 NPs on the PDT efficacy of Rose Bengal in an in vivo model of 
pancreatic cancer.  
To identify the benefit afforded by the CaO2-11 NPs on improving PDT mediated efficacy in 
vivo, the same Mia Paca-2 tumour model described in the pO2 study above, was treated 
with PDT using a Rose Bengal sensitiser in the presence and absence of the CaO2-11 NPs. 
Untreated animals and those treated with CaO2-11 NPs alone were used as controls. The 
NPs were again delivered by IV injection while Rose Bengal was administered by 
intratumoral injection, to ensure a consistent dose was administered to all of the tumours. 
Twenty minutes following IV administration of the CaO2-11 NPs, tumours were exposed to 
light treatment for 3 min. Tumour volume was monitored for 5 days following treatment 
and the results are shown in Figure 5.15(a). The results demonstrate that there was no 
significant difference in tumour volume for mice treated with PDT alone or with CaO2-11 
NPs alone 5 days after treatment, relative to the untreated control animals. In contrast, a 
significant reduction (p ≤ 0.001) of 70.5 % was observed for animals treated with the CaO2-8 
NPs and PDT over the same time period. In addition, there was no significant change in body 
weight in animals treated with the CaO2-11 NPs alone or in combination with PDT 
suggesting the treatment was well tolerated [Figure 5.15(b)]. These results highlight the 
benefit of CaO2-11 NPs in improving the PDT mediated treatment of hypoxic tumours such 
as pancreatic adenocarcinoma and may provide benefit in other treatments that are also 









Figure 5. 15 (a) Plot of % change in tumour volume against time for SCID mice bearing human xenograft Mia 
Paca-2 pancreatic tumour treated with (i) no treatment (squares) (ii) PDT only (circles) (iii) CaO2-11 NPs only 
(diamonds) and (iv) CaO2-11 NPs and PDT (triangles). (b) Plot of average body weight for each group of mice 






5.4 Conclusion  
In summary, a CaO2 NPs formulation comprising a pH-responsive coating that enables the 
generation of molecular oxygen in response to environmental pH changes has been 
developed. Specifically, the polymer coat maintains its integrity in aqueous solution at pH 
7.4, but it rapidly dissolves when the pH is lowered to pH 6.2, exposing the CaO2 particles to 
water resulting in oxygen generation. The ability of the coated particles to elevate tumour 
oxygen levels was also demonstrated in an in vivo model using mice bearing human 
xenograft Mia Paca-2 pancreatic tumour. A significant elevation in tumour pO2 was 
observed 10 mins following IV administration. This increase in tumour pO2 was also shown 
to have a dramatic effect on PDT efficacy with significant reductions in tumour growth 
observed in mice treated with CaO2-11 NPs prior to PDT.  
Hence, it can be concluded that the use of these coated NPs could not only be applied for 
used in PDT but could show other benefit versus other treatment negatively impacted by 














































6. Conclusions and future work 
The work described in this this thesis explored new approaches for the treatment of 
pancreatic cancer, which is one of the most recalcitrant forms of the disease and one in 
which survival statistics have barely changed in over 40 years. Chapters 3 and 4 explored 
the use of non-magnetic and magnetically responsive MBs respectively, to deliver combined 
SDT and antimetabolite treatment to pancreatic tumours. In Chapter 3, chemo-
sonodynamic therapy using Gemcitabine as the antimetabolite was marginally better in vitro 
and responded to a broader range of US conditions in vivo when compared to the analogous 
treatment involving 5-FU as the antimetabolite. However, there was no significant 
difference in tumour growth delay when the optimum US exposure conditions were used in 
each case. Importantly, however, tumour growth delay was extended following a second 
treatment meaning resistance to treatment did not develop quickly. Interesting effects were 
also observed when a panel of genes associated with a poor outcome in pancreatic cancer 
were analysed following treatment, with significant changes observed for treated tumours 
relative to untreated tumours. The effect this treatment on non-tumour bearing healthy 
mice was also investigated and the results confirmed MB mediated chemo-sonodynamic 
therapy to be well tolerated.  
 
The work described in Chapter 3 was extended in Chapter 4 to investigate the benefit of 
adding an additional layer of targeting to the MB platform and to determine efficacy of the 
treatment in an orthotopic mouse model of pancreatic cancer. The O2MBs were 
functionalised with SPIONs and shown capable of being retained during flow using an 
externally applied magnetic field. Treatment of orthotopic BxPc-3 Luc tumours in SCID mice 
demonstrated that efficacy was improved when combined US / magnetic fields were applied 
to the tumour during treatment compared to a US field alone, although the difference was 
non-significant. Again, the MagO2MB conjugates displayed no observable toxic effects when 
used to treat non-tumour bearing healthy mice.  
 
Combined, the results from Chapters 3 and 4 demonstrate the potential of chemo-
sonodynamic therapy using the MB platform as a minimally invasive targeted treatment for 
pancreatic cancer. Moving forward, one perceived drawback of the approach used in 
148 
 
Chapters 3 and 4 is that two separate MBs were required to deliver the combined SDT and 
antimetabolite treatment. This required mixing the MBs before injection, which effectively 
halves the concentration of each agent. Future work should explore designing a single 
biotinylated ligand carrying both the sensitiser and antimetabolite drug to enable chemo-
sonodynamic therapy to be delivered using a single MB formulation.  Another possible area 
that could be explored is to incorporate a third payload within the hydrophobic oil layer of 
the MB, in addition those attached via the biotin-avidin interaction to the shell. One such 
candidate payload is paclitaxel as it is not only extremely hydrophobic but also commonly 
used in pancreatic cancer treatment.  
 
In Chapter 5, oxygen generating nanoparticles were developed and demonstrated pH 
dependent oxygen release when coated with a pH responsive polymer. A significant 
elevation in tumour pO2 was observed when a suspension of the particles was delivered by 
IV injection and this increase in tumour oxygen was shown to enhance the efficacy of PDT 
treatment using Rose Bengal as the sensitiser. While these results were exciting, future 
work should also explore the concentration dependence of the nanoparticles on tumour pO2 
increase. Although no overt acute toxic effects were observed following administration of 
the particles to mice, a more detailed safety study like that undertaken in Chapters 3 and 4 
should also be conducted. The possibility of further modifying the pH responsive polymer to 
carry a photo-, sono- or radio-senitiser is also an area that could be explored in the future 
work and would enable these agents to be passively targeted to the tumour by virtue of the 
nanoparticle mediated EPR effect.  
Both the oxygen generating particles and oxygen carrying MBs have the potential to elevate 
tumour oxygen and increase the efficacy of treatments that depend on an adequate supply 
of oxygen to be effective. Previous work by McEwan et al. [217] has demonstrated the 
positive effect of MB mediated oxygen delivery on SDT efficacy while a recent study has 
shown a similar effect on external beam radiotherapy (EBR) efficacy. [218] Therefore, it 
would also be interesting to explore the effect of combing EBR with the oxygen generating 
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Appendix 2: This paper is related to chapter 5.
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